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 Steroids are a structurally privileged class of bioactive natural products whose architecture 
has served as the bedrock for many valuable therapeutics throughout human history. In particular, 
the cardenolide sub-class of steroids, typified by ouabain and digoxin, has been used clinically 
since the late 18th century for the treatment of congestive heart failure; a widespread and 
detrimental affliction. In addition, the recently discovered anticancer activity of cardenolides has 
brought them back into focus as highly valuable therapeutic agents, although the mechanism of 
their anticancer activity is not fully understood. Moreover, cardenolides are well known for their 
low therapeutic windows. The design and construction of novel cardenolide analogues for 
biological evaluation is highly sought after. However, the chemical complexity of cardenolides 
makes the synthesis of new analogues a long process which is economically unjustifiable in an 
industrial setting. Herein we describe our efforts toward the development of a drug-oriented, 
concise, and stereodivergent synthetic approach to the cardenolide class of steroids culminating in 
the total synthesis of several natural cardenolides and analogues. 
 Chapter 1 delves into the relevant background and history of cardenolides as well as their 
structure and bioactivity. The mechanism of action leading to a positive inotropic response is 
explained and the mode of binding to the Na+/K+ATPase is discussed. Some previously reported 
structure-activity relationship studies are described and evaluated.  
 Chapter 2 describes several landmark efforts towards the total synthesis and semi-synthesis 
of cardenolides. A comparison of these two approaches is discussed and various semi-synthetic 
xx 
 
and totally synthetic routes aimed at cardenolides are described. Special attention is paid toward 
butenolide installation, stereochemical control, and introduction of key sites of oxygenation. 
 Chapter 3 provides a detailed overview of the design and development of a conceptually 
new two-step synthetic approach to oxygenated steroidal cores. Chiral Cu(II)-BOX catalysts are 
successfully investigated for their ability to promote the enantio- and diastereoselective Michael 
addition of cyclic β-ketoesters and functionalized enones. A library of Michael adducts with 
unique A and D ring sizes, as well as C13 substitution is produced with high selectivities and yields 
(82–95% yield, 90–96% ee, and 4:1 to >20:1 dr). The Michael adducts then undergo 
stereodivergent intramolecular double aldol cyclization to afford a library of natural and unnatural 
steroidal cores. The factors controlling the diastereoselective cyclization are discussed. 
 Chapter 4 describes the elaboration of the aforementioned methodology to allow the total 
synthesis of four targets: 19-hydroxysarmentogenin, trewianin aglycone, panogenin, and cis-
panogenin. Modifications allow the pre-installation of oxygenation at the key positions C3 and 
C11. These functional handles are carried through the Michael addition/cyclization sequence to 
afford a heavily functionalized steroid intermediate with 7 stereocenters in a fused tetracyclic array 
with oxygenation installed at C3, C11, C14, C17, and C19 in only 7 linear steps. This intermediate 
is then elaborated in a stereodivergent fashion into the four target cardenolides in only 9-11 linear 
steps. Finally, a biochemical Na+/K+ATPase inhibition assay was developed and concentration-
response curves were generated for the synthesized steroids. The resulting data corroborates the 
importance of the orientation at C17 and C11, while suggesting that the configuration at C5 is of 








Steroids are a structurally privileged class of bioactive natural products found ubiquitously 
in nature. These compounds are remarkably prevalent and are used naturally for a wide array of 
purposes including hormonal/cell signaling, lipid membrane stability, and defense mechanisms.1 
The abundance of steroids as endogenous compounds makes them valuable from a therapeutic 
standpoint because the human biochemical toolkit is well adapted to recognizing and responding 
to the steroidal scaffold. 
Despite having a common tetracyclic core, steroids with unique stereochemical patterns 
and peripheral substitutions can be tuned to elicit drastically different physiological responses. For 
this reason, the steroidal core has served as the bedrock for many valuable FDA-approved drugs 
which have successfully treated human ailments such as cancer, heart failure, inflammation, 








Figure 1.1. Selected Steroidal Drug Examples. 
 
1.2. Cardiotonic Steroid Structural Features and Nomenclature 
The standard convention for steroid numbering and facial reference, which is used 
throughout this dissertation, is shown in Figure 1.2. The three 6-membered rings are labeled A, 
B, and C proceeding from left to right, and the 5-membered ring is labeled D. The carbon 
numbering begins at the northern apex of the A-ring and proceeds counter-clockwise around the 
A and B rings, and then weaves around the C and D rings with carbon units appended at the C13 
and C10 position being labeled C18 and C19 respectively. Lastly, the top face of the steroid is 
denoted the β-face, with the underside being the α-face.  
Cardiotonic steroids represent an important steroidal subclass and are specifically 
characterized by a unique cis-β-A/B ring junction, trans-B/C ring junction, and cis-β-C/D ring 
junction which impose a clear U-shape to the molecule where the β-face is convex and the α-face 
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is concave.3 It should be noted there are exceptions to the cis-β-A/B ring junction fusion, 
particularly in  cardiotonic steroids produced by milkweed (Asclepias), where the A/B ring is trans 
fused.4 Cardiotonic steroids also contain a β-C14 hydroxy and often have additional β-oriented 
hydroxy groups at various positions around the core. One of these key hydroxylated positions is 
found at C3, where the hydroxy group is often glycosylated. Non-glycosylated congeners are 
typically denoted with the suffix “-genin”. Finally, an unsaturated lactone ring is appended at the 
C17 position in a β orientation. Cardiotonic steroids can be further divided into cardenolides and 
bufadienolides, with the former being predominantly plant derived and the latter generally 
produced by animals.5 The key structural determinant which differentiates these subclasses is the 
heterocycle at C17; cardenolides possess a butenolide ring, while the bufadienolides have a 2-
pyrone ring. An example of a cardenolide, 19-hydroxysarmentogenin (1), is shown in Figure 1.2. 
These structural characteristics impart an interesting amphipathic nature to many cardiotonic 
steroids with highly polar β-faces and relatively non-polar α-faces. As a result, cardiotonic steroids 
are well matched to the Na+/K+-ATPase binding pocket. The binding mode of these steroids is 
further discussed in section 1.5. 





1.3. Brief History of Cardenolides 
Cardenolides have been used for hundreds of years for a myriad of purposes, and there is 
no doubt they have played an important part in human history. In fact, plant extracts containing 
cardenolides were used by the ancient Egyptians, Romans, Greeks, Chinese, and African Tribes 
for purposes ranging from poison arrows and rat poison to diuretics and anesthetics.6-8 
Cardenolides have even been cited as “the most ingested drugs in history” and the World Health 
Organization lists Digoxin (a cardenolide) on its Model List of Essential Medicines.9,10  
It wasn’t until the latter half of the 18th century when an English scientist named William 
Withering studied and documented how extracts of the foxglove plant, now known to contain the 
digitalis cardenolides, could be effectively prepared and used to treat congestive heart failure; a 
condition referred to as dropsy at the time.11 Withering used the scientific method to systematically 
study and understand how particular chemical components of the foxglove extracts can be properly 
dosed to treat human disease. His efforts relating to cardenolides are often cited as the “the 
beginning of modern therapeutics.”12 Withering successfully described optimized extraction and 
dosing procedures and he found great success in using the foxglove extract to treat patients 
suffering from dropsy. Cardenolides have been used to treat heart failure ever since. Some 







Figure 1.3. Selected Cardenolide Examples. 
 
1.4. Heart Failure and Cardenolide Mechanism of Action 
Heart failure is a widespread and detrimental disease which currently afflicts 5.8 million 
people in the United States alone.13 It is characterized by an enlargement or weakening of the 
heart’s ventricular muscles which dramatically impairs the heart’s ability to effectively pump and 
circulate blood throughout the body. Approximately 1 in 5 people will develop heart failure and 
about half of those who develop it will die within 5 years.14 The economic burden of heart failure 
in the United States is estimated to be $39 billion each year.13 Due to the financial strain, 
prevalence, and danger posed by heart failure, new therapies for the effective treatment of this 
cardiovascular disease are strongly sought. While significant progress in medicine in the last 
century and the advent of diuretics and angiotensin-converting-enzyme (ACE) inhibitors has 
undoubtedly curbed these numbers, there remains a large potential for improvement. 
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Cardenolides act on the heart by binding and inhibiting the catalytic α-subunit (isoforms 
α1, α2, α3, and α4) of the Na+/K+-ATPase pumps found on the surface of cardiac myocytes (Figure 
1.4.).15 The Na+/K+-ATPase functions to maintain a cell’s resting potential, regulate volume, 
participate in signal transduction of the MAPK pathway, and modulate intracellular calcium.16 Its 
mechanism of action involves the sequential transport of three Na+ ions out of the cell and two K+ 
into the cell, against their respective concentration gradients. The coupled hydrolysis of ATP 
provides the necessary energy. When the pump is bound by a cardenolide, its function is halted. 
Consequently, Na+ efflux is hindered and intracellular Na+ concentrations are increased. 
Elsewhere on the cell surface exists the Na+/Ca2+ exchanger. This antiporter uses the energy stored 
in the electrochemical gradient of Na+ across the cell membrane in order to efflux Ca2+ ions from 
the cell while allowing Na+ to influx. The increased intracellular Na+ concentrations resulting from 
Na+/K+-ATPase inhibition will slow down or stop the function of the Na+/Ca2+ exchanger. This 
decreases Ca2+ efflux, and as a result, intracellular Ca2+ accumulates and is shuttled to the 
sarcoplasmic reticulum (SR). When the cardiac myocyte receives an action potential to contract 
and undergoes calcium-induced calcium release from the SR, a surplus of Ca2+ is released and 
these ions bind to troponin to expose myosin binding sites on the actin filament. More calcium 
leads to more myosin binding sites being exposed which leads to an increased contractile strength. 
The end result is a positive inotropic response on the heart muscle, wherein the heart contractile 
force is increased.16 This physiological response directly counteracts the effects of congestive heart 






Figure 1.4. Cardenolide Mechanism of Action Schematic. 
 
 In fact, it was discovered that cardiotonic steroids are even present in small quantities as 
endogenous human hormones.17 These steroids serve as natural inhibitors of the Na+/K+-ATPase 
and have been shown to have several natural regulatory functions including arterial tension, cell 
proliferation, insulin release, and blood pressure.18 
1.5. Binding Mode of Cardenolides 
X-ray crystallographic analysis of Na+/K+-ATPase–cardenolide binding has been achieved 
and revealed valuable insights into the nature of the binding interactions involved. In one case, pig 
kidney Na+/K+-ATPase (α1 isoform) was complexed with ouabain and the x-ray was resolved to 
3.4 Å resolution.19 Ouabain is bound in the pocket vertically with the C17 butenolide ring pointing 
directly into the enzyme while the sugar moiety is nearly solvent exposed at the extracellular 
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surface of the binding pocket. It is evident that the cardenolide binding pocket on the α-subunit is 
lined with polar residues on one side and non-polar residues on other (Figure 1.5.).  
Figure 1.5. Ouabain- Na+/K+-ATPase Crystal Structure Image Created By Fedosova et al.19 
 
The pocket is well suited for cardenolides which have polar β-faces and non-polar α-faces. 
The helices αM2 and αM1 line the polar side of the pocket and protrude glutamate 117, glutamine 
111, aspartate 121, asparagine 122, and leucine 125 residues toward the bound cardenolide. These 
residues form key H-bonding and electrostatic interactions with the multiple β-oriented hydroxy 
groups on ouabain. At the same time, helices αM4 and αM5 line the opposite side of ouabain with 
non-polar phenylalanine 316/786/783, isoleucine 315, glycine 319, and leucine 793 residues 
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forming key hydrophobic van der waals contacts. In addition, the polar interactions mediated by 
residues R880 and D884 of loop αM7-8 help bind the sugar component of the steroid. 
 Some structure-activity relationships have been explored through semi-synthetic 
modifications of cardenolides.20 It has been shown that the sugar moiety at C3 influences the 
pharmacokinetic and pharmacodynamic properties. Appended rhamnose was shown to increase 
potency by a factor of 6-35, while mannose had no effect.20 In addition, glycosylated cardenolides 
tend to absorb more poorly but exhibit greater metabolic stability. The role of the lactone ring at 
C17 has also been explored. One study determined that the interaction energy afforded by the 
butenolide amounts to -4.9 kcal/mol. This is nearly equal to the -5.4 kcal/mol of interaction energy 
supplied by the rest of the steroid as a whole.21 This beneficial interactive force is eliminated if the 
orientation of the butenolide at C17 is inverted to an α-orientation.  Further evidence implicates 
the likelihood of an induced fit binding mode. The process of steroid binding likely promotes 
conformational changes within the Na+/K+-ATPase pocket which then allows deeper binding and 
optimal orientation of the butenolide ring. Since the butenolide is one of the most defining 
structural features of cardiotonic steroids, its importance for bioactivity is understandable. Some 
work has also been done to probe the role of butenolide (cardenolide) vs 2-pyrone (bufadienolides) 
rings at the C17 position. One study examined deaths resulting from cardiotonic steroids in a non-
clinical setting. From 1982 to 2003, it was apparent that bufadienolides were significantly more 
toxic than cardenolides.22 This implicates the 2-pyrone moiety as a stronger toxicophore than the 
butenolide substituent. Another important aspect to note is variance of the internal ring junction 
stereocenters. Changing the orientation of either the A/B or C/D ring junction from cis to trans 
appears to decrease interaction energy for some glycosylated cardenolides.23 However, this effect 
is not as apparent in the aglycone congeners and suggests that the cis orientation of the A/B 
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junction is necessary for proper spatial arrangement of the sugar group. Yet, there are known 
examples where aglycones with trans-C/D junctions exhibit stronger interactions with the Na+/K+-
ATPase than their cis-β-C/D counterparts.20 In addition, there are documented cases of 
glycosylated trans-A/B architectures showing strong Na+/K+-ATPase inhibition.24 Our 
understanding of cardenolide structure-activity relationships remains incomplete and additional 
work is needed in this area. 
1.6. Cardenolide Toxicity and Therapeutic Window 
Despite the historical success and widespread use of the cardenolides, there remain some 
important limitations. Even in 1775, William Withering noted the disappointingly narrow 
therapeutic window of digitalis. Cardenolides have since been well known for their poor toxicity 
profiles resulting in therapeutic indices as low as two. Cardenolides are produced naturally by 
plants, likely as a mechanism for deterring herbivores, thus the compounds are naturally designed 
and well optimized to kill animals via arrhythmia and heart-arrest.25 When cardenolides are used 
clinically, careful patient dosing is essential. For example, the target plasma concentration of 
digoxin is 0.8 – 2.0 ng/mL and toxic effects begins to occur at or above 2.0 ng/mL.26 As a result, 
patients often receive 60% of the toxic dose. 
 It is documented that two discrete receptor isoforms appear largely responsible for the 
therapeutic inotropic response and the toxicity. There is some lack of consensus in the literature 
on this topic. One report tentatively suggests the α1 isoform as the desired target for therapy with 
the α2 or α3 isoforms being responsible for toxic effects,27 while a more recent report theorizes 
that selective α2 inhibitors would best expand the therapeutic window.28 It is worth noting that the 
clinically used digitalis cardenolides show a modest preference for α2 over α1, while the less used 
ouabain shows a preference for α1 over α2; yet these differing usage levels may be a result of 
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bioavailability parameters. Furthermore, some studies report that the sugar moiety of glycosylated 
cardenolides is responsible for isoform differentiation,28 while another study found that the sugar 
actually reduced isoform selectivity in some cardenolides and went on to strongly implicate the 
butenolide region in selectivity.29 More research on this topic is needed, however, it is clear that 
isoform selective inhibitors are highly desired. At this time, the author is unaware of any α2 or α3 
co-crystal structures with a cardenolide and so direct x-ray guided structure design for generating 
isoform selectivity is unavailable. 
One study undertaken by E.J. Corey in 2006 at Harvard University demonstrated the 
capacity for cardenolide analogues to exhibit an improved therapeutic index.30 Corey and his co-
workers explored the semi-synthesis of a C11 epimer of ouabain (2) and its biological activity 
(Scheme 1.1.). They were able to bis-acetalize ouabain (2) with HCl/acetone to produce compound 
3. Selective monoacylation of the remaining sugar hydroxy in the presence of the C11 hydroxy 
generated compound 4, which was subsequently oxidized with the Dess-Martin periodinane. 
Steroid 5 was then reduced with NaBH4, wherein hydride was added to the C11 ketone exclusively 
from the α-face. After saponification of the acylated alcohols, intermediate 6 was obtained. The 
final step was hydrolysis of the acetal moieties with HCl/MeOH to furnish 11-epi-ouabain (7). It 
was discovered that this C11 epimer of ouabain retained potency as an inotropic agent and 
displayed a two-fold improvement of the therapeutic index in a dog arrhythmia test (TI = 4). 
Unfortunately, no mention or study of isoform selectivity was apparent. 
There is a clear benefit and desire to improve the toxicity profile associated with the 
cardenolides and one aspect of the work described in this dissertation aims at improving access to 
new regions of chemical space associated with these steroids in order to explore ways of increasing 
the therapeutic window and generating safer drug candidates. 
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Scheme 1.1. E. J. Corey’s Semi-synthesis of 11-epi-ouabain. 
 
1.7. Anticancer Activity of Cardenolides 
In the 1980s, Stenkvist and colleagues were studying women with breast cancer and some 
of the women being studied were also taking digitalis.31 It was discovered that the cancer cells of 
the women taking digitalis showed more benign features compared to those not taking digitalis. In 
addition, Stenkvist noted that the odds of reacquiring breast cancer five years after a mastectomy 
was 9.6 times lower for the women taking digitalis. Moreover, Stenkvist followed up with the 
same women twenty years later and reported that those taking digitalis had a 6% mortality rate 
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(6/32), while those not taking digitalis had a 34% mortality rate (48/143).32 Despite the small 
sample size, the apparent correlation sparked much interest. Many groups have since 
independently investigated and confirmed the anticancer activity of cardenolides in various cell 
lines (Table 1.1.). 33  
Table 1.1. Reported Activity of Cardiotonic Steroids in Various Cancer Cell Lines – Information 
Compiled by Prassas, I. and Diamandis, E.33  
 
 Since the discovery of cardenolide antiproliferative activity, many research projects have 
investigated the biological origin. However, the specific mechanism of action by which cardiotonic 
steroids exert their anticancer activity has not been definitively determined. Many reports have 
proffered different theories as to the origin of this anticancer activity. Some proposals include 
alteration of the Na+/K+-ATPase signalosome which mediates intracellular signaling pathways, 
inhibition of topoisomerase II, changes in gene expression profiles, increased production of 
Cancer Type Compounds Cell Lines 
Breast 
digitoxin, digoxin, proscillaridin A, 




oleandrin, ouabain, digoxin, 
bufalin, cinobufagenin 
PC-3, LNCaP, DU145 
Melanoma 
digoxin, oleandrin, digitoxin, 
proscillaridin A, ouabain, digitonin 
UACC-62, BRO 
Lung 
digitoxin, digoxin, ouabain, 
UNBS1450, oleandrin 
A549, NCI-H-358, Calu1, 
Sklu1, NCI-H6, H69AR 
Leukemia 
bufalin, oleandrin, digitoxin, 
proscillaridin A, ouabain 
HL60, U937, CCRF-
CEM, CEM-VM-1 
Neuroblastoma digoxin, ouabain SH-SY5Y, Neuro-2a 
Renal 
digitoxin, digoxin, digitoxigenin, 
proscillaridin A, ouabain 
TK-10, ACHN 
Myeloma 
digitoxin, digoxin, proscillaridin A, 




Pancreatic oleandrin PANC-1 
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reactive oxygen species (ROS), inhibition of glycolysis, disruption of ion concentrations, and 
more.33 It is important to note that there is little ambiguity about the increased activity of Na+/K+-
ATPase associated with cancerous cells.34 Most, but not all, suggestions for the anticancer activity 
are associated with binding to the Na+/K+-ATPase on tumor cells and a recent report implicates 
the α1 isoform as being a prime target for combating non-small cell lung cancers.24 
The investigation of cardiotonic steroids as potential antiproliferative agents is highly 
sought after. It is the partial aim of the work described here to improve access to novel regions of 
chemical space surrounding the cardenolides. Access to unique chemical analogues of these 
steroids could allow a more comprehensive understanding of the structure-activity relationship 
associated with the anticancer activity and possibly generate promising drug candidates.  
1.8. Conclusion 
Cardiotonic steroids are an historically important and therapeutically valuable class of 
natural products. Their use dates back to the ancient Egyptians and has continued through modern 
times. Since the late 1800’s, cardenolides have been used primarily for the treatment of heart 
failure, a widespread and detrimental affliction. However, these steroids are plagued by high 
toxicity issues which have limited their therapeutic use. Safer versions of these drugs are highly 
sought after. In addition, the recently discovered anticancer activity of cardenolides has brought 
them back into focus as highly valuable therapeutic agents. Nonetheless, the chemical complexity 
of the cardiotonic steroids make it difficult to synthesize important new analogues and access 
regions of chemical space which may provide us with safer, yet effective drugs. There is a strong 
desire within the synthetic and medicinal communities to develop new, more concise and modular 
syntheses of the cardenolide class of steroids to allow researchers improved access to novel 
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Previous Approaches to Cardenolides 
2.1. Introduction 
 The primary difficulty in studying the chemistry and biology of the cardiotonic steroids is 
the inherent chemical complexity of the molecules involved. The inability to acquire sufficient 
quantities of specific analogues makes the process slow and economically unjustified in an 
industrial setting. It is highly desirable to develop a concise and modular synthetic route to the 
cardenolide class of steroids to enhance our access to unique cardenolide like compounds for 
biological evaluation. Throughout the last century, there have been many landmark efforts and 
advancements in the field of steroidal synthesis. Some are described in sections 2.3 through 2.9. 
2.2.  Semi-Synthesis vs. Total Synthesis 
 The two most common approaches to acquiring steroids outside of natural production are 
semi-synthesis and total synthesis. In semi-synthesis, a common and inexpensive natural steroid 
is acquired through isolation from an organism. The steroid is then chemically transformed through 
a series of reactions into a different, target steroid. This approach has some benefits and limitations. 
The primary benefit is that most of the structural features of the targeted steroid, such as the 
steroidal core, peripheral substituents, and stereochemical patterns, are already present from the 
outset. Semi-synthesis is thus most useful when one can isolate, from natural sources, a steroidal 
precursor which is structurally similar to the particular analogue being targeted. This minimizes 
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the number of chemical transformations needed to convert the isolated steroid into the desired 
analogue. However, in most cases, isolating certain steroids from natural sources can itself be a 
long and expensive process with low yield. The semi-synthetic approach also has limitations. The 
steroidal precursors have preset stereochemical patterns, sites of oxidation, and peripheral 
substitutions. It can be difficult, sometimes prohibitively so, to chemically modify these 
functionalities. For example, expanding or contracting ring sizes, inverting internal stereocenters, 
and functionalizing or oxidizing inert positions are some transformations which may be difficult 
to achieve in a concise manner. In addition, enantiomers are inaccessible through semisynthetic 
approaches. The predefined chemical state of an isolated steroid can therefore significantly hinder 
access to new and important analogues. 
 In a totally synthetic approach, cheap and simple starting materials (often no more than 6-
8 carbons) are used by the chemist to construct a target steroid. Total synthesis has the benefit of 
accessing virtually any chemically viable steroid analogue. This allows researchers to explore 
unique analogues and have the best chance to find the most therapeutically valuable structures. 
The primary limitation to total synthesis is the time and number of steps required to acquire the 
target steroid. Total syntheses can often be so long (30 – 40 steps) and unwieldy that the cost does 
not justify the means and the production of analogues is too slow to maintain a viable drug 
development program. An optimal solution to the problem of synthesizing complex cardenolides 
could be a short and modular totally synthetic approach which could serve as a guiding manual for 
accessing new cardenolide cores in few steps.  
2.3. First Total Synthesis of a Steroid 
 In 1939, Bachmann and colleagues at the University of Michigan developed the first total 
synthesis of a steroid.1 While it is not a cardenolide, it represented the first successful approach to 
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synthesizing the steroidal core. Equilenin (16), a sex hormone, was synthesized in 12 steps 
(Scheme 2.1.). Tricycle 9 was first prepared from Cleve’s acid (8). Acylation with methyl 
glyoxalate using NaOMe produced triketone 10. Subsequent decarbonylative pyrolysis and 
alkylation afforded β-ketoester 11 in 86% yield over two steps. A Reformatsky reaction was then 
followed by a two-step procedure for dehydration involving the conversion of a tertiary alcohol to 
a tertiary chloride and elimination of HCl by treatment with KOH.  
 Scheme 2.1. Bachmann’s Synthesis of Equilenin. 
 
Compound 12 was then reduced with sodium amalgam and esterified to the methyl ester. 
After this reduction, the trans-C/D ring junction product could be easily obtained because the cis 
isomer would spontaneously cyclize to the anhydride. Selective saponification with methanolic 
ammonia and subsequent Arndt-Eistert homologation generated intermediate 14 in 80% yield. 
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Dieckmann condensation promoted by NaOMe successfully closed the D ring and subsequent 
decarboxylation and demethylation was accomplished by treatment with AcOH/HCl to afford 
racemic Equilenin (16). 
2.4. First Synthesis of Cardenolide Core 
 In 1979, Daniewski and co-workers reported the first synthesis toward a cardenolide core 
and completed it in 1988 (Scheme 2.2.).2,3 The approach taken includes a key aldol closure of the 
C-ring reminiscent of the strategy seen later by Deslongchamps as well as the methodology 
described in chapters 3 and 4. Another important note is the method for butenolide installation, 
which is a 7-step sequence starting from a ketone and proceeding by way of a clever Wittig reaction 
of the Bestmann ylide with an acyloin at C17. This is one of the two most common approaches to 
butenolide installation. 
 The synthesis starts with the well-known Wieland-Miescher ketone. Addition of lithium 
acetylide followed by hydrogenation produced allylic alcohol 17. Chlorination of 17 with SOCl2 
and subsequent Sn2 displacement with the sodium salt of 2-methyl-cyclopentane-1,3-dione was 
performed. Oxidation of the resulting enone with DDQ produced intermediate 18. The key 
cyclization was then initiated with NaOMe in dry methanol. The α-face of the extended enolate 
underwent an aldol reaction at the D-ring ketone with complete diastereoselectivity to produce 19 
with the desired cis-β-C/D ring junction in 21% overall yield over four steps. The desired cis-β-
A/B ring junction was then installed by successive hydrogenation using Pd/SrCO3 and Pd/C. With 
diketone 20 in hand, the C3 ketone was selectively reduced from the α-face with K-selectride. The 
Barton conditions for vinyl iodide formation were then utilized to produce vinyl iodide 21 in 47% 
yield over two steps. Transfer hydrogenation using diimide was employed for the reduction of the 
C16-C17 olefin to furnish the α-oriented iodide and radical substitution of the iodide with cyanide 
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followed by protection of the C3 hydroxy by DHP produced steroid 22 in 49% yield over 3 steps. 
The final goal was installation of the butenolide. To this end, nitrile 22 was treated with MeLi to 
produce a C17 β-oriented methyl ketone. Using a modified Vedej’s oxidation, the α position of the 
methyl ketone was successfully oxidized to produce an acyloin. Cyclization to the final product 
rac-9,11-dehydrodigitoxigenin 3-tetrahydropyranyl ether (23) was achieved by treatment with the 
Bestmann ylide.  
Scheme 2.2. Daniewski’s Synthesis of Cardenolide Core. 
 
2.5.  First Total Synthesis of a Natural Cardenolide 
 In 1996, Stork and co-workers reported the first total synthesis of a natural cardenolide, 
digitoxigenin (Scheme 2.3.), proceeding in 29 steps from the Wieland-Miescher ketone.4 The key 
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features of Stork’s approach include a diastereoselective intramolecular type 1 Diels-Alder 
reaction to close the B and C rings, radical cyclization to set the D ring, and the same 
acyloin/Bestmann ylide combination used by Daniewski to furnish the butenolide at C17.  
 The synthesis begins by ozonolysis of the trimethysilyl enol ether of 24 to yield acyloin 
25. Reduction with NaBH4 produced the diol which was oxidatively cleaved with NaIO4 to the 
dialdehyde 26. Selective reduction of the primary aldehyde in presence of the more sterically 
hindered tertiary aldehyde was accomplished with NaBH(OAc)3. Subsequent olefination by the 
method of Yamamoto furnished diene 27 in 77% yield forming the E olefin exclusively. Next, the 
dienophile component for the Diels-Alder reaction was installed. Swern oxidation of the primary 
alcohol was followed by a dithiane Hornor-Wadsworth-Emmons reaction. Upon heating to 200oC 
in toluene, intermediate 28 underwent a type I Diels-Alder reaction to close the B and C rings in 
the desired trans orientation (compound 29) in 75% yield. Hydrolysis of the acetal at C3 with 
aqueous HCl produced a C3 ketone which was subjected to Luche reduction conditions to 
selectively generate the α-oriented hydroxy at C3 in 11:1 diastereomeric ratio. Natural steroids 
have a β-oriented alcohol at this position so inversion had to be carried out. This was accomplished 
with a Mitsunobu reaction using trifluoroacetate as the nucleophile to obtain intermediate 30. 
Cleavage of the dithiane at C14 was accomplished with trimethyloxonium tetrafluoroborate. With 
concomitant hydrolysis of the C3 trifluoromethyl ester, the C11-C12 olefin could be isomerized 
into conjugation with the C14 ketone by treatment with NaOEt to generate an extended enolate 
which could be protonated at the γ-position. The C3 hydroxy was then protected with TBSCl and 
a Grignard reagent was added to the α-face of C14 thus generating intermediate 31 in 48% yield 
over 4 steps. This Grignard addition is noteworthy because it occurs selectively to set the desired 
C14-OH in a β-orientation. Next, the D ring needed to be closed in a cis orientation. Stork and co-
24 
 
workers decided to accomplish this transformation by a radical cyclization. To do so, the terminal 
alkyne was first deprotected with TBAF and the product was then subjected to AIBN and Bu3SnH. 
The tributyltin radical adds to the terminal alkyne and the resulting vinyl radical at C17 undergoes 
an allowed 5-exo-trig cyclization with the C13-C12 olefin and the resulting C12 radical abstracts 
a proton to continue the chain propagation. Destannylation is then accomplished by treatment with 
silica gel to furnish steroid 32.  




The final consideration was installation of the butenolide ring at C17. Epoxidation of the 
exocyclic olefin at C17 was achieved with mCPBA. Treatment of the epoxide with the Lewis acid 
BF3 etherate promoted 1,2-hydride shift epoxide opening which furnished the undesired α-oriented 
aldehyde. This is an indication that the epoxidation proceeded selectively from the α-face and 
subsequent hydride shift occurred on the β-face. To invert the configuration at C17, Stork and co-
workers first converted the C17 aldehyde to a nitrile by way of dehydrating an oxime and thus 
obtaining intermediate 33 in 60% yield over 3 steps from 32. Exposure of the nitrile to LiN(Et)2 
generated a dianion which would undergo selective protonation by di-tert-butyl-4-methylphenol 
from the α-face of the steroid thus producing a β-oriented nitrile (β:α > 4:1) and completing the 
desired inversion at C17. It is noteworthy that forming the dianion by means of deprotonating both 
C17 and the C14 hydroxy was a key aspect of this inversion as the effective size of the β-face is 
increased by formation of the oxyanion at C14 and the possibility of intramolecular protonation of 
the C17 anion by the C14 hydroxy is eliminated (this process would have produced no inversion 
at C17). The same result could be achieved by TMS protecting the C14 hydroxy before the 
deprotonation-reprotonation sequence. The β-oriented nitrile was then treated with BnOCH2Li to 
furnish the benzylated acyloin at C17, intermediate 34. Hydrogenolysis of the benzylated hydroxy 
was followed by treatment with the Bestmann ylide to promote cyclization to the desired 
butenolide. The final step was acidic deprotection of the C3 silyl ether with tosic acid to produce 
digitoxigenin (35) in 59% yield over 3 steps from intermediate 34.  
2.6. Overman’s Intramolecular Heck Reaction Approach to Steroidal Cores 
 In 1996, Overman and co-workers reported a unique approach to cardenolide cores.5 Their 
strategy utilized an intramolecular Heck reaction to cyclize the B ring and set the steroid scaffold. 
In 1998, the methodology was expanded upon to include some important sites of oxidation.6 
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Importantly, their method allows the pre-installation of oxygenation at C19 and C5 while the 
implementation of the Heck reaction promotes stereospecific formation of a desired cis-β A/B ring 
junction (Scheme 2.4.). In addition, the C11 and C17 positions are functionalized and amenable 
to further derivatization toward natural cardenolides.  
Scheme 2.4. Overman’s Intramolecular Heck Approach to Cardenolide Cores. 
 
 The route starts with the Hajosh-Parish ketone. The C17 ketone was selectively reduced 
with NaBH4 from the α-face. Next, Me2NNH2 was condensed with the C9 enone and the alcohol 
at C17 was protected by TMS to furnish intermediate 36 in 85% yield over 3 steps. An extended 
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metalloenamine was generated and alkylated at the α-carbon with a primary iodide. The resulting 
C14-C15 olefin was isomerized into conjugation with concomitant hydrolysis of the C9 hydrazone 
by treatment with AcOH to form tetracycle 37. The β-oriented C17 alcohol was then mesylated 
and displaced with cyanide to produce intermediate 38. This transformation occurs with net 
retention of configuration. Next, Luche reduction of the enone at C9 produces the β-oriented 
alcohol. This alcohol servers as a directing group for subsequent epoxidation with 
VO(acac)2/TBHP. Upon reoxidation of the C9 alcohol, epoxide 39 was obtained. Reductive 
opening of the epoxide was accomplished with SmI2. The resulting enolate was trapped with TMS-
imidazole and then selectively protonated at C8 from the β-face after treatment with TBAF/SiO2.  
This sequence generated compound 40 in 80% yield and completed the installation of both the 
desired β-oriented alcohol at C14 and the β-oriented hydrogen at C8. Triflation of the C9 ketone 
produces intermediate 41 which is now ready to undergo the key transformation to set the steroidal 
core. Reaction with a palladium catalyst triggered a diastereoselective intramolecular Heck 
reaction, suggested to proceed through a transition state resembling 42, which closes the A/B ring 
junction in a cis-β orientation to furnish steroid 43 in 90% yield. Importantly, 43 contains oxidation 
at C5, C14, and C19 as well as a functional handle at C17 which could be used for butenolide 
installation as demonstrated in Daniewski’s synthesis (section 2.4.). 
2.7. Deslongchamp’s Synthesis of Ouabain 
 Ouabain (2) is one of the better known cardenolides due to its historic use and chemical 
complexity. It contains β-oriented hydroxy groups at C1, C3, C5, C14, C19, and a single α-oriented 
hydroxy at C11. It’s high level of oxygenation makes the steroid difficult to synthesize and work 
with. As a result, it has been the target of several synthetic chemists. In 2008, the group of Pierre 
Deslongchamps reported the first total synthesis of ouabagenin and ouabain (2) (Scheme 2.6. and 
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Scheme 2.7. respectively).7 Their route includes a clever Michael addition cascade to set the A 
and B rings from functionalized fragments, a diastereoselective aldol reaction to close the cis-β-
C/D ring junction, and the usual C17 acyloin/Bestmann ylide combination for installing the 
butenolide. It is important to note some of the results that Deslongchamps and co-workers recorded 
when investigating the base promoted anionic polycyclization cascade to set the steroidal core. 
Some preliminary work was done on a model system using fragments 44 and 45 in order to study 
the diastereoselectivity of the reaction (Scheme 2.5.).8 In these experiments, it was noted that the 
C/D ring junction of the product steroid 46 was formed in an undesired cis-α orientation. However, 
in Daniewski’s synthesis of a cardenolide core (section 2.4.), a similar aldol reaction was used to 
close the C ring but the desired cis-β junction was obtained. The difference in diastereoselectivity 
between these two cases is attributed to the unsaturation present at C9-C11 in the case of 
Daniewski which is not present in the model system of Deslongchamps. To overcome this issue, 
Deslongchamps and co-workers desymmetrized the D ring prior to cyclization so that only one 
ketone is available for addition and aldol closure of the C ring will proceed with complete 
stereocontrol. 
Scheme 2.5. Deslongchamp’s Preliminary Studies on a Michael/Aldol Cascade. 
 
 The synthesis begins with the heavily functionalized fragments 47 and 48 (Scheme 2.6.). 
Importantly, these fragments contain preinstalled functionality at key positions including C1, C3, 
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C7, C11, C17, and C19. A-ring fragment 47 was prepared in seven steps from cyclohexenone, and 
fragment 48 was generated in fourteen steps from the Hajosh-Perish ketone. Deprotonation of 48 
with Cs2CO3 promoted its conversion to a diene which is now susceptible to undergo a Diels-Alder 
cycloaddition with dienophile 47, depicted as transition state 49. Notably, this [2+4] cycloaddition 
proceeds in 85% yield and produces a cis-β-A/B ring junction. The product β-ketoester 50 was 
then decarboxylated upon exposure to palladium tetrakis. Next, the aldehyde at C19 was reduced 
and protected as its PMB ether. Triketone 51 was then exposed to KHMDS to promote the addition 
of C8 to C14 and close the C/D ring junction in a cis-β orientation selectively. Hydrolysis of the 
C11 acetate with K2CO3 in MeOH was followed by reduction of the C1 ketone using NaBH4 to 
obtain compound 52 in 79% yield over 3 steps. Importantly, the selective reduction of the C1 
ketone to the desired β-oriented hydroxy was only possible after saponification of the C11 acetate 
and if performed at low temperature.  
The next step was to oxidize the C5 position. To accomplish this, intermediate 52 was first 
treated with DDQ to form an orthoester and protect the alcohols at C1 and C11. Subsequent 
treatment with TBSOTf and Et3N produced the C7 silyl enol ether which was oxidized to the enone 
53 upon exposure to DDQ. The enone would then undergo selective 1,2-reduction from the α-face 
by treatment with NaBH4 to generate the β-allylic alcohol at C7. It is important to note that 
selective production of the β-oriented hydroxy at this stage is crucial for the downstream 
installation of the desired β-oriented hydroxy at C5. Directed epoxidation of the C5-C6 olefin 
could now be carried out using mCPBA to produce intermediate 54 in 82% yield over 2 steps. 
Then, mesylation of the C7 alcohol was followed by treatment with LiBH4 to nucleophilically 
displace the mesylate and open the epoxide.  
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Scheme 2.6. Deslongchamp’s Total Synthesis of Ouabagenin. 
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 Subsequent exposure to mildly acidic silica gel promoted cleavage of the orthoester. This 
completed the installation of the C5 oxygenation (intermediate 55). Selective monoacylation of 
the primary alcohol at C19 was followed by desilylation with TBAF. With tetraol 56 in hand, the 
researchers used a Tamao oxidation to install oxygenation at C3 with retention of configuration to 
obtain the desired β-oriented hydroxy. Silylation of the primary alcohol followed acylation of the 
C3/C11 alcohols furnished steroid 57 in 45% yield over 3 steps. Deslongchamps and co-workers 
then focused on installation of the C17 butenolide. First, the D ring alcohol was exposed upon 
desilylation with TBAF and oxidized to the aldehyde with DMP. Rhodium (I)-catalyzed 
methylenation with TMS diazomethane afforded olefin 58. Dihydroxylation of the exocyclic olefin 
was accomplished with OsO4/NMO. The resulting diol was then reacted with (nBu)2SnO to 
produce the cyclic tin ether 59. Treatment with NBS then promoted destannylation with selective 
oxidation of the secondary alcohol to generate a C17 acyloin. Exposure to the Bestmann ylide 
triggered the desired cyclization to the β-oriented C17 butenolide intermediate 60. Final global 
saponification of the acylated alcohols at C1, C3, C11, and C19 proceeded in 85% yield to produce 
ouabagenin (61). 
Deslongchamps and co-workers then focused on the glycosylation of ouabagenin (61) to 
complete the total synthesis of the natural cardiac glycoside ouabain (2) (Scheme 2.7.). The major 
challenge impeding this conversion is the presence of multiple hydroxy groups which make 
selective glycosylation at C3 difficult. To circumvent this, the primary alcohol at C19 was first 
protected as an acetal with the C1 hydroxy. Acylation of the remaining reactive alcohols at C3 and 
C11 was accomplished by exposing 62 to acetic anhydride. At this point, the C3 acetate could be 
selectively cleaved by careful saponification with Na2CO3 to furnish steroid 63 in 55% yield over 
2 steps. With the C3 position having the only reactive alcohol exposed, glycosylation with a 
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rhamnose derived sugar donor was performed in the presence of TMSOTf to produce glycosylated 
steroid 64 in excellent yield. Importantly, anchimeric assistance from the neighboring benzoylated 
alcohols on the sugar donor allow for complete α-selective glycosylation. Finally, deacetalyzation 
of the C1/C19 alcohols was performed and subsequent sugar debenzoylation/C11 acetate cleavage 
with Na2CO3 afforded the desired final product ouabain (2). 
Scheme 2.7. Deslongchamp’s Glycosylation of Ouabagenin to Ouabain. 
 
2.8. Baran’s Semi-synthesis of Ouabagenin 
 In 2013, Phil Baran and co-workers reported a 21-step semi-synthesis of ouabagenin (61) 
starting from the readily available steroid cortisone acetate (Scheme 2.8.).9 This preparation of 
ouabagenin is considerably shorter than any other synthesis reported to date and its key features 
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include selective C-H oxidation at C19 using a redox relay strategy, Suzuki coupling for 
installation of the butenolide moiety, and oxidation at C14 to install the β-oriented alcohol. 
 Starting from cortisone acetate, intermediate 65 was prepared in two steps including an 
oxidative cleavage and acetalization of the C3 and C17 ketones. Using a redox-relay strategy, the 
oxidative information at C11 is “donated” to the C19 position through a creative two step sequence. 
First, a solid-state Norrish type II photochemical reaction is utilized to form a C19-C11 bond to 
furnish cyclobutane 66 in 68% yield. Next, treatment with N-iodosuccinimide triggers iodination 
at C19 with concomitant cleavage of the C19-C11 bond and restoration of the C11 ketone. Baran 
and co-workers speculate the presence of a transient hypoiodite species which promotes 
chemoselective homolysis of the C19-C11 bond followed by radical recombination with Iodine. 
Subsequent exposure to TiCl4 and AgOAc promotes hydrolysis of the C19 primary iodide with 
concomitant deprotection of the C3 ketone to produce diketone 67. The C19 hydroxy was then 
used to direct epoxidation to the β-face of the A ring enone with H2O2 as the oxidant. Introduction 
of unsaturation at the C1-C2 bond was accomplished by SeO2 oxidation to generate enone 68. 
Another directed epoxidation with H2O2 gave the desired bis-epoxide and completed the necessary 
oxidation of the C1 and C3 positions. Extensive investigation was then required to find the optimal 
conditions for opening both epoxides. Eventually, Baran and co-workers determined that reduction 
with aluminum amalgam in water gave the best results. Thus, the bis-epoxide could be reductively 
opened to triol 69 in 28% yield over 4 steps. Next, The C1/C19 alcohols were protected as an 
acetonide and the C3 ketone was selectively reduced to the β-oriented hydroxy using super 
hydride. During the C3 reduction, the alcohols at C3 and C5 were tethered as their ethyl boronic 




Scheme 2.8. Baran’s Semi-synthesis of Ouabagenin from Cortisone Acetate. 
 
Next, thermodynamic Birch reduction of the C11 ketone of intermediate 70 furnished the 
desired α-oriented hydroxy exclusively. This reduction is important to note because it is a 
commonly used technique for stereoselective reduction of ketones at C11 to produce the 
thermodynamic α-oriented alcohol. Deacetalization of the C17 ketone with PPTS afforded 
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intermediate 71 in 69% yield over 2 steps. The next goal was stereoselective installation of the 
C14 oxygenation. First, Saegusa-Ito oxidation of the D ring ketone generated an enone. The olefin 
could then be deconjugated to the C14-C15 position upon treatment with SiO2 and perfluorinated 
toluene. Importantly, the perfluorinated solvent proved to be an essential component for the 
success of this deconjugation. The application of Mukaiyama hydration conditions using cobalt 
and oxygen successfully oxygenated the olefin at the C14 position in an 8:1 diastereomeric ratio 
favoring the desired β-oriented hydroxy steroid 72. The final task was to append the butenolide 
ring at C17. To accomplish this, the D ring ketone was first converted to a vinyl iodide using the 
Barton procedure. Next, Stille coupling using known tributylstannyl butenolide 73 was employed 
for installing the heterocycle and producing intermediate 74 in 42% yield over two steps. Attempts 
to directly hydrogenate the C16-C17 olefin at this stage occur predominantly from the β-face to 
yield the undesired α-oriented butenolide at C17. To circumvent this, the olefins are reductively 
isomerized using CoCl2 and NaBH4 to introduce unsaturation between the C17 position and the 
butenolide ring. Next, Barton’s base was used to isomerize the olefin back into conjugation with a 
3:1 preference for the desired β-oriented butenolide ring. The final transformation was acid 
promoted deprotection of the A ring alcohols to furnish ouabagenin (61). 
2.9. Inoue’s Synthesis of 19-Hydroxysarmentogenin 
 In 2013, Inoue and co-workers reported the first total synthesis of the cardenolide 19-
hydroxysarmentogenin (1) proceeding in 34 steps.10 The key steps include a bromine promoted 
fragment coupling and a radical cyclization to close the B ring. The first task was to synthesize the 
necessary fragments 80 and 83 in preparation for their coupling (Scheme 2.9.). The A/B ring 
fragment was prepared from (S)-perillaldehyde (75). Diels-Alder reaction with Rawal’s diene 76 
proceeded with the expected regio- and facial selectivity to provide the cis-β-A/B ring junction. 
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After hydrolysis of the β-amino silyl enol ether, the bicyclic enone was obtained. Reduction with 
LiAlH4 produced a diol and the allylic alcohol at C7 was selectively reoxidized with MnO2 to 
obtain enone 77. Next, the C19 alcohol was acylated and the exocyclic olefin at C3 was 
dihydroxylated and then oxidatively cleaved to furnish intermediate 78 in 48% yield over 5 steps. 
Baeyer-Villager oxidation of the C3 acyl group was achieved upon treatment with mCPBA and 
global saponification yielded acetal 79. The diol was then bis-TBS protected. Treatment with PPTS 
promoted the regioselective desilylation of the C7 acetal with concomitant reversion to the ketone 
in excellent yield, thus affording key fragment 80 in nine total steps. 
Scheme 2.9. Inoue’s Synthesis of Key Fragments Toward 19-Hydroxysarmentogenin. 
  
 The D ring fragment was prepared from diketone 81. Exposure to DIBALH caused both 
ketones to be reduced selectively from the face opposite the terminal olefin. The resulting diol was 
bis-TBS protected and the olefin was ozonolyzed to furnish aldehyde 82. Horner-Wittig olefination 
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was utilized to convert the aldehyde to a methyl enol ether. Finally, the alcohols were deprotected 
with TBAF and subsequently acylated to complete the synthesis of D ring fragment 83 in six total 
steps and 29% yield over 6 steps. 
With the two key fragments in hand, Inoue and co-workers focused on completing the 
target 19-hydroxysarmentogenin (Scheme 2.10.). The first goal was coupling of the fragments and 
cyclizing the steroidal core. To achieve this, the D ring fragment was reacted with molecular 
bromine to generate the dibrominated intermediate 84. The A/B ring fragment 80 was then 
introduced and the C19 alcohol underwent displacement of the activated bromide to furnish acetal 
85 and successfully couple the two fragments.  
Next, Inoue and co-workers planned a radical cyclization to form the C9-C11 bond, closing 
the C ring. By treating tricycle 85 with Et3B, O2, and (TMS)3SiH, the remaining bromide is 
abstracted and the alkyl radical adds to the B ring enone thus forming the desired connection in a 
stereoselective manner, favoring the α-oriented hydrogen at C9 and furnishing tetracycle 87. A 
proposed stereochemical model for this radical addition is depicted as intermediate 86. Next, the 
acetal was eliminated under acidic conditions using meta-nitrobenzenesulfonic acid pyridinium 
salt (mNBSP) to generate a cyclic enol ether and merge the mixture of diastereomers into a single 
compound. During this elimination, some material underwent desilylation at C3, so the compound 
was fully resilylated using TBSOTf to give intermediate 88 in 65% yield over 4 steps from 80. 
Next, the D ring acetates were cleaved and oxidized to ketones. This sets the stage for an important 
aldol reaction to close the C ring and set several stereocenters. Treatment with KHMDS generates 
the B ring enolate which then adds to the C14 ketone of the D ring to furnish steroid 89. It is 
important to note that this aldol reaction occurs stereoselectively to yield a trans-B/C ring junction 
and cis-β-C/D ring junction which is necessary for synthesizing natural cardenolides.  
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Scheme 2.10. Inoue’s Completion of 19-Hydroxysarmentogenin. 
 
Next, the C7 position is deoxygenated using the Barton-McCombie radical protocol over a 
three-step sequence to yield compound 90 in 50% yield over 3 steps. The cyclic enol ether is then 
ozonolyzed, producing a C11 ketone and C19 formylated alcohol. Addition of ammonium 
hydroxide then promoted saponification at the C19 alcohol. The D ring ketone is then protected as 
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its silyl enol ether using TBSOTf, this produces steroid 91. Protecting the D ring ketone was a 
necessary step for the ensuing Birch reduction which provides exclusively the thermodynamically 
preferred α-oriented alcohol at C11. The D ring silyl enol ether is quickly and selectively 
deprotected by exposure to TBAF.  
Intermediate 92 is then subjected to the Barton conditions for vinyl iodide formation at C17 
followed by Stille cross coupling with stannylated butenolide 73 to generate the coupled product 
93 in 81% yield over 2 steps. The final goal was to install the necessary chirality at C17. Inoue and 
co-workers noted that simple hydrogenation of 93 produces primarily the undesired α-oriented 
butenolide ring. To overcome this, the C14 alcohol is protected as its TMS ether; this provides 
steric occlusion of the β-face. Now, hydrogenation proceed to deliver hydrogen predominantly 
from the α-face, affording an 8:1 mixture of β:α – oriented butenolides. Lastly, the molecule is 
subject to HCl/MeOH to promote global desilylation and furnish the target 19-
hydroxysarmentogenin (1) in 48% yield over 3 steps. After completing this synthesis, Inoue and 
co-workers went on to apply the same methodology toward the successful total synthesis of 
ouabagenin (61) in 2015.11 
2.10. Conclusion 
 There have been many landmark efforts toward synthesizing cardiotonic steroids. The 
primary challenges include setting the steroidal core, introducing oxygenation, controlling 
stereochemistry, and installing the C17 butenolide ring. Different approaches described in this 
chapter accomplish these tasks in various ways, sometimes using similar techniques. However, 
semi-synthetic techniques remain hindered by the narrow landscape of attainable chemical 
analogues while total syntheses are often unfavorably long. There continues to be a demand for 
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Concise Enantioselective Synthesis of Oxygenated Steroids via Cu(II)-BOX-Catalyzed 
Michael Addition and Intramolecular Aldol Cyclization Reactions1 
(A portion of this work has been published in: Cichowicz, N. R.; Kaplan, W.; Khomutnyk, Y.; 
Bhattarai, B.; Sun, Z.; Nagorny, P. “Concise Enantioselective Synthesis of Oxygenated Steroids 
via Sequential Copper(II)-Catalyzed Michael Addition/Intramolecular Aldol Cyclization 
Reactions” J. Am. Chem. Soc. 2015, 137, 14341.) 
3.1.  Rationale for New Synthetic Approach 
 As discussed in chapter 2, various research groups have successfully developed unique 
approaches for the total synthesis of cardenolides and other steroids.2 One of the main hurdles 
associated with these approaches is modularity; and the design of more drug-oriented approaches 
remains a formidable challenge. When a synthetic route is conceived specifically to access a single 
complex target, it is often not amenable to diversification and the accessible chemical space 
surrounding the target is limited. For the purpose of exploring new therapeutic agents, it is highly 
desirable that a methodological approach features access to an entire class of natural products. In 
this regard, modularity and plasticity should be ingrained in the synthetic foundation of the 
approach. Designing such a method requires a convergent technique. Ideally, unique fragments 
containing pre-installed functional handles and diversity elements can be coupled into a steroidal 
core in an assembly-line like practice. Importantly, the process of coupling the fragments needs to 
be robust enough to accommodate a wide range of structurally diverse fragments. By inputting the 
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oxidative complexity and functional handles on the chemically simpler fragments, one can 
circumvent the need for difficult, sometimes prohibitively so, late-stage functionalizations and 
redox manipulations on more complicated intermediates; especially when those late-stage 
intermediates are scarce.  
  In addition to controlling the peripheral sites of substitution and levels of oxidation, 
stereochemical modulation is a key consideration. Steroidal systems are rigid by nature as a result 
of their fused tetracyclic array and their internal stereocenters have a profound impact on the 
overall 3D shape of the molecule. As such, changing stereochemical patterns of the ring system or 
peripheral moieties can significantly alter the binding contacts within the Na+/K+ATPase pocket.3 
A useful approach to synthesizing cardenolides and their analogues must incorporate access to 
chemical space which encompasses a diverse pattern of substitution, oxidation, and 
stereochemistry. 
3.2.  Methodological Design Overview 
 The method designed and delineated in this chapter originated from a key conceptual 
disconnection of the steroidal framework. A two-step approach to the steroidal core was 
envisioned as illustrated in Scheme 3.1. A nucleophilic β-ketoester (94, the A ring) is added 
conjugatively to an electrophilic enone (95) to produce a Michael adduct (96), which can 
subsequently undergo two intramolecular aldol reactions to close the B and C rings and set the 
steroidal frame (97). The key features of this approach are the capacity to pre-install functionality 
on the starting fragments, specifically at C3, C5, C7, C11, C14, C17, and C19, controlling internal 
stereocenters with asymmetric catalysis, and setting the steroidal core in only two steps. 
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Scheme 3.1. General Overview of Two-step Approach to Steroidal Core. 
 
3.3. Michael Donor Fragment Design 
 The Michael donor fragment houses the eventual A ring as well as carbons 1-5, 10, and 19. 
The β-ketoester moiety, which grants the fragment its nucleophilicity at C10, affords pre-installed 
oxygenation at the key C5 and C19 positions. In order to make steroidal cores viably accessible 
through this methodology, the Michael donor fragments must be readily accessible, either through 
commercial vendors or a small number of synthetic steps. One of the key advantages of the 
approach outlined in section 3.2. is the ability to access steroids with expanded or contracted A/D 
ring sizes, a type of architecture which may be difficult to access semi-synthetically. As such, 
efforts were focused on the Michael reaction using two donor fragments 94 and 98, Figure 3.1. 
Fragment 94 is a six-membered A ring Michael donor which would provide the natural series of 
steroids, while fragment 98 is a five-membered Michael donor which would generate steroid-like 
scaffolds with contracted A rings, allowing access to a unique class of steroidal chemical space. 
Both are inexpensive and commercially available. 




3.4.  Michael Acceptor Fragment Design  
 The Michael acceptor fragment contains the eventual D ring and the carbon chain which 
forms the eventual B and C ring architecture. Oxygenation is preset at key positions including C7, 
C14, and C17. As with the Michael donors, the acceptor fragments must be amenable to 
modification and readily accessible. In order to explore the tolerance of the desired approach to 
variations in the size of the D ring and substitution at C13, various enones were designed and 
synthesized to serve as coupling partners. These Michael acceptors are shown in Scheme 3.2.  
Scheme 3.2. Synthesis and Structure of Michael Acceptor Fragments. 
 
Importantly, each acceptor could be synthesized in multi-gram quantities in just two steps. 
Michael acceptors 95 and 103 represent precursors to the natural steroid series with a 5-membered 
D ring; the only difference being the presence of a -Me group as opposed to an -Et group at C13, 
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respectively. Importantly, this simple distinction exemplifies the types of difficult modifications 
attainable through a modular totally synthetic approach. It would be very difficult to chemically 
transform a C13 methyl group into an ethyl group through semi-synthetic techniques; whereas this 
modality is readily achievable through the approach described in this chapter. Fragment 106 would 
result in a steroid-like derivative containing a 6-membered D ring. Finally, a linear enone (107), 
containing no D ring was also used in these studies. Fragments 103 and 106 were prepared by Dr. 
Nathan Cichowicz.  
The synthesis of enones 95 and 103 are similar and proceed from the commercially 
available diketones 99 and 101, respectively. Stirring the diketones with acrolein in water 
facilitates a Michael reaction which produces the corresponding aldehydes 100 and 102. These 
aldehydes can undergo Wittig olefination with 1-(triphenylphosphoranylidene)-2-propanone in 
THF to furnish the desired fragments. The route to fragment 106 is different from the previous 
fragments because the starting diketone has a smaller population of the enol tautomer in solution 
than the 5-membered diketones. As such, the process was modified by Dr. Cichowicz by adding 
base and using an aprotic solvent. This proved effective for promoting the conjugate addition to 
acrolein and generating aldehyde 105. The same Wittig olefination procedure can now be used to 
convert the aldehyde to the target enone 106. Finally, the linear Michael acceptor 107 is 
commercially available. 
3.5. Investigation of Racemic Michael Reactions 
 The preliminary investigative work described in this section was performed by Dr. Nathan 
Cichowicz. The construction of vicinal quaternary and tertiary stereocenters via conjugate addition 
is challenging and not well precedented due to the steric resistance to forming such a moiety.4,5 As 
such, the first step in developing this methodology was to investigate the racemic Michael 
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additions of the aforementioned fragments in order to determine the optimal conditions for 
promoting such a difficult transformation. After screening several acids and bases for their ability 
to promote the Michael addition of 94 to enone 95, Dr. Cichowicz determined that Cu(OTf)2 was 
the most reliable catalyst for promoting conversion to Michael adduct 96 and controlling 
diastereoselectivity (Scheme 3.3.). 
Scheme 3.3. Copper(II)-Triflate Catalyzed Michael Addition of Fragments 94 and 95. 
 
The reaction proceeded with 86% yield and 4:1 diastereomeric ratio (dr) favoring the 
desired natural isomer. With the optimal catalyst in hand, the substrate scope was investigated. To 
this effect, each Michael donor and acceptor were coupled using the Cu(OTf)2 conditions 
elucidated from the catalyst screen. The results are shown in Scheme 3.4. Fortunately, each donor 
94 and 98 could be successfully coupled to enone fragments 95, 103, 106, and 107, to produce 
Michael adducts 108-117 in good conversion and diastereomeric ratio. 
Several trends became apparent. Reactions with the 5-membered A ring fragment 98 
generally proceeded faster and with greater diastereoselectivity than its 6-membered counterpart 
94. Specifically, adducts generated from ketoester 98 had diastereomeric ratios (dr) generally 
better than 17:1, whereas adducts produced from 94 showed dr around 5:1. It is proposed that 
enolization of the 5-membered ketoester is more facile compared to the 6-membered ketoester due 
to an enhanced favorability of unsaturation in 5-member rings resulting from decreased torsional 
strains; thus, a larger population of the nucleophilic tautomer might be present at a given time, 
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causing faster reaction. Additionally, slower kinetics are observed upon increasing steric hindrance 
of the enone, and adducts 111 and 117 require extended reaction times. Overall, a good catalytic 
system was discovered for promoting the diastereoselective Michael addition of various β-
ketoesters to 2-substituted enones in order to produce interesting Michael adducts with unique 
steroidal features including expanded and contracted ring sizes and peripheral substitutions. The 
next goal of further developing this approach was incorporating an asymmetric component for 
production of enantioenriched steroids and steroid-like precursors. 




3.6. Catalyst Screen for Enantioselective Michael Additions 
 The process of developing a novel method for producing cardenolide cores requires 
stereocontrol. Due to the chiral nature of biological targets and variable bioactivity of enantiomeric 
compounds, it is strongly desirable that synthetic approaches toward natural products allow access 
to highly enantioenriched compounds. To incorporate this aspect, an enantioselective variant of 
the Cu(II)-catalyzed Michael additions was investigated. The first attempts utilized literature 
reported chiral catalysts for promoting the asymmetric Michael reactions. There exist only few 
reported conditions for asymmetric synthesis of vicinal tertiary and quaternary stereocenters via 
conjugate addition. Three of the studies most applicable to ours are illustrated in Scheme 3.5.6-8  




However, attempts to use the reported chiral catalysts 120, 124, or 128 for promoting the 
asymmetric Michael addition of 94 and 95 failed, and other methods were sought. The first task 
toward developing an asymmetric protocol for the Michael reaction was a catalyst screen. With 
copper(II) serving as the Lewis acid, the bisoxazoline class of ligands were investigated. There is 
considerable literature review on the use and effectiveness of these ligands, particularly when 
complexed with copper(II) salts, for the purpose of catalyzing Mukaiyama Michael additions.9-12 
However, some previous attempts to use Cu(II)-BOX catalytic systems toward the Michael 
addition of 1,3-dicarbonyls and enones were unable to produce enantioselectivity.13,14 In order to 
determine the best method and ligand for promoting the enantioselective Michael additions of our 
substrates, various Cu(II)-BOX/PyBOX catalysts were synthesized and screened alongside Dr. 
Nathan Cichowicz and Dr. Zhankui Sun.  
Early on in the catalyst screening stage we discovered the chiral enrichment of our Michael 
adducts via column chromatography with an achiral stationary phase. This phenomenon occurs as 
a result of diastereomeric interactions between the enantiomers of the substrate. If a sample 
contains some enantiomeric excess and is prone to forming diastereomeric dimeric complexes, it 
is possible for the minor enantiomer to be dragged (via complexation) either ahead of or behind 
the pure portion of the major enantiomer during chromatography. The result of this effect is a 
gradual change in enantiomeric excess of the material eluting from the column. Over the course of 
our studies, we discovered that our chiral Michael adducts were prone to this self-promoted 
enantioenrichment. As a result, we had to adjust our method of determining enantiomeric excess 
to ensure accurate measurement. This was accomplished by assaying the diastereomeric mixtures 
of Michael adducts. At this stage, we chose to reevaluate the catalyst screen. The results of the 
revised screen are summarized in Scheme 3.6.  
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Scheme 3.6. Copper(II)-Based Catalyst Screen for Asymmetric Michael Reactions. 
 
After extensive screening, the first important discovery was the improved reactivity of 
Cu(SbF6)2 over the original Cu(OTf)2 system in the presence of BOX ligands. It is suggested that 
the non-coordinating hexafluorantimonate anion effectively boosts the reactivity of the copper 
center and allows lower reaction temperatures to be employed without a large setback to reaction 
times. This capacity to lower the reaction temperatures resulted in a significant improvement in 
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the enantio- and diastereoselectivity. Ligands with tert-butyl or benzyl dimethyl-bisoxazoline 
substituents (catalysts 130, 131, 140, and 141) did not promote the desired reaction. Moreover, 
PyBOX ligands and scandium proved disappointingly ineffective. It is also worth noting that the 
use of a cyclopropyl bridge (135) as opposed to a gem-dimethyl bridge (134) on the ligand often 
afforded improved yields and diastereoselectivity. Eventually, it was determined that the best 
combination of yield and selectivity could be obtained with catalyst 139 under neat conditions at 
-10oC for 48 hours. 
When comparing the results from the catalyst screen (performed with Michael donor 94) 
to earlier studies with Michael donor 98, we observed some interesting results. We found that 
while donor 94 would provide the best results with diphenyl catalyst 139 at -10oC under neat 
conditions, the 5-membered β-ketoester 98 had originally been optimized with tetraphenyl catalyst 
136 at -20oC in THP as a solvent, providing 93% ee upon Michael reaction with substrate 95. This 
resulted from the observation that donor 98 provided improved enantioselectivities with catalyst 
136 as compared to catalyst 139 when run at room temperature and in THF (Scheme 3.7.). We 
considered the possibility of describing two unique substrate specific protocols, one for each donor 
94 and 98 using catalysts 139 and 136, respectively. However, in light of our discovery that donor 
94 was exhibiting improved selectivities under neat conditions, we fortunately revisited the 
optimization of donor 98 and found that at -10oC, and under neat conditions, the use of catalyst 
139 in conjunction with acceptor 95 provided highly satisfactory results of 96% ee, >20:1 dr, and 
87% yield. This aspect of improved selectivities under neat conditions is noteworthy and may 
result from fewer competing coordinative interactions from solvent molecules. This allowed a 




Scheme 3.7. Optimization of Asymmetric Michael Addition with Donor 98. 
 
Another course which we investigated was to perform the asymmetric Michael reactions 
via a Mukaiyama-Michael approach. Given the large steric demands of the Michael additions we 
were studying, we postulated that the silyl enol ethers of the Michael donors 94 and 98 may display 
enhanced reactivity. This method essentially locks the Michael donors in their nucleophilic 
tautomer, increasing the chance of productive collision with an activated Michael acceptor. To 
investigate this possibility, I generated the TES enol ether of Michael donor 98 and treated it with 
enone 95 in the presence of various Cu(II)-BOX/PyBOX catalysts (Scheme 3.8.).  
As anticipated, the Michael reaction would readily proceed. However, the use of various 
Cu(II)-BOX catalysts, and attempts to optimize the reaction were unsuccessful and the 




Scheme 3.8. Attempt at Mukaiyama-Michael Approach. 
 
We reasoned that silylation of 98 inhibits its ability to effectively coordinate with the Cu(II) 
center. In order to obtain high selectivities, it is essential that the coordinative interactions involved 
in the transition state are compact and well defined. This type of coordination is best attainable 
with a bidentate substrate, which is a feature of Michael donor 98 that is destroyed upon silylation. 
Generally, selective Mukaiyama-Michael reactions are done with bidentate Michael acceptors 
containing 1,3-dicarbonyl motifs, allowing tight bidentate complexation within the chiral pocket.9-
12 This feature is absent in the Michael acceptors we are using and is likely the reason that the 
attempts at Mukaiyama-Michael reactions within our system were unsuccessful. In light of these 
disappointing enantioselectivities, we decided to abandon this Mukaiyama-Michael approach in 
favor of the more reliable and selective Michael additions using the unsilylated donors 94 and 98. 
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3.7.  Substrate Scope for Enantioselective Michael Reactions and Proposed Mechanism 
After determining the optimized catalyst and conditions for the enantioselective Michael 
reaction, the substrate scope was again explored to investigate selectivities in unnatural steroid-
like systems. With the assistance of Dr. Cichowicz, I treated Michael donors 94 and 98 with 
Michael acceptor fragments 95, 103, 106, and 107 under the optimized Cu(SbF6)2 –139 system at 
-10oC for either 24 or 48 hours to generate a library of enantioenriched adducts 96, 143-149 
(Scheme 3.9.). 
Scheme 3.9. Substrate Scope for Enantioselective Michael Addition. 
 
 Due to the quicker reaction time of the 5-membered fragment 98, those reactions were 
complete within 24 hours; whereas the Michael additions with donor 94 required 48 hours to reach 
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completion. Yields were excellent and ranged from 82% to 95%. The diastereoselectivity was also 
good and ranged from 4:1 to 10:1 for donor 94, and from 19:1 to >20:1 for donor 98. This follows 
the same trend noted earlier of better diastereoselectivity with the 5-membered β-ketoester. Lastly, 
the enantiomeric excess was greater than 90% for each adduct and up to 96% at the highest. 
Overall, a library of steroid and steroid-like precursors was constructed in a single enantioselective 
step with excellent yield, enantioselectivity, and diastereoselectivity for each case. Importantly, 
the method developed allows construction of the Michael adducts containing vicinal quaternary 
and tertiary stereocenters and with the desired stereochemical configuration at both C9 and C10.  
 Based on our work, we propose a mechanism for the Cu(II)-BOX-catalyzed Michael 
additions depicted in Scheme 3.10. The Cu(II)-BOX complex 139 undergoes chelation with the 
enol tautomer of Michael donor 94. This provides planar complex I-94. The coordination of a 1,3-
dicarbonyl Michael donor to the Lewis acidic copper center promotes electron withdrawal of the 
carbonyls, resulting in increased acidity of the Michael donor. Subsequent coordination of the 
copper center with the Michael acceptor promotes activation of the enone LUMO and the resulting 
conjugate addition of donor 94 within the chiral pocket of the BOX ligand, generating the 
zwitterionic complex I-96. A rapid proton transfer can occur from the C5 carbonyl to the resulting 
enolate, affording the catalyst-adduct complex I-97. Finally, the Michael adduct is decomplexed 







Scheme 3.10. Proposed Mechanism of Cu(II)-BOX-catalyzed Michael Additions.  
 
3.8. Cyclization of Michael Adducts into Steroidal Cores 
 After successfully developing an asymmetric variant of the key Michael reaction, 
conditions for the cyclization step were explored. In order to completely set the steroidal scaffold, 
the Michael adducts must undergo a double aldol cyclization. The first aldol must occur between 
C6 and the C5 carbonyl of adduct 96, thus closing the B ring, while the second aldol must form a 
bond between C8 and the C14 carbonyl, closing the C ring and furnishing a full steroid core 150 
or 151 (Scheme 3.11.). This process also sets three to four new stereocenters (C5, C8, C13, and 
C14) and the best conditions must provide adequate diastereocontrol.  
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Scheme 3.11. Approach to Cyclization of Michael Adducts. 
 
In the interest of pursuing biological evaluation of both natural and unnatural cardenolides, 
the goal in these studies was to delineate stereodivergent cyclization conditions to allow for the 
production of unique steroidal isomers. Controlling the internal ring junction stereocenters is a key 
tenant of our approach. The configuration at the ring junction carbons has a profound effect on the 
overall shape of the steroid and can readily modulate binding contacts in such rigid ring systems. 
We are interested in exploring how this region of chemical space can affect isoform selectivity and 
antiproliferative activity. In order to accomplish this, multiple cyclization procedures must be 
developed to provide access to unique ring junctions. Initial screening studies performed by Dr. 
Cichowicz were aimed at understanding how different conditions favor discrete steroidal products. 
His studies revealed the production of four major steroidal scaffolds depending on the conditions 
used. A summary of the conditions and results are shown in Table 3.1.  
Many conditions provided insufficient conversion or selectivity (entries 1, 2, 6-8). 
However, the use of DBU in refluxing THF delivered steroid 153 exclusively and in high isolated 
yield (94%, entry 4). Steroid 153 is the result of an aldol addition at C5 which forms a natural cis-
β-A/B ring junction and an aldol addition at C14 which provides an unnatural cis-α-C/D ring 
junction. In addition, the newly formed stereocenter at C8 has an absolute configuration of R, 
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forming the desired trans-B/C ring junction. The origin of this selectivity is discussed in section 
3.9.  
Table 3.1. Major Products from Cyclization of Michael Adduct 96. 
 
Entry Conditions Conversion 
(yield) 
Products Selectivity 
1 D- or L-proline, DMF, r.t., 24 h 0   
2 TiCl4, Et3N, THF, -78 to 0oC decomposition   
3 p-TSA, toluene, reflux, 18 h >98 155 only 
4 DBU, THF, reflux, 18 h >98 (94) 153 only 
5 piperidine, THF, reflux, 18 h >98 153 only 
6 piperidine, LiCl, THF, reflux, 18 h >98 153,152,155,154 10:8:43:39 
7 KHMDS (1 eq.), THF, r.t., 24 h >98 152,155,154 35:50:15 




With good conditions for the exclusive production of steroidal core 153, additional 
conditions were explored to investigate the possibility of selecting for other steroidal scaffolds 
starting from the same Michael adduct 96. After exploring the use of stronger bases and fine tuning 
the reaction conditions, Dr. Cichowicz discovered that Cs2CO3 in DMF at 140
oC would effectively 
promote the cyclization of adduct 96 into steroid 154 exclusively (entry 9). Importantly, scaffold 
154 results from aldol condensation across C5-C6, producing an enone, with closure of the C/D 
ring occurring with a cis-β orientation. This replicates the stereochemical pattern of natural 
cardenolides at all positions with stereogenic carbons. In short, we were able to discover 
stereodivergent conditions for the cyclization of Michael adduct 96 into unique steroidal cores 
with high yield and selectivity. 
3.9. Origin of Stereodivergent Cyclization Results 
 In the interest of understanding the physical origin of the stereodivergence observed during 
the cyclization studies, some observations, calculations, and previously reported results were 
considered. Over the course of our studies, we have observed some trends in factors controlling 
the diastereoselectivity of the cyclization step. These observations are summarized in Scheme 
3.12. Importantly, the trends described here mirror the results noted by Deslongchamps during his 
studies on polyanionic cyclizations of steroidal cores.2g,2h There are four likely reaction pathways 
for completing the cyclization of a Michael adduct into a steroidal core. These are labeled paths 1-
4. In paths 1 and 2, the C ring is closed prior to the B ring. In these cases, we observe exclusive 
formation of a monocyclized compound with a cis-α-C/D ring junction, intermediate 156. At this 
point the reaction pathway can follow one of two options. 
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Scheme 3.12. Suggested Pathways for Diastereoselective Michael Adduct Cyclization. 
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 In path 1, the B ring is closed via an aldol reaction which halts prior to dehydration of the 
resulting C5 hydroxy, producing steroid 153. In path 2, the B ring is closed via an aldol 
condensation reaction which generates an olefin at C5-C6 (155). In either case, the C/D ring 
junction remains in a cis-α orientation. In contrast, paths 3 and 4 begin with closure of the B ring 
prior to closure of the C ring. This can proceed via aldol reaction, path 3, producing monocyclized 
intermediate 157, or by means of an aldol condensation, path 4, producing enone 158. Subsequent 
closure of the C ring proceeds in a diastereoselective fashion depending on the absence (path 3) or 
presence (path 4) of unsaturation at C5-C6. In the case of a path 3, containing a C5 hydroxy group, 
closure of the C ring proceeds stereoselectively from 157 to furnish an unnatural cis-α-C/D ring 
junction 153, the same product which results from path 1. However, when the B ring has closed 
via aldol condensation path 4, producing enone 158, subsequent C ring closure proceeds 
selectively to yield the natural cis-β oriented C/D ring junction steroid 154.  
The cyclization step was investigated computationally (DFT, geometry optimization, 
B3LYP, 6-31+G*). Based on these DFT calculations, the cis-α-C/D junction product 153 resulting 
from intermediate 157 is thermodynamically preferred by 1.8 kcal/mol over its cis-β-C/D junction 
congener 152 (path 3). On the other hand, the natural cis-β-C/D product 154 produced from enone 
158 is thermodynamically more stable than its cis-α-C/D isomer 155 by 2.1 kcal/mol. We suggest 
this outcome is a result of torsional or angle strains introduced by the C5-C6 unsaturation which 
dictate a unique confirmation of the A and B rings. This strain bias may be effectively 
“transmitted” through the ethylene tether at C9 and could impose a conformational preference on 
the D ring, orienting the pro-cis-β-C14 carbonyl for aldol addition. Such a conformational bias 
would be absent in the case of path 3, intermediate 157, wherein the C5-C6 bond is saturated. It is 
likely, though not necessary, that the factors which cause a thermodynamic preference for the 
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formation of cis-β-C/D junction product 154 from enone 158 are also present in the transition state 
(162) leading to that product. 
 Lastly, it was found that steroids containing a cis-α-C/D ring junction with C5-C6 
unsaturation (155) could be epimerized to the thermodynamically preferred cis-β-C/D junction by 
means of reversible aldol reaction. By treating steroids of structure 155 with base, the C14 hydroxy 
can be deprotonated and the resulting alkoxide is able to undergo a retro-aldol reaction. This puts 
the opening and closing of the C ring in flux and promotes thermodynamic equilibration between 
the two possible C/D junction stereoisomers. In this case, the presence of unsaturation at the C5-
C6 bond imposes a preference for the cis-β-C/D junction. As a result, we can observe the base 
promoted epimerization of the C/D ring junction. 
3.10. Stereodivergent Cyclization of Adducts to a Library of Steroidal Cores 
With effective conditions in hand for promoting the diastereoselective cyclization of 
Michael adducts, a library of natural and unnatural steroidal cores was synthesized. With the help 
of co-worker Bijay Bhattarai, Dr. Cichowicz applied the optimized cyclization procedures to the 
previously prepared Michael adducts. DBU in refluxing THF was used to promote the formation 
of cis-α-C/D steroidal scaffolds (Scheme 3.13.). Steroidal cores 153, 163-167 containing an 
unnatural cis-α-C/D junction could be obtained in good yield and excellent diastereomeric ratio 
with no erosion of enantiomeric access. Steroid-like substrates containing expanded 6-membered 
D rings (164, 167) and contracted 5-membered A rings (165-167) could be readily accessed. In 
addition, the formation of C13 ethyl substituted products (163, 166) could be achieved; such an 
architecture would be very difficult to generate semi-synthetically. The stereochemistry of 
products 153 and 165 were determined unambiguously by X-ray crystallographic analysis. 
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Scheme 3.13. Formation of cis-α-C/D Steroidal Scaffolds via DBU Promoted Cyclization. 
   
After successfully synthesizing a library of steroid and steroid-like cores with unnatural 
configuration at the C/D ring junction, attention was turned toward the selective production of 
steroidal scaffolds with a natural cis-β-C/D junction (Scheme 3.14.). Unfortunately, the initially 
discovered conditions of Cs2CO3 in DMF at 140
oC proved ineffective. Only the natural series 
steroidal scaffold with a 6-membered A ring and 5-memebered D ring could be reliably cyclized 
with these conditions; other substrates would provide a complex mixture of degraded products. As 
such, a new approach was investigated. With an improved knowledge of the factors which govern 
the configuration of the C/D ring junction, we envisioned a two-step cyclization procedure. First, 
the B ring would be closed via an aldol condensation followed by subsequent base-promoted aldol 
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reaction to close the C ring. This approach would allow complete control over the introduction of 
unsaturation at the C5-C6 bond prior to the key C ring closure. Based on our previous research, 
we anticipated that this mode of reaction would preferentially deliver the natural cis-β-C/D 
junction. 
Scheme 3.14. Two-step Cyclization Approach to cis-β-C/D Steroidal Cores. 
 
The aldol condensation closure of the B ring could be effectively produced by treatment 
with pyrrolidine and acetic acid in ethyl acetate, presumably via an enamine formed at C7. 
Subsequent closure of the C ring was then accomplished upon treatment with metal 
hexamethyldisilazides in THF. As expected, this C8-C14 bond forming reaction to set the steroid 
core would furnish the desired cis-β-C/D junction orientation. Accordingly, steroids 154, 168, and 
169 could be synthesized using this two-step approach (Scheme 3.15.). In addition, modified 
Hajos-Parish and Wieland-Miescher ketones 170 and 171, respectively, could be produced upon 
cyclization with pyrrolidine and acetic, but cannot be further cyclized due to the absence of 
available D ring carbonyls. This two-step procedure was successful in delivering the desired 
stereocontrol in good yields and without erosion of the enantiomeric excess. In the case of 
producing steroid 169, it was found that cyclization with LiHMDS in THF provided insufficient 
diastereoselectivity. After some investigation, it was found that the thermodynamic product could 
biased by refluxing with NaHMDS in toluene.  
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Scheme 3.15. Synthesis of cis-β-C/D Steroidal Cores Via Two-step Protocol. 
 
Overall, a library of structurally diverse steroid and steroid-like compounds were 
synthesized. The key aspects of this concise methodology include the enantio- and 
diastereoselective Cu(II)-BOX catalyzed Michael reaction which forms sterically congested 
vicinal quaternary and tertiary stereocenters, stereodivergent cyclization conditions used to control 
for natural cis-β or unnatural cis-α-C/D ring junctions, and pre-installed functional handles at C5, 
C7, C14, C17, and C19. Future work is aimed at increasing the complexity of the substrates and 




3.11. Experimental (as appears in the corresponding publication)1 
General 
 All reagents and solvents were purchased from commercial sources and were used as 
received without further purification unless specified. THF and DMF were purified by Innovative 
Technology’s Pure-Solve System. All reactions were carried out under a positive pressure of 
nitrogen in flame- or oven-dried glassware with magnetic stirring. Reactions were cooled using 
cryocool or external cooling baths (sodium chloride/ice water (-10 °C) or dry ice/acetone (- 78°C)). 
Heating was achieved by use of a silicone bath with heating controlled by electronic contact 
thermometer. Deionized water was used in the preparation of all aqueous solutions and for all 
aqueous extractions. Solvents used for extraction and chromatography were ACS or HPLC grade. 
Purification of reactions mixtures was performed by flash chromatography using SiliCycle 
SiliaFlash P60 (230-400 mesh). Yields indicate the isolated yield of the title compound ≥95% pure 
as determined by 1H NMR analysis. Whereas the yields in the article are the average yields of two 
or more experiments, the yields in the supporting information describe the result of a single 
experiment. Diastereomeric ratios were determined by 1H NMR analysis. Enantiomeric excess was 
determined by HPLC analysis using a Waters e2695 Separations Module with a Waters 2998 
photodiode array detector. 1H NMR spectra were recorded on Varian vnmrs 700 (700 MHz) 
spectrometer and chemical shifts (δ) are reported in parts per million (ppm) with solvent resonance 
as the internal standard (CDCl3 at δ 7.26). Data are reported as (s = singlet, d = doublet, t = triplet, 
q = quartet, qn = quintet, sext = sextet, m = multiplet; coupling constant(s) in Hz; integration). 
Proton-decoupled 13C NMR spectra were recorded on Varian vnmrs 700 (700 MHz) spectrometer 
and chemical shifts (δ) are reported in ppm with solvent resonance as the internal standard (CDCl3 
at δ 77.0). High resolution mass spectra (HRMS) were performed and recorded on Micromass 
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AutoSpec Ultima or VG (Micromass) 70-250-S Magnetic sector mass spectrometers in the 
University of Michigan mass spectrometry laboratory. Infrared (IR) spectra were recorded as thin 
films on NaCl plates on a Perkin Elmer Spectrum BX FT-IR spectrometer. Absorption peaks were 
reported in wavenumbers (cm-1). 
 




2-Methylcyclopentane-1,3-dione (5.37 g, 47.9 mmol, 1.0 equiv.) was taken in H2O (120 ml, 0.4 
M). Acrolein (4.8 mL, 71.9 mmol, 1.5 equiv.) was added. The reaction mixture was allowed to stir 
overnight and then concentrated in vacuo. The reaction mixture was diluted with EtOAc, dried 
over MgSO4, and concentrated in vacuo to afford 3-(1-methyl-2,5- dioxocyclopentyl)propanal1 
(8.05 g, 47.9 mmol, quantitative) as a colorless oil. Unpurified 3-(1- methyl-2,5-
dioxocyclopentyl)propanal (8.05 g, 47.9 mmol, 1 equiv.) was then taken in THF (145 mL, 0.33 
M). Added 1-(triphenylphosphoranylidene)-2-propanone (21.3 g, 67.1 mmol, 1.4 equiv.) and the 
reaction mixture was allowed to stir overnight. The reaction mixture was then concentrated in 
vacuo and purified directly by column chromatography (grad. 20%→33% EtOAc in hexanes) to 
afford (E)-2-methyl-2-(5-oxohex-3-en-1-yl)cyclopentane-1,3-dione (95) (9.268 g, 44.6 mmol, 
93% yield) as a colorless oil. 1H NMR (700MHz, CDCl3) δ 6.61 (dt, J = 6.8, 16.0 Hz, 1H), 5.98 
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(d, J = 16.0 Hz, 1H), 2.86-2.79 (m, 2H), 2.73-2.66 (m, 2H), 2.22 (s, 3H), 2.14-2.11 (m, 2H), 1.86-
1.83 (m, 2H), 1.15 (s, 3H) ; 13C NMR (175 MHz, CDCl3) δ 215.9, 198.2, 146.2, 131.9, 56.1, 35.0, 
32.6, 27.7, 26.8, 20.4; HRMS (ESI): m/z calcd for C13H18O3Na
+ [M+Na]+ 231.0992, found 





2-Ethylcyclopentane-1,3-dione (3.498 g, 27.8 mmol, 1.0 equiv.) was taken in H2O (70 mL ml, 0.4 
M). Acrolein (2.8 mL, 41.6 mmol, 1.5 equiv.) was added. The reaction mixture was allowed to stir 
overnight and then concentrated in vacuo. The reaction mixture was diluted with EtOAc, dried 
over MgSO4, and concentrated in vacuo to afford 3-(1-ethyl-2,5-dioxocyclopentyl)propanal (5.07 
g, 27.8 mmol, quantitative) as a colorless oil. Unpurified 3-(1-ethyl-2,5- 
dioxocyclopentyl)propanal (5.07 g, 27.8 mmol, 1 equiv.) was then taken in THF (84 mL, 0.33 M). 
Added was 1-(triphenylphosphoranylidene)-2-propanone (13.3 g, 41.7 mmol, 1.5 equiv.) and the 
reaction mixture was allowed to stir overnight. The reaction mixture was then concentrated in 
vacuo and purified directly by column chromatography (grad. 20%→33% EtOAc in hexanes) to 
afford (E)-2-ethyl-2-(5-oxohex-3-en-1-yl)cyclopentane-1,3-dione (103) (3.948 g, 17.8 mmol, 64% 
yield) as a colorless oil. 1H NMR (700MHz, CDCl3) δ 6.60 (dt, J = 7.0, 15.8 Hz, 1H), 5.97 (d, J = 
16.0 Hz, 1H), 2.79-2.73 (m, 2H), 2.70-2.61 (m, 2H), 2.21 (s, 3H), 2.08 (d, J = 6.8 Hz, 2H), 1.85-
1.82 (m, 2H), 1.67 (q, J = 7.5 Hz, 2H), 0.82 (t, J = 7.5 Hz, 3H); 13C NMR (175 MHz, CDCl3) δ 
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216.5, 198.3, 146.4, 131.9, 60.9, 36.0, 31.3, 29.2, 27.8, 26.8, 8.7; HRMS (ESI): m/z calcd for 
C13H18O3Na





2-Methylcyclohexane-1,3-dione was taken (2.06 g, 16.4 mmol, 1.0 equiv.) was taken in EtOAc 
(41 mL, 0.4M). TEA (3.4 mL, 24.6 mmol, 1.5 equiv.) and acrolein (1.7 mL, 24.6 mmol, 1.5 equiv.) 
was added. The reaction mixture was allowed to stir overnight and then concentrated in vacuo to 
afford 3-(1-methyl-2,6-dioxocyclohexyl)propanal (2.06 g, 16.4 mmol, quantitative) as a colorless 
oil. Unpurified 3-(1-methyl-2,6-dioxocyclohexyl)propanal (3.0 g, 16.4 mmol, quantitative) was 
then taken in THF (40 mL, 0.33 M). Added was 1-(triphenylphosphoranylidene)-2- propanone 
(7.3 g, 22.9 mmol, 1.5 equiv.) and the reaction mixture was allowed to stir overnight. The reaction 
mixture was then concentrated in vacuo and purified directly by column chromatography (grad. 
20%→33% EtOAc in hexanes) to afford (E)-2-methyl-2-(5-oxohex-3-en-1- yl)cyclohexane-1,3-
dione (106) (3.1 g, 13.9 mmol, 84% yield) as a colorless oil. 1 H NMR (700MHz, CDCl3) δ 6.67 
(dt, J = 6.8, 16.0 Hz, 1H), 5.99 (d, J = 16.0 Hz, 1H), 2.77-2.66 (m, 2H), 2.62-2.58 (m, 2H), 2.20 
(s, 3H), 2.05-2.02 (m, 2H), 1.95-1.89 (m, 4H), 1.27 (s, 3H); 13C NMR (175 MHz, CDCl3) δ 209.9, 
198.5, 146.9, 131.5, 64.7, 37.9, 33.7, 27.9, 26.8, 22.0, 17.4; HRMS (ESI): m/z calcd for 
C13H18O3Na
+ [M+Na]+ 245.1148, found 245.1150; IR (thin film, cm-1): 2956, 1724, 1692, 1672, 








Bis-(S)-4-phenyl-4,5-dihydrooxazol-2-yl)methane (1.0 g, 3.26 mmol, 1.0 equiv.) was dissolved in 
THF (30 mL, 0.1 M). 1,2-dibromoethane (562 µl, 6.5 mmol, 2.0 equiv.) and LiHMDS (1.48 g, 
8.86 mmol, 2.7 equiv.) were added sequentially. The reaction mixture was allowed to stir for 6 
hours. Additional 1,2-dibromoethane (281 µL, 3.26 mmol, 1.0 equiv.) and LiHMDS (1.08 g, 6.47 
mmol, 2.0 equiv.) was added. The reaction mixture was allowed to stir for an additional 16 hours. 
Then, the reaction mixture was quenched with saturated NH4Cl solution and then saturated 
NaHCO3 solution was added. The aqueous solution was extracted with EtOAc (3 times). The 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude 
mixture was purified by column chromatography (silica gel was pretreated with TEA, grad. 
50%→100% EtOAc in hexanes) to afford (4S,4'S)-2,2'-(cyclopropane-1,1-diyl)bis(4-phenyl-4,5- 









(4S,4'S)-2,2'-(cyclopropane-1,1-diyl)bis(4-phenyl-4,5-dihydrooxazole) (950 mg, 2.86 mmol, 1.0 
equiv.) and copper(II) chloride (380 mg, 2.86 mmol, 1.0 equiv.) were taken in DCM (14 mL, 0.2 
M) and stirred for 3 hours. Silver hexafluoroantimonate(V) (1.97 g, 5.72 mmol, 2.0 equiv.) was 
added as a solution in DCM (4 mL). The resulting reaction mixture was allowed to stir for 2 hours. 
The reaction mixture was diluted with THP (25 mL) and filtered through a plug of celite. The 
catalyst solution was concentrated in vacuo and then azeotroped with toluene (3 times). The 
catalyst was further dried by diluting with DCM (30 mL) and stirred with 4 Å MS (2.0 g) overnight. 
The green solution was decanted via cannula and the DCM was removed by flow of nitrogen to 
afford (4S,4'S)-2,2'-(cyclopropane-1,1-diyl)bis(4-phenyl-4,5-dihydrooxazole) copper(II) 
hexafluoroantimonate (139) (1.9 g, 2.2 mmol, 85% yield) as a dark green solid. 
 
General procedure for the synthesis of racemic Michael adducts 108 - 117: 
Michael acceptor (1.0 equiv.), Michael donor (1.0-1.1 equiv.), and copper(II) triflate (0.1 equiv.) 






General procedure for the synthesis of chiral Michael adducts 96, 143 - 149: 
Michael acceptor (1.0 equiv.) and bis(oxazoline)copper(II) complex (0.1 equiv.) were cooled to -
10°C. Michael donor (1.1-2.0 equiv.) was then added and the reaction mixture was stirred neat at 
-10°C until completion (24-48 h). Copper catalyst can be removed by dissolving the reaction 
mixture in EtOAc and filtering through a plug of silica gel and eluting with Et2O. Alternatively, 





Michael acceptor 95 (238 mg, 1.14 mmol, 1.0 equiv.) and bis(oxazoline)copper(II) complex (95 
mg, 0.11 mmol, 0.1 equiv.) were cooled to -10 °C. Michael donor 94 (0.36 mL, 2.29 mmol, 2 
equiv.) was then added and the reaction mixture was stirred neat at -10 °C for 48 hours. The 
reaction mixture was purified directly by column chromatography (grad. 20%→33% EtOAc in 
hexanes) to afford ethyl (R)-1-((R)-1-(1-methyl-2,5-dioxocyclopentyl)-5-oxohexan-3-yl)-2- 
oxocyclohexane-1-carboxylate (96) (404 mg, 1.07 mmol, 93% yield, 5:1 dr, 92% ee) as a colorless 
oil. Major Diastereomer: [α]26D = +15.7 (c 1.0, CHCl3); 
1 H NMR (700 MHz, CDCl3) δ 4.14- 
4.12 (m, 1H), 4.07-4.05 (m, 1H), 2.73-2.69 (m, 4H), 2.55(dd, J = 4.9, 18.2 Hz, 1H), 2.49-2.47 (m, 
1H), 2.37-2.31 (m, 3H), 2.18(dd, J = 4.9, 18.2 Hz, 1H), 2.09 (s, 3H), 1.91-1.89 (m, 1H), 1.74-1.71 
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(m, 1H), 1.63-1.39 (m, 5H), 1.21 (t, J = 7.0 Hz, 3H) , 1.20-1.18 (m, 1H), 1.01 (s, 3H), 0.93-0.91 
(m, 1H); 13C NMR (175 MHz, CDCl3) δ 216.2, 216.0, 207.4, 207.1, 171.4, 64.2, 61.5, 56.8, 45.1, 
41.2, 36.1, 35.0, 35.0, 33.7, 32.9, 30.1, 26.9, 26.9, 22.2, 18.8, 14.0; HRMS (ESI): m/z calcd for 
C21H32O6
+ [M+H]+ 379.2115, found 379.2117; IR (thin film, cm-1): 2937, 1706, 1363, 1206, 1093. 
Enantiopurity was determined to be 93% ee by chiral HPLC (DAICEL CHIRALPAK AD-H, 25 
cm x 4.6 mm, hexanes/2-proponal = 85/15, flow rate = 1 mL/min, λ = 282.0 nm, RT(minor) = 9.5 
min, RT(major) = 12.8 min). Minor Diastereomer: 1 H NMR (700 MHz, CDCl3) δ 4.19-4.14 (m, 
2H), 2.76-2.71 (m, 4H), 2.59 (dd, J = 4.2, 18.2 Hz, 1H), 2.52-2.48 (m, 1H), 2.43-2.26 (m, 4H), 
2.14 (s, 3H), 1.96-1.93 (m, 1H), 1.77-1.75 (m, 1H), 1.62-1.53 (m, 5H), 1.50-1.46 (m, 1H), 1.28-
1.22 (m, 4H), 1.05 (s, 3H), 0.91-0.85 (m, 1H); 13C NMR (175 MHz, CDCl3) δ 216.2, 216.1, 207.2, 
207.2, 171.3, 64.5, 61.5, 56.8, 45.7, 41.4, 36.4, 35.1, 35.0, 33.7, 33.3, 30.1, 27.1, 26.7, 22.4, 19.0, 
14.1; HRMS (ESI): m/z calcd for C21H31O6Na






Michael acceptor 103 (241 mg, 1.17 mmol, 1.0 equiv.) and bis(oxazoline)copper(II) complex (104 
mg, 0.12 mmol, 0.1 equiv.) were cooled to -10 °C. Michael donor 94 (0.37 mL, 2.33 mmol, 2 
equiv.) was then added and the reaction mixture was stirred neat at -10 °C for 48 hours. The 
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reaction mixture was purified directly by column chromatography (grad. 20%→33% EtOAc in 
hexanes) to afford ethyl (R)-1-((R)-1-(1-ethyl-2,5-dioxocyclopentyl)-5-oxohexan-3-yl)-2- 
oxocyclohexane-1-carboxylate (143) (384 mg, 0.98 mmol, 90% yield, 4:1 dr, 90% ee) as a 
colorless oil. [α]25D = +17.9 (c 1.0, CHCl3). 
1 H NMR (700MHz, CDCl3) δ 4.19-4.07 (m, 2H), 
2.74-2.64 (m, 4H), 2.58 (dd, J = 4.9, 18.6 Hz, 1H), 2.51-2.48 (m, 1H), 2.43-2.32 (m, 3H), 2.23 (dd, 
J = 5.5, 18.6 Hz, 1H), 2.12 (s, 3H), 1.94-1.91 (m, 1H), 1.76-1.73 (m, 1H), 1.65-1.40 (m, 7H), 1.27-
1.18 (m, 4H), 0.94-0.89 (m, 1H), 0.74 (t, J = 7.5 Hz, 3H); 13C NMR (175 MHz, CDCl3) δ 217.0, 
216.7, 207.4, 207.1, 171.5, 66.2, 61.5, 61.5, 45.1, 41.2, 36.3, 36.1, 36.1, 36.0, 33.0, 32.5, 30.1, 
29.1, 26.9, 22.2, 14.0, 9.0; HRMS (ESI): m/z calcd for C22H32O6Na
+ [M+Na]+ 415.2091, found 
415.2098; IR (thin film, cm-1): 2937, 1713, 1234, 1208, 1046. Enantiopurity was determined to be 
90% ee by chiral HPLC (DAICEL CHIRALPAK AD-H, 25 cm x 4.6 mm, hexanes/2- proponal = 





Michael acceptor 106 (200 mg, 0.90 mmol, 1.0 equiv.) and bis(oxazoline)copper(II) complex (78 
mg, 0.09 mmol, 0.1 equiv.) were cooled to -10 °C. Michael donor 94 (0.29 mL, 1.80 mmol, 2 
equiv.) was then added and the reaction mixture was stirred neat at -10 °C for 48 hours. The 
reaction mixture was purified directly by column chromatography (grad. 20%→33% EtOAc in 
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hexanes) to afford ethyl (R)-1-((R)-1-(1-methyl-2,6-dioxocyclohexyl)-5-oxohexan-3-yl)-2- 
oxocyclohexane-1-carboxylate (144) (310 mg, 0.79 mmol, 88% yield, 7:1 dr, 92% ee) as a 
colorless oil. [α]26D = +17.8 (c 1.2, CHCl3); 
1 H NMR (700 MHz, CDCl3) δ 4.14-4.11 (m, 1H), 
4.07-4.04 (m, 1H), 2.73-2.69 (m, 2H), 2.61-2.55 (m, 4H), 2.37-2.33 (m, 3H), 2.20(dd, J =4.9, 17.5 
Hz, 1H), 2.10 (s, 3H), 2.00-1.97 (m, 1H), 1.92-1.85 (m, 2H), 1.80-1.71 (m, 2H), 1.63 (td, J = 4.2, 
13.3 Hz, 1H), 1.57-1.53 (m, 2H), 1.44-1.42 (m, 1H), 1.22 (t, J = 7.0 Hz, 3H), 1.17-1.13 (m, 1H), 
1.13 (s, 3H), 0.89-0.83 (m, 1H); 13C NMR (175 MHz, CDCl3) δ 210.1, 210.0, 207.3, 207.2, 171.4, 
65.9, 64.2, 61.5, 45.1, 41.2, 37.7, 37.6, 36.1, 36.1, 32.3, 30.1, 27.3, 26.8, 22.2, 18.5, 17.8, 14.0. 
HRMS (ESI): m/z calcd for C22H34O6
+ [M+H]+ 393.2272, found 393.2274; IR (thin film, cm-1): 
2940, 1692, 1363, 1206. Enantiopurity was determined to be 91% ee by chiral HPLC (DAICEL 
CHIRALPAK AD-H, 25 cm x 4.6 mm, hexanes/2-proponal = 85/15, flow rate = 1 mL/min, λ = 




Michael acceptor 107 (141 mg, 1.12 mmol, 1.0 equiv.) and bis(oxazoline)copper(II) complex (95 
mg, 0.11 mmol, 0.1 equiv.) were cooled to -10 °C. Michael donor 94 (0.20 mL, 1.23 mmol, 1.1 
equiv.) was then added and the reaction mixture was stirred neat at -10 °C for 48 hours. The 
reaction mixture was purified directly by column chromatography (grad. 0%→10% EtOAc in 
hexanes) to afford ethyl (R)-1-((R)-4-methyl-2-oxooctan-4-yl)-2-oxocyclohexane-1-carboxylate 
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(145) (318 mg, 1.07 mmol, 96% yield, 10:1 dr, 92% ee) as a colorless oil. [α]26D = +14.7 (c 1.0, 
CHCl3); 
1 H NMR (700 MHz, CDCl3) δ 4.17-4.12 (m, 1H), 4.10-4.05 (m, 1H), 2.70-2.67 (m, 1H), 
2.55 (dd, J = 4.9, 17.5 Hz, 1H), 2.42-2.35 (m, 3H), 2.28 (dd, J = 5.6, 18.2 Hz, 1H), 2.09 (s, 3H), 
1.92-1.89 (m, 1H), 1.77-1.75 (m, 1H), 1.62-1.58 (m, 3H), 1.34-1.08 (m, 9H), 0.82 (t, J = 7.0 Hz, 
3H); 13C NMR (175 MHz, CDCl3) δ 207.7, 207.4, 171.7, 64.5, 61.2, 45.6, 41.2, 36.1, 32.7, 31.8, 
30.3, 29.9, 26.9, 22.8, 22.2, 14.0, 14.0; HRMS (ESI): m/z calcd for C17H30O4
+ [M+H]+ 297.2060, 
found 297.2063; IR (thin film, cm-1): 2936, 1708, 1363, 1205, 1134. Enantiopurity was determined 
to be 94% ee by chiral HPLC (DAICEL CHIRALPAK AD-H, 25 cm x 4.6 mm, hexanes/2- 






Michael acceptor 95 (265 mg, 1.27 mmol, 1.0 equiv.) and bis(oxazoline)copper(II) complex (113 
mg, 0.13 mmol, 0.1 equiv.) were cooled to -10 °C. Michael donor 98 (0.38 mL, 2.29 mmol, 2 
equiv.) was then added and the reaction mixture was stirred neat at -10 °C for 24 hours. The 
reaction mixture was purified directly by column chromatography (grad. 20%→33% EtOAc in 
hexanes) to afford ethyl (R)-1-((R)-1-(1-methyl-2,5-dioxocyclopentyl)-5-oxohexan-3-yl)-2- 
oxocyclopentane-1-carboxylate (146) (396 mg, 1.09 mmol, 86% yield, 96% ee) as a colorless oil. 
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[α]26D = -32.1 (c 1.1, CHCl3); 
1 H NMR (700 MHz, CDCl3) 4.01 (q, J = 7.0 Hz, 2H), 2.90 (dd, J = 
4.9, 18.2 Hz, 1H), 2.73-2.63 (m, 4H), 2.40-2.37 (m, 1H), 2.31-2.30 (m, 1H), 2.24-2.12 (m, 3H), 
2.04 (s, 3H), 1.93-1.89 (m, 1H), 1.85-1.77 (m, 2H), 1.48 (t, J = 8.4 Hz, 2H) , 1.14 (t, J = 7.0 Hz, 
3H) ,1.11-1.08 (m, 1H), 1.05-1.01 (m, 1H), 0.97 (s, 3H); 13C NMR (175 MHz, CDCl3) δ 216.0, 
216.0, 214.2, 207.6, 170.2, 63.4, 61.3, 56.6, 44.7, 38.3, 36.6, 35.0, 34.9, 33.4, 31.9, 29.9, 26.6, 
19.2, 19.0, 13.9; HRMS (ESI): m/z calcd for C20H30O6
+ [M+H]+ 365.1959, found 365.1960; IR 
(thin film, cm-1): 2966, 1714, 1363, 1223, 1157. Enantiopurity was determined to be 96% ee by 
chiral HPLC (DAICEL CHIRALPAK AD-H, 25 cm x 4.6 mm, hexanes/2-proponal = 88/12, flow 





Michael acceptor 106 (200 mg, 0.90 mmol, 1.0 equiv.) and bis(oxazoline)copper(II) complex (78 
mg, 0.11 mmol, 0.1 equiv.) were cooled to -10 °C. Michael donor 98 (0.27 mL, 1.80 mmol, 2 
equiv.) was then added and the reaction mixture was stirred neat at -10 °C for 24 hours. The 
reaction mixture was purified directly by column chromatography (grad. 20%→33% EtOAc in 
hexanes) to afford ethyl (R)-1-((R)-1-(1-methyl-2,6-dioxocyclohexyl)-5-oxohexan-3-yl)-2- 
oxocyclopentane-1-carboxylate (147) (295 mg, 0.78 mmol, 86% yield, 20:1 dr, 95% ee) as a 
colorless oil. [α]26D = -30.4 (c 1.0, CHCl3); 
1 H NMR (400 MHz, CDCl3) 4.07 (q, J = 7.2 Hz, 2H), 
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2.90 (dd, J = 5.6, 18.4 Hz, 1H), 2.64-2.58 (m, 4H), 2.46-2.42 (m, 2H), 2.31-2.17 (m, 3H), 2.10 (s, 
3H), 1.97-1.82 (m, 5H), 1.74-1.69 (m, 2H), 1.19 (t, J = 7.2 Hz, 3H), 1.15 (s, 3H), 1.09-1.02 (m, 
2H); 13C NMR (175 MHz, CDCl3) δ 214.4, 210.1, 210.1, 207.9, 170.2, 65.5, 63.8, 61.4, 45.0, 38.4, 
37.8, 37.8, 36.9, 35.3, 31.7, 30.1, 27.2, 20.1, 19.3, 17.6, 14.0; HRMS (ESI): m/z calcd for 
C21H32O6
+ [M+H]+ 379.2115, found 379.2116; IR (thin film, cm-1): 2963, 1713, 1692, 1364, 1224, 
1160. Enantiopurity was determined to be 95% ee by chiral HPLC (DAICEL CHIRALPAK AD-
H, 25 cm x 4.6 mm, hexanes/2-proponal = 90/10, flow rate = 1 mL/min, λ = 291.0 nm, RT(minor) 





Michael acceptor 103 (181 mg, 0.82 mmol, 1.0 equiv.) and bis(oxazoline)copper(II) complex (71 
mg, 0.08 mmol, 0.1 equiv.) were cooled to -10 °C. Michael donor 98 (0.24 mL, 1.63 mmol, 2 
equiv.) was then added and the reaction mixture was stirred neat at -10 °C for 24 hours. The 
reaction mixture was purified directly by column chromatography (grad. 20%→33% EtOAc in 
hexanes) to afford ethyl (R)-1-((R)-1-(1-ethyl-2,5-dioxocyclopentyl)-5-oxohexan-3-yl)-2- 
oxocyclopentane-1-carboxylate (148) (254 mg, 0.67 mmol, 82% yield, 19:1 dr, 92% ee) as a 
colorless oil. [α]26D = -23.1 (c 1.0, CHCl3); 
1H NMR (700 MHz, CDCl3) δ 4.10 (q, J = 7.2 Hz, 2H), 
2.04 (dd, J = 6.1, 18.4 Hz, 1H), 2.72-2.65 (m, 4H), 2.47 (qn, J = 6.0 Hz, 1H) 2.37-2.21 (m, 4H), 
79 
 
2.12 (s, 3H), 2.01-1.97(m, 1H), 1.93-1.85 (m, 2H), 1.64-1.54 (m, 4H), 1.22 (t, J = 7.2 Hz, 3H), 
1.19- 1.15 (m, 1H), 1.21-1.06 (m, 1H), 0.76 (t, J = 7.5 Hz, 3H); 13C NMR (175 MHz, CDCl3) δ 
216.8, 216.7, 214.4, 207.8, 170.3, 63.4, 61.5, 61.4, 44.6, 38.4, 36.9, 36.1, 36.0, 32.3, 30.1, 28.4, 
26.8, 19.3, 14.0, 8.9; HRMS (ESI): m/z calcd for C21H30O6Na
+ [M+Na]+ 401.1935, found 
401.1939; IR (thin film, cm-1): 2968, 1713, 1222, 1157, 1023. Enantiopurity was determined to be 
92% ee by S9 chiral HPLC (DAICEL CHIRALPAK AD-H, 25 cm x 4.6 mm, hexanes/2-proponal 
= 90/10, flow rate = 1 mL/min, λ = 286.0 nm, RT(minor) = 12.0 min, RT(major) = 15.6 min). 
 
 
Ethyl (R)-1-((R)-4-methyl-2-oxooctan-4-yl)-2-oxocyclopentane-1-carboxylate (149) 
Michael acceptor 107 (150 mg, 1.19 mmol, 1.0 equiv.) and bis(oxazoline)copper(II) complex (100 
mg, 0.12 mmol, 0.1 equiv.) were cooled to -10 °C. Michael donor 98 (0.19 mL, 1.31 mmol, 1.1 
equiv.) was then added and the reaction mixture was stirred neat at -10 °C for 48 hours. The 
reaction mixture was purified directly by column chromatography (grad. 0%→10% EtOAc in 
hexanes) to afford ethyl (R)-1-((R)-4-methyl-2-oxooctan-4-yl)-2-oxocyclopentane-1-carboxylate 
(149) (295 mg, 1.05 mmol, 88% yield, 91% ee) as a colorless oil. [α]26D = -58.5 (c 1.0, CHCl3); 
1 
H NMR (700 MHz, CDCl3) δ 4.10 (q, J = 7.0 Hz, 2H), 2.95 (dd, J = 6.3, 18.2 Hz, 1H), 2.62-2.58 
(m, 1H), 2.53-2.50 (m, 1H), 2.33-2.22 (m, 3H), 2.11 (s, 3H), 2.02-1.87 (m, 3H), 1.30-1.11(m, 9H), 
0.84 (t, J = 7.0 Hz, 3H); 13C NMR (175 MHz, CDCl3) δ 214.6, 208.0, 170.4, 64.0, 61.3, 45.2, 38.6, 




283.1904, found 283.1902; IR (thin film, cm-1): 2957, 1714, 1222, 1156. Enantiopurity was 
determined to be 91% ee by chiral HPLC (DAICEL CHIRALPAK OD-H, 25 cm x 4.6 mm, 
hexanes/2-proponal = 99/1, flow rate = 1 mL/min, λ = 295.0 nm, RT(major) = 7.5 min, RT(minor) 
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Concise Enantioselective Total Synthesis and Biological Evaluation of Cardiotonic Steroids 
19-Hydroxysarmentogenin, Trewianin Aglycone, Panogenin, and cis-Panogenin1 
(A portion of this work has been published in: Kaplan, W.; Khatri, H. R.; Nagorny, P. “Concise 
Enantioselective Total Synthesis of the Cardiotonic Steroids 19-Hydroxysarmentogenin and 
Trewianin Aglycone” J. Am. Chem. Soc. 2016, 138, 7194.) 
4.1. Introduction 
 Steroids are some of the most pervasive, naturally occurring small molecules. Despite 
having a common tetracyclic core motif, steroids with differing stereochemical patterns and 
peripheral substitutions can elicit a remarkable range of therapeutic effects.2-6 One particularly 
useful class of steroids are the cardenolides. These plant-derived steroids are potent inhibitors of 
the Na+/K+-ATPase pump on cardiac myocytes; an activity which causes a positive inotropic 
response in humans and helps combat the effects of congestive heart failure.7 Additionally, recent 
work has demonstrated the anticancer activity of cardenolides.8-10 However, a narrow therapeutic 
window and lack of understanding regarding the antiproliferative effects of cardenolides 
necessitates the synthesis of new steroid analogues in pursuit of therapeutically optimized drug 
candidates. The purpose of the work described here is to delineate a new and more effective 
approach for the synthesis of cardenolide steroids; one which allows unprecedented access to a 
number of cardenolide and cardenolide-like compound. By developing a concise route to these 
polyoxygenated steroids, we strive to improve the synthetic access to the region of chemical space 
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surrounding the cardenolides. This may eventually allow for the development of safer and more 
effective cardenolide-based therapeutics with improved pharmacokinetic, pharmacodynamic, 
metabolic, and toxicity profiles for the treatment of congestive heart failure and cancer. 
4.2. Selected Targets and Approach Toward Total Synthesis 
 The initial targets of interest chosen were 19-hydroxysarmentogenin (1), trewianin 
aglycone (172), panogenin (173), and cis-panogenin (174). 19-hydroxysarmentogenin was chosen 
because it was synthesized previously by Inoue and co-workers and would serve as a valuable 
benchmark for comparison.11 Trewianin aglycone, panogenin, and cis-panogenin represent the 
remaining three possible stereoisomers of the C5 and C11 positions. The goal of this decision is to 
eventually explore how the configuration at these positions affect the binding and biological 
activity of these cardenolides. The primary vehicle for synthesizing these targets was predicated 
upon the methodology outlined in chapter 3.12 By optimizing and expanding on the tandem 
Michael addition/intramolecular double aldol approach to steroidal cores developed previously, 
we envisioned concise access to a number of natural and unnatural cardenolides. This approach, 
however, necessitates certain modifications. The targets chosen contain oxygenation at both C3 
and C11. The functionality of these sites is absent in the methodology described previously, 
wherein both C3 and C11 are unoxidized. Additionally, our developed method (Chapter 3) results 
in oxygenation of the C7 position of the steroidal products, while natural cardenolides do not 
contain oxygenation at C7 and so this position must be reduced to a methylene. Finally, 
stereodivergent routes for constructing the differential chirality at C5 and C11 must be devised 
and the characteristic β-oriented butenolide ring at C17 must be installed. These required 




Figure 4.1. Required Modifications to Previous Methodology and Selected Targets. 
  
 In order to accomplish the stereodivergent total synthesis of all the targets, we envisioned 
a retrosynthetic design wherein all four cardenolides could be elaborated from a common, highly 
functionalized key intermediate. It is desirable to develop a synthetic plan wherein the point of 
divergence to each individual target occurs as a late as possible – allowing scalable synthesis of 
the key intermediate which can then be diverted to a desired target in as few steps as possible. To 
this effect, and utilizing the same disconnection approach described in chapter 3, we conceived of 
a retrosynthetic design as depicted in Scheme 4.1. Divergence occurs from the key intermediate 
175. Importantly, this steroidal core contains pre-installed oxidative information at all positions 
required for concise, stereodivergent elaboration to the natural cardenolides. Additionally, the 
construction of 175 is readily attainable from steroid 176. Fragments of architecture 178 and 179 
would be coupled via Michael addition/cyclization to produce intermediate 176. By pre-installing 
the oxidative information and functional handles on the chemically simpler starting fragments 
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prior to coupling and cyclization, we can avoid more difficult late stage redox manipulations and 
the need to functionalize inert positions – allowing more concise access to a chemically complex 
and heavily functionalized key intermediate. 
Scheme 4.1. Retrosynthesis of Selected Targets via Key Intermediate 175. 
 
4.3. Installing C11 Oxygenation 
 The first functionality we examined was the stereoselective pre-installation of C11 
oxygenation on the enone fragment. Back-tracing the carbon atoms through the synthetic design 
reveals that the eventual C11 position is the γ-carbon of the enone fragment. With a well-
established and scalable route to the bare enone already established, we examined possibilities for 
modifying the known route to incorporate oxidation of the γ-carbon with minimal added steps. To 
achieve this, we quickly focused on the intermediate aldehyde 100 (Scheme 4.2.). At this stage, 
the C11 carbon is α to an aldehyde and most amenable to derivatization due to its high reactivity. 
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We envisioned here an asymmetric organocatalytic α-oxidation of the aldehyde to install 
oxygenation in a stereoselective manner, producing structure 180. Importantly, this early 
incorporation of oxygenation with a high level of stereocontrol ensures the enantiopurity of all 
remaining intermediates of the synthesis – requiring only diastereocontrol to set relative 
configurations at downstream stages in the route. 
Scheme 4.2. Plan for Pre-installation of C11 Oxygenation. 
 
 The first conditions we examined for the oxidation utilizes a proline-derived catalyst for 
the induction of asymmetry via formation of a chiral enamine in conjunction with nitrosobenzene 
as the electrophilic oxygen source (Scheme 4.3.).13 The proline-derived catalyst is readily 
synthesized.14 We suspected that the oxidation procedure could be coupled with the subsequent 
Wittig olefination in a single pot procedure to afford the desired oxidized enone fragment in one 
step. Initial attempts at this one-pot oxidation/Wittig olefination were promising and successfully 
delivered the desired C11 oxidized enone 181 in moderate yield. However, subsequent attempts to 
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reduce the O-N bond under various conditions were unsuccessful, leading to a complex mixture 
of products, or failing to produce the desired allylic alcohol.  Attention was turned toward a similar 
report of an asymmetric α-oxidation of aldehydes which utilized dibenzoyl peroxide (BPO) as the 
stoichiometric oxidant.15,16 This procedure has the added benefit of delivering a benzoyl protected 
alcohol directly.  
Scheme 4.3. Asymmetric Organocatalytic α-Oxidation of Aldehyde 100. 
 
Initial attempts at a one-pot oxidation/olefination procedure were disappointingly 
unfruitful due to the production of a complex mixture of side products, including triphenyl 
phosphine oxide (TPPO), which greatly complicated the isolation procedure. However, since the 
mechanism of oxidation is ionic, and BPO is a known radical generating reagent, the addition of 
catalytic hydroquinone as a radical scavenger was able to diminish side-product formation. 
Unfortunately, this modification alone was insufficient to allow high isolated yields from a single-
pot oxidation/olefination procedure. Rather, we found that isolation of the α-oxidized aldehyde by 
column chromatography prior to Wittig olefination afforded much better overall isolated yields. 
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Importantly, the silica gel purification procedure results in little to no epimerization of the chiral 
C11 center. After Wittig olefination, the desired fragment 182 with pre-installed oxygenation at 
C11 could be isolated in 56% yield (over three steps) on a 15 gram scale and in 95% enantiomeric 
excess as determined by HPLC. The primary concern regarding the development of such a C11 
oxidized fragment is steric crowding of the electrophilic β-carbon of the enone potentially leading 
to an incompatibility in the key Cu(II)-catalyzed Michael addition or unexpected 
diastereoselectivity in the ensuing cyclization step. 
 To investigate the viability of fragment 182, we tested its reactivity with the 
unfunctionalized A ring β-ketoester fragment 94 (Scheme 4.4.). Fortunately, the Michael addition 
proceeded to afford the desired adduct 183. Based on the results of our previously developed 
methodology, we attempted the cyclization of adduct 183 with DBU in refluxing THF. 
Scheme 4.4. Michael Addition and Cyclization Tests with Fragment 182. 
 
 As anticipated, these cyclization conditions afforded a steroidal core of architecture 184, 
containing a cis-β-A/B ring junction, the desired natural configuration at C8, C9, and C10, as well 
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as the expected cis-α-C/D ring junction. X-ray crystallographic analysis confirmed the relative 
stereochemistry of the steroidal core. With sufficient evidence that the current C11 oxidized 
fragment 182 is able to participate in the designed approach without affecting the mode of 
diastereoselective cyclization, we turned our attention toward the design of a compatible C3 
oxidized A ring fragment. 
4.4. Installing C3 Oxygenation 
 The ability to oxygenate cardenolides at C3 is crucial because all natural cardenolides 
contain oxygenation at this position. In addition, the C3 hydroxy group serves as the point of sugar 
attachment for glycosylated cardenolides. Any future efforts at installing glycosides and 
investigating their effect on biological activity would rely on the presence of C3 oxygenation. 
Lastly, all cardenolides have a β-oriented hydroxy group at C3, so the ability to control this 
stereogenic carbon is another downstream task we had to consider. 
 Back-tracing the carbon positions through the retrosynthetic design reveals that the β’ 
carbon of the β-ketoester fragment is the eventual C3 position and so we focused on a method for 
pre-installing the necessary oxidative information at this position (Scheme 4.5.).  
Scheme 4.5. Plan for Pre-installation of C3 Oxygenation. 
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We first devised of three different structural approaches to accomplishing this task, these 
β-ketoester architectures are shown as 185, 186, and 178. In the case of 185, we envisioned a 
stereoselective oxidation of the C3 carbon so that the desired hydroxy group would be installed 
with the desired configuration. However, the primary concerns with this approach were twofold: 
1) Too much complexity was being added at too early a stage. That is, we wanted to avoid the need 
for another catalytic chiral controller and rather let substrate control determine the configuration 
at C3 during a later stage, to allow for a more stereodivergent approach. And 2) β-hydroxyketone 
motifs of the type present in 185 are prone to E1cb-type elimination and may generate an enone 
during either the copper(II)-catalyzed Michael addition or cyclization steps, destroying the 
chirality. Architecture of type 186 was also considered and seemed more viable. However, the 
presence of an olefin, while providing a useful functional handle, still requires additional 
downstream steps for installing oxygenation at the desired C3 position. To avoid this, we looked 
at β-ketoesters of structure 178. This somewhat combines the desirable aspects of both 185 and 
186 and allows for the direct incorporation of oxygenation at C3 (so we won’t have to install it 
later), while avoiding the issues of elimination and enantioselectivity. The primary issue we 
anticipated with β-ketoesters like 178 was diminished reactivity. The enol ether moiety is a strong 
electron donator by resonance and is expected to reduce the acidity of the β-ketoester, perhaps by 
100-fold or more if a rough comparison is made to the pKa’s of ethyl acetoacetate (pKa ≈ 11, H2O) 
and dimethyl malonate (pKa ≈ 13, H2O). This could lead to a lower concentration of the 
nucleophilic enol tautomer, and thus slow or halt the Michael addition with fragment 182. 
 Initial attempts at making a C3 oxygenated fragment were successful and straightforward. 
The readily available enol ether 187 could be kinetically enolized with LHMDS and then acylated 
with diethyl carbonate to afford β-ketoester 188 in a single step and good yield. However, attempts 
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to couple fragment 188 with enone 182 via Cu(II)-catalyzed Michael addition were unsuccessful 
(Scheme 4.6.). As we feared, the added steric occlusion of the enone in conjunction with the 
deactivation of the β-ketoester resulted in a complete lack of reactivity despite attempts at 
optimization. 
Scheme 4.6. Initial Attempt at Michael Addition with Fragment 188. 
 
 To overcome this, we considered the possibility of activating fragment 188 as its silyl enol 
ether. This effectively locks the entire population of molecules in an enol-like configuration and 
may thus promote Mukaiyama Michael addition with enone 182 in the presence of Lewis acidic 
Cu(II). We were encouraged by various reports of other Cu(II)-catalyzed Mukaiyama Michael 
additions.17,18 Fortunately, 188 is readily enolized with LHMDS and trapped by the addition of 
TESCl to provide silyl enol ether 189 (Scheme 4.7.). Initial attempts at the Cu(OTf)2-catalyzed 
Mukaiyama Michael addition of 189 and 182 were very promising and the reaction would readily 
go to completion, producing Michael adduct 190. However, the reaction resulted in a disappointing 
diastereoselectivity of 3:1 at best and would produce a complex mixture of silylated and desilylated 
Michael adducts. We could optimize the procedure slightly to include the addition of TBAF or 
AcOH after the reaction was complete to convert any silylated Michael adduct to its desilylated 
congener, making the mixture easier to interpret and purify. Despite the low diastereomeric ratio, 
we could isolate useful quantities of the desired major diastereomer 190.  
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Scheme 4.7. Attempts at Mukaiyama Michael Addition and Subsequent Cyclization. 
 
We surmise that the low diastereoselectivity is a result of the silylation of the β-ketoester, 
effectively hindering its ability to undergo coordination with copper which may have otherwise 
produced a tighter transition state and better selectivity. A significant amount of time and effort 
was then expended, unfruitfully, on the cyclization of Michael adduct 190. While the conversion 
to a silyl enol ether was sufficient for affecting the desired Michael addition, the problem of the 
electron rich enol ether rose again and attempts to cyclize adduct 190 were made difficult by the 
attenuated electrophilicity of the C5 carbonyl. The use of the well-established DBU conditions 
failed to promote the cyclization and we turned instead to stronger bases. Unfortunately, the use 
of metal hexamethyldisilazides resulted in a complex mixture of degradation with significant 
amounts of retro-Michael products. Next, we explored the use of soft enolization conditions. At 
last, using a combination of TiCl4 and Et3N, we could observe the formation of some fully cyclized 
product 191. However, the yields were very low and several attempts at optimization ultimately 
failed to produce useful quantities. Unfortunately, the determination of stereochemistry via NOE 
spectroscopy is only easily accomplished on the rigid steroidal systems following successful 
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cyclization. Adducts such as 190 have too much rotational freedom and conformational flexibility 
for reliable NOE analysis under standard conditions. As such, the stereochemical pattern of 190 
and 191 have not been elucidated.  
 It was clear that the electron-rich enol ether moiety was causing too many downstream 
issues so we focused on a redesign of the A ring fragment. Keeping in theme with the same overall 
architecture of type 178, we imagined replacing the enol ether motif with a vinyl chloride, making 
fragment 192.12 This modification still permits straightforward conversion to oxygenation at a later 
stage without any additional steps and has the benefit of being an inductive activator of the C5 
carbonyl, and a much weaker resonance donator; potentially enough to overcome the reactivity 
issues faced with fragment 188. The vinyl chloride fragment can be synthesized in two steps from 
β-ketoester 188 (Scheme 4.8.). First, the enol ether is hydrolyzed with HCl and water in THF. 
Subsequent chlorination with PCl3 in CHCl3 provides the desired chloroketoester 192 in good yield 
and high regioselectivity. We found that attempts at chlorination via Vilsmeier-Haack type 
reaction with oxalyl chloride and DMF produced only 1:1 regioselectivity. The synthesis of 192 
was later optimized to allow for its preparation on a 100 gram scale. 
 With 192 in hand, we explored its ability to react conjugatively with enone 182 (Scheme 
4.8.). Fortunately, chloroketoester 192 was sufficiently reactive to participate in the desired 
Michael addition without the need for conversion to its silyl enol ether, and Michael adduct 194 
could be isolated in 70% yield and 6:1 diastereoselectivity favoring the desired, natural 
configurations at C10 and C9. However, as we would expect, the reaction proceeds slowly with 
the typical 10 mol% loading of Cu(OTf)2. We discovered that by increasing the loading to 50 
mol% and running the reaction at high concentration, it is typically complete in less than nine 
hours. A transition state model 193 is proposed to explain the observed diastereoselectivity. Three 
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major steric and stereoelectronic interactions are invoked. First, the potential for a vinylogous polar 
Felkin-Ahn interaction between the σ bonding electrons of the C11-OBz bond and the π-system of 
the enone may orient the -OBz group to block one face of the enone. Second, the avoidance of A1,3 
strain between C12 and the olefinic hydrogen would preferentially orient the -OBz group over the 
re face of the enone, exposing the se face for the Michael addition. Third, the chiral center at C11, 
due its saturation, will protrude radially out of the plane of the π-system and the chloroketoester 
may prefer an approach which places the rotatable -OEt group of the ester, rather than the flat and 
rigid ring system, closest to the chiral center at C11.  
Scheme 4.8. Synthesis and Michael Addition of Chloroketoester Fragment 192. 
 
Finally, the last important result of the Michael addition to note is the production of side-
product 195. This compound results from the Cu(OTf)2-catalyzed C ring closure aldol reaction 
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between C8 and a C14 carbonyl of the Michael adduct 194 and affords approximately 20% yield 
of the half-cyclized material which is readily isolated form the desired Michael adduct via column 
chromatography. We found that the Michael addition is best if monitored closely and halted 
quickly upon complete consumption of the enone 182, extended reactions times often allow side-
products to accumulate. 
 With Michael adduct 194 in hand, we focused on the key cyclization step. Keeping in mind 
the factors which we believe to influence the diastereoselectivity of the cyclizations (Chapter 3, 
scheme 3.12.), we anticipated the production of a cis-α-C/D ring junction no matter which 
conditions we used. This expectation is explained by the following two observations: 1) The C5 
carbonyl of adduct 194 is mildly deactivated as an electrophile due to its conjugation as an enone 
and so we expect the aldol addition between C8 and C14 to occur faster, this means the reaction 
would proceed either through path 1 or 2 (Chapter 3, scheme 3.12.) and afford a cis-α-C/D ring 
junction. And 2) Our studies on the Michael addition of chloroketoester 192 and enone 182 
revealed the production of half-cyclized side product 195 which already contains a cis-α-C/D 
junction; again, consistent with our previous observations. Nonetheless, and to our dismay, the 
usual DBU conditions were unsuccessful to promote cyclization of adduct 194. It appeared the C5 
carbonyl was still sufficiently deactivated to serve as an electrophile. Moreover, the use of stronger 
metal hexamethyldisilazides bases again failed due to the retro-Michael pathway. We reasoned 
that the generation of an enolate via strong bases is sufficient for creating significant negative 
charge at C8. In conjunction with the sterically congested C10-C9 bond, the enolized Michael 
adduct succumbs to rapid degradation and retro-Michael fragmentation before undergoing the 
desired cyclization. To combat this, we considered an acid-promoted cyclization. Such an 
approach would allow the double aldol cyclization to proceed by means of enols, not enolates 
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(Scheme 4.9.). This could translate to a weaker build-up of negative charge at C8 and would hinder 
the retro-Michael pathway, allowing cyclization to proceed. In addition, the production of half-
cyclized side product 195 from the Cu(OTf)2-catalyzed Michael addition provided some evidence 
that acidic conditions may allow for the desired aldol reaction to outcompete the retro-Michael 
pathway. 
Scheme 4.9. Attempts and Conditions for Cyclization of Adduct 194 to Steroidal Core. 
 
The use of p-TSA to promote adduct cyclization was precedented in our methodology 
development described in Chapter 3 (table 3.1.). As such, we investigated its application toward 
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the cyclization of adduct 194. Fortunately, the p-TSA promoted cyclization proceeded smoothly. 
After some optimization, the use of excess p-TSA in MeCN at 55oC for 48 hours proved highly 
effective for the cyclization of adduct 194 into the steroidal core 196, in 68% yield on a 5 gram 
scale and with complete diastereoselectivity. Importantly, 196 results from the dehydration product 
at C5, delivering an extended enone, and contains the expected but undesired cis-α-C/D ring 
junction stereochemistry.  
Additionally, the half-cyclized side product 195 from the Michael reaction could be 
subjected to the same p-TSA cyclization protocol to affect its conversion to the same steroidal core 
196, albeit in a lower 56% yield. With 196 in hand, we focused on its conversion to the key 
functionalized intermediate 175. To accomplish this task, several transformations are required. 
First, the C/D ring junction must be converted to the natural cis-β orientation. Second, oxygenation 
must be removed from C7 and installed at C3. Third, the C19 and C11 hydroxy groups must be 
reduced/deprotected. 
4.5. Synthesis of Key Intermediate 175 
 With the successful modification of our developed methodology to allow for the pre-
installation of both C11 oxygenation on the enone fragment and C3 oxygenation on the A ring 
fragment, we focused on the concise synthesis of our idealized key intermediate 175 containing 
all the necessary functionality for divergence to our target cardenolides. The first objective was to 
epimerize the cis-α-C/D ring junction to a natural cis-β-C/D ring junction. We knew from our 
previous investigations into cyclization protocols that the presence of unsaturation at C5 would 
thermodynamically favor a cis-β-C/D junction. Thus, we imagined that the cis-α-C/D junction of 
steroid 196 could be epimerized under equilibrating conditions which puts the opening and closing 
of the C ring in flux. Both acidic and basic conditions were extensively tested for their ability to 
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promote this key epimerization. Unfortunately, acidic conditions would often result in elimination 
of the C14 hydroxy group prior to, or competing with, any retro-aldol process.  Focusing on the 
use of base, we discovered that weak alkyl amine bases were insufficient to promote any desired 
reaction. However, the more basic metal hexamethyldisilazides were able to generate the necessary 
C14 alkoxide, and upon heating, a diastereomeric mixture of steroids was produced. Interestingly, 
the sodium cation provided the best results in terms of isolated yield and the use of a non-
coordinating solvent, toluene in this case, was required. More polar solvents such as THF or DMF 
would cause formation of an unidentified side-product (perhaps resulting from epimerization at 
C9) which was very difficult to isolate from the desired product. Using NaHMDS in toluene, 
steroid 196 could be epimerized to the cis-β-C/D junction intermediate 197 in a 2.5:1 
diastereomeric ratio (Scheme 4.10.). The desired product 197 could be isolated in 48% yield (68% 
BRSM) and the starting material could be recovered in 30% yield, allowing it to be effectively 
recycled. 
Scheme 4.10. Epimerization of C/D Ring Junction, Affording Steroid 197. 
 
 The remaining transformations included reduction of C7 and C19, oxygenation at C3, and 
deprotection of the C11-OBz group. To accomplish this, we envisioned an imaginative global 
reduction/transposition sequence. First, steroid 197 would be reduced globally, generating a 
primary alcohol at C19, secondary alcohols at C7 and C17, and deprotection of the C11 hydroxy 
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group (intermediate 198, Scheme 4.11.). Importantly, the C7 allylic alcohol is then susceptible to 
acid-promoted allylic transposition. Ionization could occur under acidic conditions to generate a 
doubly allylic carbocation. Thus, positions C3, C5, and C7 are activated as electrophiles and can 
undergo hydration in the presence of water. However, the presence of the chlorine at C3 provides 
a key thermodynamic sink for hydration to eventually occur at that position. When C3 is hydrated, 
the chlorine can be rapidly eliminated, affording a carbonyl which no longer undergoes reversible 
ionization. If hydration occurs at C5 or C7, the resulting allylic alcohol can be re-ionized under 
the acidic reaction conditions to regenerate the doubly allylic carbocation intermediate 199. Only 
hydration at C3 leads to irreversible formation of a product and over time, all rehydration pathways 
converge to produce key intermediate 175 (Scheme 4.11.). 




 Various reducing agents were evaluated for their ability to promote the global reduction. 
LiAlH4 failed because it would reduce the vinyl chloride moiety presumably via single electron 
transfer. While LiBH4/B(OMe)3 provided the desired reactivity, the reaction was too operationally 
cumbersome. Fortunately, the use of excess DIBALH at elevated temperature in THF affected the 
desired reduction of all carbonyls. By starting the reduction at -78oC and allowing the reaction to 
warm slowly to ambient temperature, the configuration at C17 could be biased and an 8:1 
diastereomeric ratio could be achieved favoring the α-orientation; this simplifies the isolation 
procedure and subsequent transformations.  
Upon complete global reduction, the reaction mixture could be quenched with water and 
acidified with formic acid without the need to isolate intermediate 198. By heating the acidic 
solution to 85oC, ionization of C7 is initiated and the transposition proceeds to generate the key 
intermediate 175 in 72% yield in a single step from 197. Initially, we explored the use of the 
weaker acid AcOH to promote the transposition, however, these conditions appeared to produce 
unwanted side products resulting from elimination and so the switch to the stronger formic acid 
was sufficient to avoid this issue. This transposition process achieves both the removal of 
oxygenation from C7 and the installation of oxygenation at C3. Overall, key intermediate 175 
could be synthesized in 7 linear steps from the commercially available building blocks. 
Remarkably, 175 contains all the preset oxygenation for synthesizing the target cardenolides, as 
well as seven contiguous stereocenters in a fused tetracyclic array. Up to this point, an incredible 
amount of chemical complexity is installed in very few steps. This foundation was a key tenant of 





4.6. Elaboration of Intermediate 175 into 19-Hydroxysarmentogenin 
 The only previous total synthesis of 19-hydroxysarmentogenin was accomplished by Inoue 
and co-workers in 2013.11 Their synthesis proceeded in 34 total steps and is described in Chapter 
2, section 2.9. Our goal is to utilize a modular, drug-oriented approach to develop a more concise 
route to 19-hydroxysarmentogenin. In order to elaborate key intermediate 175 into the target, 
several important structural transformations must be made. The C3 carbonyl must be reduced 
stereoselectively to a β-oriented hydroxy, the C5 position must be reduced to a cis-β-A/B ring 
junction, the C11 hydroxy group must be epimerized to a β-orientation, and finally the butenolide 
ring must be installed stereoselectively at C17. The first issue we examined was the hydrogenation 
of the extended enone moiety to set the A/B ring junction. Unfortunately, simple hydrogenation 
of 175 with activated Pd/C in methanol generated a 1:1 diastereomeric ratio of cis and trans A/B 
ring junctions (Scheme 4.12.). However, we reasoned that we could utilize the inherent structural 
features of the substrate to help bias hydrogenation to occur predominantly from the desired β-
face, specifically the primary hydroxy group at C19. Heterogeneous hydrogenations over Pd/C are 
typically not as susceptible to substrate coordination control from polar moieties such as alcohols, 
amines, amides, or acids as are homogenous hydrogenations. However, exposed hydroxy groups 
are known to allow directed heterogenous hydrogenation under certain circumstances.19 In this 
vein, we imagined running the hydrogenation under basic conditions in order to generate some 
population of the C19 alkoxide which may be sufficient for adsorbing to the palladium and 
directing hydrogenation to occur from the same face. Gratifyingly, running the hydrogenation with 
1% KOH in methanol had the desired effect and the cis-β-A/B ring junction steroid 200 could be 




Scheme 4.12. Total Synthesis of 19-Hydroxysarmentogenin. 
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Next, the C19 primary hydroxy group had to be protected. This would protect it from 
downstream oxidations. Surprisingly, attempts to selectively protect C19 as a TBS ether in the 
presence of other hindered secondary alcohols failed due to rapid bis-silylation of the substrate. 
Only TIPS was sufficiently bulky to allow for the selective silylation of C19 and 200 could be 
readily protected with TIPSCl and imidazole in DMF. At this point we focused our attention to the 
reduction of the C3 carbonyl. We realized that the hydroxy groups at C11 and C17 had to be 
oxidized at a later stage, and that this may cause complications if the C3 position is already set as 
a β-oriented hydroxy. As such, we opted to first oxidize the C11 and C17 position to carbonyls 
prior to attempting a regio- and stereoselective reduction of the C3 ketone. To this effect, the C19 
protected steroid was readily oxidized upon exposure to the Dess-Martin periodinane in DCM to 
afford triketone 201. We rationalized that a sterically hindered nucleophilic hydride source would 
allow the selective reduction at C3 for two reasons: 1) the C11 and C17 carbonyls are flanked by 
substituted positions, sterically encumbering the approach of a nucleophile, and 2) bulky hydride 
sources are known to prefer an equatorial approach to conformationally biased cyclohexanones.20 
Due to the presence of a cis-β-A/B ring junction, a hydride delivered equatorially to the C3 
carbonyl will approach from the desired α-face. Additionally, the C19-OTIPS group provides 
additional steric occlusion of the β-face, further biasing a bulky hydride source to react on the 
desired re face at C3. For these reasons, we used K-selectride. At -35oC in THF, the reduction 
proceeded smoothly to produce intermediate 202 and the desired β-oriented C3 hydroxy 
exclusively. The next task was to set an α-oriented hydroxy group at C11. To accomplish this, we 
mimicked the approach used by Inoue and co-workers in 2013.11 A thermodynamic Birch 
reduction of the C11 position is known to provide the α-oriented equatorial hydroxy as opposed to 
the use of nucleophilic hydride sources which appear to reduce C11 kinetically to afford a β-
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oriented hydroxy. First, the C17 carbonyl is protected as its TBS enol ether upon exposure to 
TBSOTf and Et3N; the C3 hydroxy undergoes concomitant silylation under these conditions 
affording 203. Subsequent Birch reduction with lithium in ammonia generates a C11 carbanionic 
intermediate which undergoes exclusive protonation from the β-face. Rapid exposure to TBAF in 
THF at -78oC will quickly desilylated the C17 TBS enol ether, re-exposing the carbonyl and 
delivering intermediate 204. Steroid 204 represents the fully complete core of 19-
hydroxysarmentogenin. All oxygenation is properly installed at this stage and with the desired 
configuration. 
 The final task is installation of the β-oriented C17 butenolide ring. Here, we employed a 
known 5-step sequence.11 In fact, this 5-step approach is rather general and is used for butenolide 
installation on all four of our original targets. First, the Barton conditions for vinyl Iodide 
formation can be utilized to convert 204 into intermediate 205. Next, vinyl iodide 205 is subjected 
to a Stilled coupling with known stannyl butenolide 73 in the presence of Pd0 and Cu(I). The 
coupling proceeds smoothly and in high yield to afford coupled product 206. At this stage, the 
chiral center at C17 must be set. However, the cis-trans-cis ring junction pattern imposes convexity 
to the β-face and concavity to the α-face, rendering the β-face more sterically accessible. As such, 
direct heterogenous hydrogenation of 206 results in hydrogen being delivered to the convex β-face 
and delivers primarily the undesired α-oriented butenolide. To overcome this, Inoue and co-
workers devised and successfully employed the solution of silylating the C14 hydroxy group. This 
sterically occludes the β-face and helps promote hydrogenation from the α-face. Global silylation 
of 206 with TMSOTf and 2,6-lutidine initially produces intermediate 207, wherein the butenolide 
ring has aromatized as a silyl enol ether. The silylated furan is very labile and undergoes rapid 
desilylation upon exposure to SiO2. Subsequent purification affords the desired C14-OTMS 
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intermediate 208. In our hands, the silylation procedure would often provide variable and mediocre 
yields despite the appearance of clean conversion to the desired product based on TLC and NMR 
analysis. With the C14 hydroxy silylated, hydrogenation over 10% Pd/C could proceed. Whereas 
Inoue and co-workers reports 8:1 dr favoring the β-oriented butenolide, our hydrogenation 
provided only 2.7:1 dr favoring 209. Nonetheless, with the desired configuration set at C17, only 
a global desilylation step remained. To accomplish this, we used HF in a ternary solvent system 
comprised of MeCN, DCM, and water. Over the course of 3 days, the compound was fully 
desilylated and pure 19-hydroxysarmentogenin (1) could be isolated. Our synthetic sample of 19-
hydroxysarmentogenin matched all available spectroscopic data reported by Inoue and co-workers. 
Additionally, the measured optical rotation ([α]D
25 = +13.4 (c = 0.1, MeOH) indicates that the 
desired natural enantiomer was synthesized. In summary, the complete total synthesis of 19-
hydroxysarmentogenin was accomplished in 21 total steps (compared to the previous route which 
required 34 steps). 
4.7. Elaboration of Intermediate 175 into Trewianin Aglycone 
 The synthesis of Trewianin aglycone was accomplished by a post-doctoral researcher in 
our lab Dr. Hem Raj Khatri. Trewianin is a naturally occurring cardenolide, similar to 19-
hydroxysarmentogenin except that it is epimeric at C5, containing a trans-A/B ring junction.21 
Intermediate 175 was successfully converted to the core of trewianin aglycone, intermediate 210, 
in 6 steps and 47% overall yield. Importantly, 210 contains the desired trans-A/B ring junction, 
and configuration at C11. From there, the same 5-step sequence for butenolide installation was 




Scheme 4.13. Summary of Trewianin Aglycone Total Synthesis. 
 
4.8. Elaboration of Intermediate 175 into Panogenin 
 Panogenin (173) is the aglycone of the naturally occurring cardenolide panoside.22 The 
important features of panogenin include a β-oriented hydroxy at C11, and a trans-A/B ring 
junction. The primary concern for synthesizing panogenin was controlling these stereocenters. 
Previously completed targets (19-hydroxysarmentogenin and trewianin aglycone) both incorporate 
α-oriented hydroxy groups at C11. A new approach for the stereocontrol of the key C5 and C11 
centers had to be devised. Conveniently, the C11-OH of intermediate 175 is already in the same 
configuration as panogenin. Rather than allowing the C11 position to be oxidized and then reduced 
at a later stage as was done previously, we opted to preserve the stereochemical information at 
C11 from the outset – we imagined this approach would reduce the total number of transformations 
required to complete the synthesis. To accomplish this, we envisioned the formation of an acetal 
between the C19 and C11 hydroxy groups. Importantly, such a transformation effectively controls 
stereochemistry at both C11 and C5 because C11 is protected from downstream oxidation, and the 
presence of an acetal on the β-face of the steroid provides a steric bias for the hydrogenation of C5 
to occur from the desired α-face. We first investigated formation of a cyclic silyl acetal via 
Si(tBu)2Cl2. However, these attempts produced a complex mixture of products. Instead, 
acetalization was attempted with 2,2-dimethoxypropane in DMF with catalytic S-camphorsulfonic 
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acid. This acetalization proceeded smoothly to afford cyclic acetal intermediate 211 (Scheme 
4.14.). Next, the C17 hydroxy group was oxidized with the Dess-Martin periodinane to cleanly 
afford compound 212. 




 At this stage, the C5 position could be hydrogenated. The C19-C11 acetal successfully 
provides some steric occlusion of the se face at C5, allowing hydrogenation over Pd/C to proceed 
in 2.5:1 dr favoring the desired trans-A/B ring junction 213. The next goal was the regio- and 
stereoselective reduction of the C3 carbonyl. At this stage, there is an important conformational 
distinction to be made between 213 and the corresponding triketone of 19-hydroxysarmentogenin, 
compound 201. In the case of 201, the desired hydride reduction at C3 would provide an axial C3 
hydroxy group, therefore requiring an equatorial approach of the hydride source. However, with 
intermediate 213, the desired reduction at C3 will provide an equatorial β-oriented C3 hydroxy 
and so an axial approach of the hydride source is necessary. For this, we opted to use LiAl(OtBu)3H 
(LATBH). Though it may seem like a sterically bulky hydride source, similar to K-selectride, 
LATBH often behaves as a small hydride source and is known to reduce conformationally biased 
cyclohexanones via axial approach.23 Indeed, the use of LATBH at -35oC to reduce triketone 213 
provided the desired mode of reactivity, and intermediate 214 could be isolated with an 
equatorially β-oriented hydroxy at C3 with complete diastereoselectivity. Here, the complete core 
of panogenin, emulating all natural oxygenation and stereochemistry, is completed and only the 
butenolide installation remains. 
The known 5-step sequence could be employed again for successful butenolide installation. 
In this regard, conversion of panogenin core 214 to vinyl iodide 215 was accomplished via the 
Barton vinyl iodide protocol. Subsequent Stille coupling of iodide 215 with the stannyl butenolide 
73 afforded coupled product 216. Global silylation with TMSOTf and 2,6-lutidine set the stage for 
diastereoselective hydrogenation. Interestingly, hydrogenation of 217 over Pd/C proceeded 
exclusively from the α-face and the crude material could be immediately subjected for global 
deprotection. This completely diastereoselective hydrogenation is also observed during the 
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synthesis of cis-panogenin (174) described in the next section – perhaps a result of the β-oriented 
hydroxy group at C11 in these substrates. The presence of the C19-C11 acetal caused us to modify 
the method for deprotection. Rather than using the usual HF method, we employed the same 0.3 
M HCl in MeOH conditions utilized by Inoue and co-workers for deprotection of 218. In just 30 
minutes, all hydroxy groups are deprotected and desired target panogenin (173) is produced in 19 
total steps. The observed optical rotation ([α]D
27 = +22.4 (c = 0.08, CH3OH)) closely matches the 
reported value of +25.8, indicating the natural enantiomer was prepared.24 
4.9. Elaboration of Intermediate 175 into cis-Panogenin 
 cis-Panogenin (174) has not yet been discovered from natural sources. Its key architectural 
difference from panogenin is the presence of a cis-α-A/B ring junction and it represents the last of 
four possible diastereomers among the C5 and C11 stereocenters. In an effort to acquire cis-
panogenin (174), intermediate 175 was hydrogenated with KOH to produce a cis-β-A/B ring 
junction intermediate 200 (Scheme 4.15.). The C19 hydroxy was then silylated with TIPS. Next, 
the material was subjected to the Dess-Martin periodinane with the expectation of acquiring 
triketone 201 on route to 19-hydroxysarmentogenin. However, only monoxidation of C17 was 
observed, affording 219 with the C11 hydroxy group unoxidized and retaining a β-orientation. 
This was a good opportunity to take advantage of the unexpected result and divert the synthesis 
toward the final remaining C5/C11 diastereomer, cis-panogenin (174). With a cis-β-A/B ring 
junction installed, the C3 carbonyl could be reduced with K-selectride in a regio- and 
stereoselective manner to generate intermediate 220. At this stage, the full core of cis-panogenin 
had been completed, containing all the necessary sites of oxygenation, a cis-β-A/B ring junction, 




Scheme 4.15. Total Synthesis of cis-Panogenin. 
 
The final sequence commenced with vinyl iodide formation using the usual Barton 
protocol, followed by Stille coupling with the stannyl butenolide to produce the coupled product 
222. Unfortunately, subsequent silylation of the C14 hydroxy provided poor yield of the desired 
product 223 for unknown reasons. Nonetheless, the ensuing hydrogenation proceeded with 
complete diastereoselectivity. Generating the β-oriented butenolide 224 exclusively. Global 
deprotection occurred completely in just 45 minutes upon exposure to 0.3 M HCl in MeOH to 
afford the target cis-panogenin (174) in 19 total steps. Despite the presence of a TIPS group on the 
C19 hydroxy, the final deprotection procedure was changed from the previously described 
approach with HF in MeCN, DCM, and water because the method using HF should not be 
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performed in borosilicate glassware and so was found to be operationally more difficult than 
simple acid-promoted deprotection. Despite the successful synthesis of cis-panogenin, it is likely 
that we would use a revised route for any future attempts at synthesizing this target. This proposed 
route is outlined in Scheme 4.16. The cis-β-A/B ring junction is installed by the same C19 directed 
hydrogenation under basic conditions. However, a more reliable method for setting the 
stereochemistry at C11 is likely via acetalization of the C19 and C11 hydroxy groups, producing 
acetal 225. Subsequent oxidation with the Dess-Martin periodinane and C3 carbonyl reduction by 
K-selectride could provide cis-panogenin core 226. The same 5-step butenolide installation 
procedure could be employed to acquire the final target. This proposed route would avoid the need 
to reproduce the unusual monoxidation leading to 219 and may provide more straightforward 
access cis-panogenin (174). 





4.10. Evaluation via Biochemical Assay 
 The biological evaluation of cardenolides has much precedence. Some studies have 
focused on the ability of cardenolides to act as anticancer agents, while others have sought to 
explore their ability to specifically inhibit the Na+/K+ATPase.25 The nature of Na+/K+ATPase 
inhibition is better understood due to structure-activity relationship studies and X-ray co-
crystallographic analysis.26,27 However, only the common cardenolides such as ouabain (2) and 
digitalis tend be used in these studies. Moreover, the connection between Na+/K+ATPase 
inhibition, anticancer activity, isoform selectivity, and therapeutic window is not well understood. 
Access to new cardenolides and their analogues for further exploration of these connections is 
highly desirable. It is the goal of our group to synthesize new cardenolides for the purpose of 
biological evaluation. Specifically, we hope to explore the connection, if any, between 
Na+/K+ATPase isoform inhibition and anticancer activity and to better understand the structural 
features which modulate the antiproliferative and toxic effects of cardenolides. 
  As part of a collaborative effort funded by the Chemistry-Biology Interface training 
program at the University of Michigan, I spent a 10-week sabbatical in the lab of Dr. Dan Michele 
(Department of Molecular and Integrative Physiology, University of Michigan) developing a 
biochemical assay for the evaluation of the cardenolides we’ve synthesized (Scheme 4.17.). In a 
non-inhibited state, the Na+/K+ATPase will bind ATP, followed by three Na+ ions.28 The bound 
ATP is then hydrolyzed, leading to phosphorylation of an aspartate residue. This phosphorylation 
promotes a conformational change and subsequent release of the Na+ ions on the extracellular 
surface of the pump. Two K+ ions will then bind the extracellular surface and dephosphorylation 
ensues – releasing one equivalent of inorganic phosphate per cycle. Upon release of phosphate, 
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the enzyme reverts to its original confirmation and the bound K+ is released from the intracellular 
surface of the pump, thus refreshing the catalytic cycle. 
Scheme 4.17. Schematic for Mechanism of Na+/K+ATPase Biochemical Assay. 
 
 In the presence of an inhibitor, the enzyme’s function is slowed or halted and the rate of 
hydrolysis of ATP is reduced. Therefore, the amount of phosphate produced is directly correlated 
with the enzyme’s activity level. In the assay we developed, the production of phosphate is 
measured by use of a commercial colorimetric reagent, BIOMOL green (Enzo Life Sciences). This 
reagent is a preparation of molybdate/malachite green-based phosphate detection. In a manner 
dependent on the phosphate concentration, a solution of BIOMOL green will display increased 
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optical density at 620 nm. A non-inhibited Na+/K+ATPase control will freely produce large 
quantities of phosphate, resulting in high optical density at 620 nm (OD620) following addition of 
BIOMOL green. In the presence of a strong inhibitor, the production of phosphate will be slowed 
and the OD620 will remain flat after analysis with BIOMOL green. A concentration-response curve 
can be generated by measuring the OD620 which results after the enzymatic reaction is performed 
in the presence of an inhibitor at serial dilutions. The percent activity of the Na+/K+ATPase in each 
test well was determined by subtracting the background signal of the blank wells of the same plate, 
and then dividing by the signal of the uninhibited controls containing only vehicle. 
The Na+/K+ATPase used in our assay was isolated from the porcine cerebral cortex. All 
three pig isoforms show >99% amino acid identity with the human isoforms.29 A concentration-
response curve of commercially acquired ouabain (2) was generated to compare with the measured 
IC50 values of our test compounds (Figure 4.2.). The IC50 value of ouabain was determined to be 
660 nM. Neither of the steroids WK-5-197 or WK-5-199 showed any activity at concentrations 
below 399 µM or 150 µM, respectively. This is likely due to the absence of a C17 butenolide ring, 
which has previously been implicated as a key moiety necessary for binding. Steroid WK-5-198 
is an interesting case. This compound contains an installed butenolide but has a C16-C17 olefin; 
meaning there is no stereochemical information at C17. Steroid WK-5-198 showed no obvious 
ability to inhibit the Na+/K+ATPase in our assay at concentrations lower than 100 µM. Yet in 
contrast to the other analogues WK-5-197 and WK-5-199, WK-5-198 appeared to show the onset 














However, simple reduction of the C16-C17 olefin of compound WK-5-198 generates 
panogenin (173), which showed much stronger inhibition of the Na+/K+ATPase with an IC50 of 
819 nM. This corroborates the notion that the correct orientation of the C17 butenolide is crucial 
for proper binding. Additionally, both 19-hydroxysarmentogenin (1) and cis-panogenin (174) 
showed reliable concentration response curves, with IC50 values of 1.44 µM and 706 nM, 
respectively. We suspected that the trans-A/B ring junction compound panogenin would exhibit 
poorer binding than its cis-β-A/B counterparts, cis-panogenin and 19-hydroxysarmentogenin, due 
its unique 3D shape, but this was not observed to a significant degree and both panogenin and cis-
panogenin showed similar concentration-response curves. Moreover, the synthetic steroids 
panogenin and cis-panogenin displayed IC50 values approximately half of that for 19-
hydroxysarmentogenin (1). This result may suggest that a β-oriented C11 hydroxy group affords 
lower IC50 values, while the orientation at C5 is of little consequence. However, a previous study 
has implicated the importance of a trans-A/B ring junction in α1 isoform selectivity and anticancer 
activity.30 Our measured IC50 values are compiled in Table 4.1.  
Table 4.1. Summary of IC50 Values for Tested Compounds. 
Compound IC50 
19-hydroxysarmentogenin (1) 1.44 µM (error range 1.27 – 1.64 µM) 
panogenin (173) 819 nM (error range 729 – 918 nM) 
cis-panogenin (174) 706 nM (error range 625 – 797 nM) 
ouabain (2) 660 nM (error range 571 – 763 nM) 
WK-5-197 >1 mM 
WK-5-198 >1 mM 




Unfortunately, the preparation of Na+/K+ATPase we acquired from Sigma Aldrich was a 
mixture of all three α isoforms from the porcine cerebral cortex, and so no isoform selectivity 
information could be extracted. We hope to acquire purified Na+/K+ATPase isoforms for use in 
the developed assay to allow for comparisons of isoform selectivity. Furthermore, we aim to 
investigate concentration-response curves of additional cardenolides, including some C3 
glycosylated derivatives for which we are currently developing synthetic access.  
 In addition to the biochemical assay developed for Na+/K+ATPase inhibition, we have 
recently begun a collaboration with Dr. Yimon Aye at Cornell University. Her group is set to assist 
with the evaluation of the antiproliferative effects of the steroids we have synthesized. In 
conjunction with the results from Aye group, we aim to explore Na+/K+ATPase inhibition and 
isoform selectivity to understand how certain structural features modulate binding and bioactivity, 
and whether there are significant correlations between Na+/K+ATPase isoform selectivity and 
anticancer effects. 
4.11. Conclusion 
 We have successfully expanded on the methodology described in chapter 3 to gain 
expedient access to the cardenolides 19-hydroxysarmentogenin (1), panogenin (173), trewianin 
aglycone (172), and cis-panogenin (174). By discovering reliable means of pre-installing key 
oxygenation on the simple starting substrates in an asymmetric fashion, we circumvented the need 
for late stage redox manipulations at otherwise inert positions. In doing so, we completed the 
synthesis of heavily functionalized key intermediate 175 in only 7 linear steps from simple and 
commercially available building blocks. From there, 175 could be readily diverted to a number of 
natural and unnatural cardenolides, allowing the concise total synthesis of all four C5/C11 isomers 
of the general 19-hydroxysarmentogenin architecture (in 19 to 21 total steps). Upon completing 
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the synthesis of the four major targets, we subjected them to a biochemical assay to determine IC50 
values of Na+/K+ATPase inhibition and discovered some interesting potential structure-activity 
relationships. The β-orientation of the C17 butenolide ring appeared to be crucial for effective 
inhibition while the stereochemistry at C5 had little to no effect. Additionally, a β configuration at 
C11 may have promoted a slight lowering of the IC50 value.  
 We hope to continue the methodology expansion to access even more heavily oxidized 
cardenolides such as ouabain. Further, we aim to establish a lasting collaboration for testing the 
antiproliferative activity of the steroids we synthesize – to further understand the structural features 
















All reagents and solvents were purchased from commercial sources and were used as 
received without further purification unless otherwise specified. THF and DMF were purified by 
Innovative Technology’s Pure-Solve System using basic alumina. All reactions were carried out 
under a positive pressure of nitrogen in flame- or oven-dried glassware with magnetic stirring. 
Reactions were cooled using a cryocool or external cooling baths (sodium chloride/ice water (-
10°C) or dry ice/acetone (-78°C)). Heating was achieved by use of a silicone oil bath with heating 
controlled by electronic contact thermometer. Deionized water was used in the preparation of all 
aqueous solutions and for all aqueous extractions. Solvents used for extraction and 
chromatography were ACS or HPLC grade. Purification of reactions mixtures was performed by 
flash chromatography using SiliCycle SiliaFlash P60 (230-400 mesh). Alternatively, purifications 
were achieved using CombiFlash Rf+ Lumen Automated Flash Chromatography System with UV 
and ELSD detector using either SiliCycle SiliaFlash P60 (230-400 mesh) or Teledyne RediSep Rf 
Gold Silica (20-40 m spherical). Yields indicate the isolated yield of the title compound with 
≥95% purity as determined by 1H NMR analysis. Whereas the yields in the article are the average 
yields of two or more experiments, the yields in the supporting information describe the result of 
a single experiment. Diastereomeric ratios were determined by 1H NMR analysis. Enantiomeric 
excess was determined by HPLC analysis using a Waters e2695 Separations Module with a Waters 
2998 photodiode array detector on a Chiralcel AD-H column. 1H NMR spectra were recorded on 
a Varian vnmrs 700 (700 MHz), Varian vnmrs 500 (500 MHz), Varian vnmrs 400 (400 MHz), or 
a Varian Inova 500 (500 MHz) spectrometer and chemical shifts (δ) are reported in parts per 
million (ppm) with solvent resonance as the internal standard (CDCl3 at δ 7.26, D3COD at δ 3.31). 
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Tabulated 1H NMR Data are reported as s = singlet, d = doublet, t = triplet, q = quartet, qn = 
quintet, sext = sextet, m = multiplet, ovrlp = overlap, and coupling constants in Hz. Proton-
decoupled 13C NMR spectra were recorded on Varian vnmrs 700 (700 MHz) spectrometer and 
chemical shifts (δ) are reported in ppm with solvent resonance as the internal standard (CDCl3 at 
δ 77.0, D3COD at δ 49.0). High resolution mass spectra (HRMS) were performed and recorded on 
Micromass AutoSpec Ultima or VG (Micromass) 70-250-S Magnetic sector mass spectrometers 
in the University of Michigan mass spectrometry laboratory. Infrared (IR) spectra were recorded 
as thin films a Perkin Elmer Spectrum BX FT-IR spectrometer. Absorption peaks are reported in 
wavenumbers (cm-1). Optical rotations were measured at room temperature in CHCl3 or H3COH 
on a Jasco P-2000 polarimeter. 
Reaction Protocols and Compound Characterization 
 
 
(S,E)-1-(1-methyl-2,5-dioxocyclopentyl)-5-oxohex-3-en-2-yl benzoate (182) 
Benzoyl peroxide (18.7 g, 77.4 mmol) and hydroquinone (990 mg, 9 mmol) were solvated in THF 
(300 mL) and H2O (0.5 mL). Then, (S)-2- (diphenyl((trimethylsilyl)oxy)methyl)pyrrolidine (1.95 
g, 6.0 mmol) was added followed by 3-(1-methyl-2,5-dioxocyclopentyl)propanal (10.0 g, 59.5 
mmol). The reaction mixture was then stirred at room temperature under N2 until the disappearance 
of starting material by 1H NMR. After 1.5 h, the reaction mixture was concentrated in vacuo and 
directly purified using flash column chromatography with 30% EtOAc in hexanes to afford (S)-1-
(1-methyl-2,5-dioxocyclopentyl)-3-oxopropan-2-yl benzoate (13.5 g, 46.8 mmol) as viscous oil in 
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79% yield. The material was immediately used for the next step without further purification. (S)-
1-(1-methyl-2,5-dioxocyclopentyl)-3-oxopropan-2-yl benzoate (13.5 g, 46.8 mmol) was solvated 
in toluene (300 mL) and Wittig reagent 1-(tripheylphosphoranylidene)-2-propanone (22.2 g, 69.7 
mmol) was added. The reaction was allowed to stir at room temperature for 12 h. The solution was 
then concentrated in vacuo and directly purified by flash column chromatography with 20% → 
30% EtOAc in hexanes to afford title compound (S,E)-1-(1-methyl-2,5-dioxocyclopentyl)-5-
oxohex-3-en-2-yl benzoate (182) (11.5 g, 35.0 mmol) as a white solid in 75% yield, 95% ee 
(Chiralpak AD-H, 12% iPrOH in hexanes, R-enantiomer 13.2 minutes, S-enantiomer 28 minutes), 
Rf = 0.3 (33% EtOAc in Hexanes). 1H NMR (700 MHz, CDCl3): δ 7.61 (t, J = 7.4 Hz, 1H), 7.48 
(t, J = 7.8 Hz, 2H), 6.64 (dd, J = 16.1, 5.3 Hz, 1H), 6.19 (dd, J = 16.1, 1.2 Hz, 1H), 5.63 - 5.49 (m, 
1H), 2.82 - 2.69 (m, 2H), 2.57 - 2.49 (m, 1H), 2.49 - 2.36 (m, 2H), 2.25 (s, 3H), 2.15 (dd, J = 14.6, 
3.3 Hz, 1H), 1.19 (s, 3H). 13C NMR (175 MHz, CDCl3): δ 215.7, 214.8, 197.6, 165.4, 142.7, 133.8, 
130.6, 129.7, 128.7, 128.7, 70.1, 54.3, 37.9, 34.7, 34.6, 27.4, 23.1. HRMS (ESI): m/z calcd for 
C19H20O5Na
+ [M+Na]+ 351.1203, found 351.1206. IR (film, cm-1): 1722, 1678, 1364, 1252, 1100, 
1070, 982, 715. [α]D
25 = -29 (c = 1.0, CHCl3). 
 
 
Ethyl (5R,8R,9S,10S,11S,13R,14R)-11-(benzoyloxy)-5,14-dihydroxy-13-methyl-17 oxohexa 
decahydro-10H-cyclopenta[a]phenanthrene-10-carboxylate (184) 
(S,E)-1-(1-methyl-2,5-dioxocyclopentyl)-5-oxohex-3-en-2-yl benzoate 182 (328.0 mg, 1.0 mmol), 
and ethyl 2-oxocyclohexane-1-carboxylate 94 (500 mg, 2.94 mmol) were successively added to a 
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flask with a stir bar and the vessel was purged with nitrogen. Then, Cu(OTf)2 (54 mg, 0.015 mmol) 
was added and the reaction was allowed to stir at room temperature overnight. The next day, the 
residue was filtered through a plug of silica with diethyl ether as eluent. The crude mixture was 
then purified by flash column chromatography with 10% → 50% EtOAc in hexanes. The resultant 
adduct was used for cyclization without further purification. It was solvated in THF (2.5 mL), and 
1,8- diazabycyclo[5.4.0]undec-7-ene (50.4 mg, 49 µL, 0.33 mmol) was added via syringe. The 
solution was allowed to reflux for 18 h. Afterwards, the solution was cooled and concentrated in 
vacuo. The resulting residue was directly purified by flash column chromatography with 30% 
EtOAc in hexanes to afford title compound ethyl (5R,8R,9S,10S,11S,13R,14R)-11-(benzoyloxy)-
5,14-dihydroxy-13-methyl-17-oxohexadecahydro-10H-cyclopenta[a]phenanthrene-10-
carboxylate (184) (219.1 mg, 0.44) in 44% unoptimized yield, Rf = 0.2 (30% EtOAc in hexanes). 
The product was then crystallized from hexanes/CH2Cl2 and submitted for X-ray analysis. 
1H 
NMR (500 MHz, CDCl3): δ 7.86 (d, J = 7.2 Hz, 2H), 7.54 (t, J = 7.4 Hz, 1H), 7.42 (t, J = 7.7 Hz, 
2H), 5.41 (d, J = 1.1 Hz, 1H), 4.41 (s, 1H), 3.85 - 3.73 (m, 2H), 3.71 (d, J = 12.6 Hz, 1H), 3.31 (s, 
1H), 2.58 (dd, J = 15.1, 3.3 Hz, 1H), 2.55 - 2.38 (m, ovrlp, 5H), 2.34 - 2.21 (m, 1H), 2.08 – 2.21 
(m, 2H), 1.98 (d, J = 14.5 Hz, 1H), 1.63 - 1.45 (m, ovrlp, 6H), 1.41 - 1.28 (m, 1H), 0.98 (s, 3H), 
0.92 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 216.1, 212.8, 174.1, 165.0, 133.2, 129.7, 
129.6, 128.3, 77.5, 74.9, 67.4, 61.0, 54.1, 51.8, 51.6, 49.0, 40.2, 35.8, 34.8, 33.4, 31.7, 21.1, 20.4, 






Ethyl 4-chloro-2-oxocyclohex-3-ene-1-carboxylate (192) 
Ethyl 2,4-dioxocyclohexanecarboxylate (11.0 g, 59.8 mmol, 1.0 equiv.) was taken in chloroform 
(110 mL, 0.54 M) and cooled to 0°C. PCl3 (10.5 mL, 119.6 mmol, 2.0 equiv.) was added. After 1 
hour, the reaction mixture was warmed to room temperature and additional PCl3 (7.0 mL, 79.7 
mmol, 1.3 equiv.) was added. The reaction mixture was allowed to stir at room temperature and 
monitored by TLC analysis. After 7 hours, the reaction mixture was concentrated in vacuo and 
purified by column chromatography (grad. 5%→10% EtOAc in hexanes) to afford ethyl 4- chloro-
2-oxocyclohex-3-ene-1-carboxylate (192) (8.1 g, 40.1 mmol, 67% yield) as a colorless oil. 1H 
NMR (700 MHz, CDCl3) δ 6.27 (t, J = 1.4 Hz, 1H), 4.25-4.18 (m, 2H), 3.36 (dd, J = 4.9, 9.0 Hz, 
1H), 2.83 (dt, J = 5.8, 18.9 Hz, 1H), 2.70 (dt, J = 6.5, 18.9 Hz, 1H), 2.48-2.43 (m, 1H), 2.25 (dq, J 
= 5.1, 16.7 Hz, 1H); 13C NMR (175 MHz, CDCl3) δ 191.3, 169.2, 158.6, 127.7, 61.6, 51.8, 32.3, 
25.1, 14.1; HRMS (ESI): m/z calcd for C9H11ClO3 [M+Na]




dioxocyclopentyl)-5-oxohexan-2-yl benzoate (194).  
(S,E)-1-(1-methyl-2,5-dioxocyclopentyl)-5-oxohex-3-en-2-yl benzoate 182 (5.7 g, 17.3 mmol), 
ethyl 4-chloro-2-oxocyclohex-3-ene-1-carboxylate 192 (7.0 g, 34.5 mmol), and copper(II) triflate 
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(3.1 g, 8.6 mmol) were added successively to a flame dried flask. The vessel was purged with N2 
and dry CH2Cl2 (10 mL) was added. The reaction mixture was allowed to stir at room temperature 
until starting material was completely consumed as determined by TLC. After 9 h, the reaction 
mixture was filtered through a pad of silica gel and eluted with diethyl ether. The filtrate was 
concentrated and directly purified by flash column chromatography with 30% → 50% EtOAc in 
hexanes to afford title compound (2S,3S)-3-((S)-4-chloro-1-(ethoxycarbonyl)-2-oxocyclohex-3-
en-1-yl)-1-(1-methyl-2,5-dioxocyclopentyl)-5-oxohexan-2-yl benzoate (194) (6.4 g, 12.1 mmol) 
as a white foam in 70% yield, Rf = 0.2 (33% EtOAc in Hexanes), and 6:1 d.r. as well as crude 
fractions of half cyclized aldol product (3aR,5S,6S,7R,7aR)-7-acetyl-6-((S)-4-chloro-1-
(ethoxycarbonyl)-2-oxocyclohex-3-en-1-yl)-7a-hydroxy-3a-methyl-3-oxooctahydro-1H-inden-5-
yl benzoate (195) (1.8 g, 3.45 mmol) in 20% yield.  
(2S,3S)-3-((S)-4-chloro-1-(ethoxycarbonyl)-2-oxocyclohex-3-en-1-yl)-1-(1-methyl-2,5-
dioxocyclopentyl)-5-oxohexan-2-yl benzoate (194): 1H NMR (500 MHz, CDCl3): δ 7.89 (d, J = 
7.2 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.45 (t, J = 7.7 Hz, 2H), 6.18 (d, J = 1.2 Hz, 1H), 5.20 (d, J 
= 8.6 Hz, 1H), 3.90 - 3.79 (m, 2H), 3.21 (t, J = 4.8 Hz, 1H), 3.04 (dd, J = 19.1, 5.7 Hz, 1H), 2.84 
(dd, J = 19.1, 4.2 Hz, 1H), 2.81 - 2.71 (m, ovrlp, 3H), 2.70 - 2.60 (m, 1H), 2.55 (dt, J = 19.5, 4.6 
Hz, 1H), 2.48 - 2.36 (m, ovrlp, 2H), 2.23 (s, 3H), 2.20 (d, J = 10.1 Hz, 1H), 2.08 (dd, J = 14.9, 2.7 
Hz, 1H), 1.94 (ddd, J = 14.2, 9.2, 5.3 Hz, 1H), 1.11 (s, 3H), 1.08 (t, J = 7.1 Hz, 3H). 13C NMR 
(100 MHz, CDCl3): δ 215.0, 214.8, 206.0, 191.9, 169.0, 166.4, 156.8, 133.5, 129.5, 128.6, 127.8, 
70.6, 61.9, 58.1, 55.6, 39.5, 39.23, 37.4, 34.19, 34.15, 31.6, 30.0, 27.3, 24.3, 13.7. HRMS (ESI): 
m/z calcd for C28H31ClO8Na
+ [M+Na]+ 553.1600, found 553.1603. IR (film, cm-1): 2934, 1722, 
1685, 1618, 1419, 1276, 1184, 1070, 715. [α]D 




hydroxy-3a-methyl-3-oxooctahydro-1H-inden-5-yl benzoate (195): 1H NMR (500 MHz, CDCl3): 
δ 7.87 (d, J = 7.4 Hz, 2H), 7.57 (t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.7 Hz, 2H), 6.07 (s, 1H), 5.45 (d, 
J = 1.6 Hz, 1H), 4.31 (s, 1H), 4.11 (d, J = 11.6 Hz, 1H), 3.78 (dq, J = 14.3, 7.1 Hz, 1H), 3.44 (dq, 
J = 14.3, 7.2 Hz, 1H), 2.92 (d, J = 11.6 Hz, 1H), 2.78 - 2.30 (m, 10H), 2.22 - 2.00 (m, 1H), 1.90 
(dd, J = 13.5, 8.8 Hz, 1H), 1.74 (dd, J = 15.4, 3.3 Hz, 1H), 1.02 (s, 3H), 0.87 (t, J = 7.1 Hz, 3H). 
13C NMR (100 MHz, CDCl3): δ 217.3, 214.5, 193.2, 168.5, 165.3, 154.1, 133.3, 129.7, 129.5, 
128.4, 126.3, 78.0, 68.2, 61.4, 57.3, 51.5, 49.1, 38.6, 36.1, 34.6, 32.5, 31.0, 30.8, 28.5, 19.8, 13.5. 
HRMS (ESI): m/z calcd for C28H32ClO8
+ 531.1786 [M+H]+, found 531.1773. IR (film, cm-1): 
3457(br), 2916, 1743, 1722, 1682, 1620, 1359, 1271, 1185, 1072, 1043, 756, 713. [α]D 
25 = +91.9 
(c = 0.5, CHCl3).  
Minor diastereomer of adduct 194 characteristic 1H NMR peaks (400 MHz, CDCl3): δ 7.88 (d, J = 
7.4 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.45 (t, J = 7.7 Hz, 2H), 6.09 (s, 1H), 5.32 (d, J = 10.2 Hz, 
1H), 4.16 - 3.95 (m, 2H), 3.24 (t, 1H), 2.99 (dd, J = 16.3, 5.7 Hz, 1H), 2.23 (s, 3H), 2.00 - 1.88 (m, 














hydroxy-3a-methyl-3-oxooctahydro-1H-inden-5-yl benzoate 195 (7.0 g, 13.2 mmol) and p-
toluenesulfonic acid monohydrate (26.0 g, 136.8 mmol) were solvated in acetonitrile (350 mL) 
and the solution was heated to 55oC for 48 h. The reaction mixture was then concentrated and 
CH2Cl2 (400 mL) was added. The p-TSA precipitated and was filtered off. The filtrate was then 
concentrated and directly purified by flash column chromatography with 10% → 30% EtOAc in 
hexanes to afford title compound ethyl (8R,9S,10S,11S,13R,14R)-11-(benzoyloxy)-3-chloro-14-
hydroxy-13-methyl-7,17-dioxo-1,2,7,8,9,11,12,13,14,15,16,17-dodecahydro-10H-
cyclopenta[a]phenanthrene-10-carboxylate (196) (3.8 g, 7.4 mmol) as a white solid in 56% yield, 
Rf = 0.4 (50% EtOAc in Hexanes). 1H NMR (700 MHz, CDCl3): δ 7.80 (d, J = 8.3 Hz, 2H), 7.54 
(t, J = 7.4 Hz, 1H), 7.41 (t, J = 7.8 Hz, 2H), 6.31 (d, J = 1.9 Hz, 1H), 5.95 (s, 1H), 5.54 (s, 1H), 
3.68 (dq, J = 10.9, 7.1 Hz, 1H), 3.41 (d, J = 13.2 Hz, 1H), 3.32 (dq, J = 10.9, 7.1 Hz, 1H), 3.19 (dd, 
J = 13.0, 9.2 Hz, 1H), 3.08 (s, 1H), 2.87 - 2.74 (ovrlp, 2H), 2.64 (dd, J = 15.1, 3.6 Hz, 1H), 2.56 - 
2.44 (ovrlp, 3H), 2.39 - 2.29 (m, 1H), 2.12 (td, J = 12.5, 9.7 Hz, 1H), 1.63 (ddd, J = 13.0, 11.9, 6.1 
Hz, 1H), 1.56 (dd, J = 15.1, 2.4 Hz, 1H), 1.00 (s, 3H), 0.89 (t, J = 7.1 Hz, 3H). 13C NMR (175 
MHz, CDCl3): δ 216.5, 200.8, 169.6, 164.8, 152.0, 144.2, 133.3, 129.8, 129.4, 128.3, 126.8, 125.3, 




+ [M+H]+ 513.1675, found 513.1680. IR (film, cm-1): 3507(br), 2911, 1724, 
1697, 1658, 1625, 1451, 1350, 1277, 1177, 1074, 1027, 900, 717. [α]D 







dioxocyclopentyl)-5-oxohexan-2-yl benzoate 194 (8.0 g, 15.1 mmol) and p-toluenesulfonic acid 
monohydrate (28.7 g, 150.9 mmol) were solvated in acetonitrile (400 mL) and the solution was 
heated to 55oC for 48 h. The reaction mixture was then concentrated and CH2Cl2 (500 mL) was 
added. The p-TSA precipitated and was filtered off. The filtrate was then concentrated and directly 
purified by flash column chromatography with 10% → 30% EtOAc in hexanes to afford title 
compound ethyl (8R,9S,10S,11S,13R,14R)-11-(benzoyloxy)-3-chloro-14-hydroxy-13-methyl-
7,17-dioxo-1,2,7,8,9,11,12,13,14,15,16,17-dodecahydro-10H-cyclopenta[a]phenanthrene-10-
carboxylate (196) (5.3 g, 10.4 mmol) as a white solid in 68% yield, Rf = 0.4 (50% EtOAc in 
Hexanes). 1H NMR (700 MHz, CDCl3): δ 7.80 (d, J = 8.3 Hz, 2H), 7.54 (t, J = 7.4 Hz, 1H), 7.41 
(t, J = 7.8 Hz, 2H), 6.31 (d, J = 1.9 Hz, 1H), 5.95 (s, 1H), 5.54 (s, 1H), 3.68 (dq, J = 10.9, 7.1 Hz, 
1H), 3.41 (d, J = 13.2 Hz, 1H), 3.32 (dq, J = 10.9, 7.1 Hz, 1H), 3.19 (dd, J = 13.0, 9.2 Hz, 1H), 
3.08 (s, 1H), 2.87 - 2.74 (ovrlp, 2H), 2.64 (dd, J = 15.1, 3.6 Hz, 1H), 2.56 - 2.44 (ovrlp, 3H), 2.39 
- 2.29 (m, 1H), 2.12 (td, J = 12.5, 9.7 Hz, 1H), 1.63 (ddd, J = 13.0, 11.9, 6.1 Hz, 1H), 1.56 (dd, J 
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= 15.1, 2.4 Hz, 1H), 1.00 (s, 3H), 0.89 (t, J = 7.1 Hz, 3H). 13C NMR (175 MHz, CDCl3): δ 216.5, 
200.8, 169.6, 164.8, 152.0, 144.2, 133.3, 129.8, 129.4, 128.3, 126.8, 125.3, 78.5, 66.8, 62.03, 52.1, 
46.8, 46.4, 45.7, 34.8, 33.5, 32.1, 31.8, 30.3, 20.6, 13.6. HRMS (ESI): m/z calcd for C28H30ClO7
+ 
[M+H]+ 513.1675, found 513.1680. IR (film, cm-1): 3507(br), 2911, 1724, 1697, 1658, 1625, 1451, 
1350, 1277, 1177, 1074, 1027, 900, 717. [α]D 








(2.0 g, 3.9 mmol) was solvated in dry toluene (30 mL) and cooled to -78oC under N2. Then, a 
solution of sodium bis(trimethylsilyl)amide (860 mg, 4.7 mmol) in toluene (10 mL) was added 
dropwise to the reaction vessel. The solution was allowed to stir at -78oC for 1 hour before it was 
slowly warmed to room temperature and subsequently placed in a 42oC oil bath where it was stirred 
for an additional 45 minutes. The reaction was cooled and quenched with a saturated NH4Cl 
solution (5 mL), concentrated in vacuo, and directly adsorbed onto silica gel and purified by flash 





(197) (960 mg, 1.9 mmol) as an off white solid in 48% yield and 68% BRSM, Rf = 0.5 (50% 
EtOAc in Hexanes). 1H NMR (700 MHz, CDCl3): δ 8.01 (d, J = 7.2 Hz, 2H), 7.61 (t, J = 7.4 Hz, 
1H), 7.47 (t, J = 7.8 Hz, 2H), 6.35 (d, J = 2.1 Hz, 1H), 5.96 (s, 1H), 5.74 (d, J = 2.5 Hz, 1H), 5.24 
(s, 1H), 3.79 (dq, J = 10.9, 7.1 Hz, 1H), 3.66 (d, J = 13.6 Hz, 1H), 3.46 (dq, J = 10.9, 7.1 Hz, 1H), 
2.96 - 2.83 (m, 1H), 2.79 (dd, J = 13.1, 5.3 Hz, 1H), 2.64 - 2.56 (m, 1H), 2.53 (dd, J = 19.6, 5.7 
Hz, 1H), 2.41 (ddd, J = 19.3, 6.5, 4.0 Hz, 1H), 2.28 (dd, J = 13.6, 2.2 Hz, 1H), 2.06 - 2.00 (m, 2H), 
1.90 (dd, J = 15.6, 3.1 Hz, 1H), 1.65 (ddd, J = 13.3, 11.3, 6.1 Hz, 1H), 1.45 (dd, J = 15.6, 2.8 Hz, 
1H), 1.21 (s, 3H), 0.93 (t, J = 7.1 Hz, 3H). 13C NMR (175 MHz, CDCl3): δ 218.9, 202.7, 168.9, 
164.8, 153.8, 145.3, 133.7, 129.8, 129.2, 128.6, 126.0, 125.1, 80.9, 66.1, 62.2, 51.7, 49.1, 45.5, 
45.2, 34.9, 33.1, 31.6, 30.0, 27.8, 16.9, 13.6. HRMS (ESI): m/z calcd for C28H30ClO7
+ [M+H]+ 
513.1675, found 513.1680. IR (film, cm -1): 3485 (br), 2926, 1724, 1646, 1615, 1353, 1273, 1076, 
1026, 760. [α]D 





To a flame dried flask containing ethyl (8R,9S,10S,11S,13S,14S)-11-(benzoyloxy)-3-chloro-14-
hydroxy-13-methyl-7,17-dioxo-1,2,7,8,9,11,12,13,14,15,16,17-dodecahydro-10H-
cyclopenta[a]phenanthrene-10-carboxylate 197 (600.0 mg, 1.17 mmol) in THF (35 mL) under N2 
and cooled to -78oC was added diisobutyl aluminum hydride (3.3 g, 4.2 mL, 23.4 mmol) dropwise. 
The reaction was allowed to stir at -78oC for 1 h before being heated to 60oC for 12 h. After 
132 
 
completion, the reaction flask was cooled to 0oC and quenched cautiously by the addition of water 
(~10 mL) until the formation of a viscous emulsion. The solution was gradually acidified with 
formic acid (~8 mL total) until the emulsions dissipated and the solution became homogeneous 
(pH < 4). The mixture was then heated to 85oC for 1 h and then quenched by the addition of a 
saturated NaHCO3 solution (10 mL) and solid Na2CO3 (2 g). The suspension was then filtered 
through celite with excess MeOH and concentrated. The crude mixture was then adsorbed onto 
silica gel (with MeOH) and purified directly by flash column chromatography with 5% → 10% 
MeOH in CH2Cl2 to afford title compound (8R,9S,10S,11S,13R,14S,17R)-11,14,17-trihydroxy-10-
(hydroxymethyl)-13-methyl-1,2,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-
cyclopenta[a]phenanthren-3-one (175) (281 mg, 0.842 mmol) in 72% yield and 8:1 d.r., Rf = 0.2 
(10% MeOH in CH2Cl2). 
1H NMR (700 MHz, D3COD): δ 6.49 (dd, J = 9.9, 1.8 Hz, 1H), 6.25 (dd, 
J = 9.9, 2.6 Hz, 1H), 5.69 (s, 1H), 4.18 (d, J = 1.6 Hz, 1H), 4.04 (t, J = 8.9 Hz, 1H), 3.75 (d, J = 
12.2 Hz, 1H), 3.43 (d, J = 12.2 Hz, 1H), 2.93 (d, J = 11.4 Hz, 1H), 2.65 - 2.51 (ovrlp, 2H), 2.37 
(dd, J = 16.8, 4.8 Hz, 1H), 2.01 (ddd, J = 13.5, 9.3, 4.2 Hz, 1H), 1.84 (ddd, J = 14.6, 12.8, 4.8 Hz, 
1H), 1.76 - 1.64 (m, 2H), 1.61 (dd, J = 11.5, 1.2 Hz, 1H), 1.52 - 1.42 (m, 1H), 1.41 - 1.32 (ovrlp, 
2H), 1.30 (s, 3H). 13C NMR (175 MHz, D3COD): δ 202.0, 162.9, 141.6, 129.7, 124.6, 84.1, 82.9, 
64.9, 61.8, 51.1, 48.4, 43.3, 39.6, 36.4, 34.4, 30.3, 29.0, 28.9, 21.6. HRMS (ESI): m/z calcd for 
C19H27O5
+ [M+H]+ 335.1853, found 335.1855. IR (film, cm-1): 3320(br), 2930, 1642, 1610, 1350, 
1280, 1228, 1181, 1055, 1021, 971, 874. [α]D 









1,2,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one 175 (60 mg, 
0.180 mmol) and 10% Pd on activated carbon (15 mg, 25% w/w loading) was solvated in 5.2 mL 
of MeOH containing 1% KOH (w/v) and 1% quinoline (v/v). The reaction vessel was purged with 
N2, and then H2, and allowed to stir vigorously at room temperature under an atmosphere of H2. 
After 30 minutes, TLC showed complete conversion. The solution was quenched with 600 µL of 
pH = 7 phosphate buffer. The crude mixture was directly adsorbed onto silica gel in vacuo and 
purified by flash column chromatography with 0% → 5% → 10% MeOH in DCM to afford 
compound (5R,8R,9S,10R,11S,13R,14S,17R)-11,14,17-trihydroxy-10-(hydroxymethyl)-13-
methylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one (200) (51 mg, 0.151 mmol) 
exclusively in 84% yield as a white solid, Rf = 0.2 (10% MeOH in CH2Cl2). 
1H NMR (400 MHz, 
D3COD): δ 4.29 (d, J = 11.6 Hz, 1H), 4.21 (d, J = 2.3 Hz, 1H), 4.09 (t, J = 8.8 Hz, 1H), 3.23 (d, J 
= 11.6 Hz, 1H), 2.79 (, J = 15.4 Hz, 1H, ), 2.48 (td, J = 14.7, 5.7 Hz, 1H), 2.41 - 2.31 (m, 1H), 2.29 
- 2.13 (m, ovrlp, 3H), 2.13 - 2.01 (m, ovrlp, 2H), 2.00 - 1.84 (m, ovrlp, 3H), 1.84 - 1.68 (m, ovrlp, 
2H), 1.63 - 1.32 (m, ovrlp, 5H), 1.32 - 1.22 (ovrlp, 4H). 13C NMR (100 MHz, D3COD): δ 215.5, 
86.0, 83.4, 68.5, 66.1, 47.8, 44.1, 43.0, 40.6, 40.5, 37.6, 36.6, 36.2, 32.2, 30.4, 28.7, 26.2, 21.1, 
20.3. HRMS (ESI): m/z calcd for C19H31O5
+ [M+H]+ 339.2166, found 339.2158. IR (film, cm-1): 
3392 (br), 2940, 1536, 1512, 1466, 1251, 1177, 1033, 814. [α]D 







methylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one 200 (40 mg, 0.118 mmol) and 
imidazole (130 mg, 1.912 mmol) were solvated in dry DMF (5 mL) at room temperature. 
Triisopropylsilyl chloride (155 µL, 140 mg, 0.724 mmol) was added by syringe. The reaction 
mixture was allowed to stir at ambient temperature for 6 h, until all starting material was consumed. 
The solution was then quenched with a saturated NaHCO3 solution (2 mL) and diluted with EtOAc 
(5 mL). The organic layer was washed 3x with 1:1 H2O:brine, dried over Na2SO4, filtered, 
concentrated, and directly purified by flash column chromatography with 0% → 30% → 50% → 
65% EtOAc in hexanes to afford title compound (5R,8R,9S,10R,11S,13R,14S,17R)-11,14,17-
trihydroxy-13-methyl-10-(((triisopropylsilyl)oxy)methyl)hexadecahydro-3H-
cyclopenta[a]phenanthren-3-one (200a) (48 mg, 0.097 mmol) in 82% yield as a white solid, Rf = 
0.7 (10% MeOH in CH2Cl2). 
1H NMR (400 MHz, CDCl3): δ 4.70 (s, 1H), 4.44 (d, J = 10.4 Hz, 
1H), 4.24 - 4.13 (m, ovrlp, 2H), 3.35 (d, J = 10.4 Hz, 1H), 2.64 (t, J = 14.4 Hz, 1H), 2.48 - 2.39 
(m, 1H), 2.34 - 2.26 (m, ovrlp, 2H), 2.26 - 2.08 (m, ovrlp, 2H), 2.09 - 1.98 (m, ovrlp, 2H), 1.98 - 
1.80 (m, ovrlp, 4H), 1.68 - 1.45 (m, ovrlp, 4H), 1.41 - 1.23 (m, ovrlp, 6H), 1.19 - 1.00 (m, ovrlp, 
21H). 13C NMR (100 MHz, CDCl3): δ 211.8, 85.0, 82.6, 69.4, 64.3, 46.7, 43.5, 42.0, 40.2, 39.3, 




+ [M+H]+ 495.3500, found 495.3509. IR (film, cm-1): 3408 (br), 2941, 2866, 1709, 
1462, 1264, 1058, 1016, 882, 734. [α]D 





(((triisopropylsilyl)oxy)methyl)hexadecahydro-3H-cyclopenta[a]phenanthren-3-one 200a (90 
mg, 0.182 mmol) and the Dess-Martin periodinane (400 mg, 0.943 mmol) was solvated in dry 
CH2Cl2 (4.0 mL) and pyridine (75 µL). The reaction mixture was allowed to stir at room 
temperature for 2 h until the starting material was consumed. The reaction was quenched with a 
saturated Na2S2O3 solution (2 mL) and a saturated NaHCO3 solution (2 mL) and allowed to stir 
vigorously for 1 hour. The resulting mixture was extracted 3x with CH2Cl2 (4 mL each), dried over 
Na2SO4, filtered, adsorbed onto silica gel, and directly purified by flash column chromatography 
with 30% → 40% → 50% EtOAc in hexanes to afford title compound (5R,8R,9S,10R,13S,14S)-
14-hydroxy-13-methyl-10 (((triisopropylsilyl)oxy)methyl)dodecahy dro-1H-
cyclopenta[a]phenanthrene-3,11,17(2H)-trione (201) (80 mg, 0.163 mmol) in 89% yield as a white 
solid, Rf = 0.3 (50% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3): δ 4.28 (d, J = 9.5 Hz, 1H), 
3.95 (d, J = 9.6 Hz, 1H), 2.79 (d, J = 12.7 Hz, 1H), 2.66 - 2.30 (m, ovrlp, 7H), 2.26 - 2.05 (m, 
ovrlp, 6H), 2.00 (d, J = 13.3 Hz, 1H), 1.97 - 1.87 (m, ovrlp, 2H), 1.68 - 1.54 (m, 1H), 1.51 - 1.40 
(m, 1H), 1.18 - 0.99 (m, ovrlp, 24H). 13C NMR (100 MHz, CDCl3): δ 216.1, 212.3, 205.9, 80.4, 
63.4, 56.5, 48.9, 47.1, 43.6, 41.6, 39.7, 37.4, 34.5, 32.9, 30.8, 27.5, 25.5, 20.2, 18.1, 18.1, 13.4, 
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12.0. HRMS (ESI): m/z calcd for C28H46O5SiNa
+ [M+Na]+ 513.3007, found 513.2996. IR (film, 
cm-1): 3457 (br), 2939, 2866, 1734, 1708, 1462,1210, 1094, 882. [α]D 






1H-cyclopenta[a]phenanthrene-3,11,17(2H)-trione 201 (39 mg, 0.080 mmol) was solvated in dry 
THF (5 mL) and cooled to -78oC under a N2 atmosphere. Then, 1M K-Selectride (0.170 mL, 0.170 
mmol) was added slowly via syringe. The reaction was allowed to warm to -35oC where it was 
stirred for 1.5 h until the reaction was complete. The reaction was then quenched with a saturated 
NH4Cl solution (2 mL) and allowed to warm to room temperature. The mixture was then extracted 
3x with CH2Cl2 (4 mL), dried over Na2SO4, filtered, adsorbed onto silica gel, and directly purified 
by flash column chromatography with 30% → 40% → 50% EtOAc in hexanes to afford title 
compound (3S,5R,8R,9S,10R,13S,14S)-3,14-dihydroxy-13-methyl-10-(((triisopropylsilyl)oxy) 
methyl) tetradecahydro-1H-cyclopenta[a]phenanthrene-11,17-dione (202) (30 mg, 0.061 mmol) in 
77% yield as a white solid, Rf = 0.3 (50% EtOAc in hexanes). 1H NMR (700 MHz, CDCl3): δ 4.14 
(d, J = 9.7 Hz, 1H), 4.07 (s, 1H), 3.97 (d, J = 9.7 Hz, 1H), 2.76 (d, J = 12.8 Hz, 1H), 2.57 - 2.53 
(m, 2H), 2.48 - 2.41 (m, 2H), 2.35 (d, J = 13.0 Hz, 1H), 2.26 (td, J = 12.6, 3.9 Hz, 1H), 2.09 (ddd, 
J = 13.6, 5.8, 5.3 Hz, 1H), 2.00 - 1.91 (m, 3H), 1.84 - 1.77 (m, ovrlp, 3H), 1.64 - 1.55 (m, 2H), 
1.51 - 1.43 (m, 2H), 1.37 - 1.29 (m, 2H), 1.25 (dd, J = 8.9, 3.5 Hz, 1H), 1.17 - 1.05 (m, ovrlp, 21H), 
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1.02 (s, 3H). 13C NMR (175 MHz, CDCl3): δ 216.7, 206.9, 80.8, 66.1, 64.6, 56.6, 47.4, 46.5, 43.5, 
40.4, 33.3, 33.0, 28.3, 28.0, 27.5, 25.6, 22.7, 20.2, 18.2, 18.1, 13.6, 12.0. HRMS (ESI): m/z calcd 
for C28H49O5Si
+ [M+H]+ 493.3344, found 493.3341. IR (film, cm-1): 3473 (br), 2928, 2862, 1737, 
1718, 1460, 1378, 1097. [α]D 






tetradecahydro-1H-cyclopenta[a]phenanthrene-11,17-dione 202 (29 mg, 0.059 mmol) was 
solvated in dry CH2Cl2 (2.5 mL) and triethylamine (225 µL) and cooled to -78
oC under a N2 
atmosphere. Then, Tert-butyldimethylsilyl trifluoromethanesulfonate (135 µL, 110 mg, 0.495 
mmol) was added via syringe. The reaction was allowed to warm to -30oC where it was stirred for 
1.5 h until the reaction was complete. The solution was then quenched with a saturated NaHCO3 
solution (1 mL) and extracted 3x with CH2Cl2 (2 mL), dried over Na2SO4, filtered, concentrated, 
and directly purified by flash column chromatography with 0% → 5% EtOAc in hexanes to afford 
title compound (3S,5R,8R,9S,10R,13S,14S)-3,17-bis((tert-butyldimethylsilyl)oxy)-14-hydroxy-
13-methyl-10-(((triisopropylsilyl)oxy)methyl)-1,2,3,4,5,6,7,8,9,10,12,13,14,15-tetradecahydro-
11H-cyclopenta[a]phenanthren-11-one (203) (40 mg, 0.056 mmol) in 95% yield as a white solid, 
Rf = 0.7 (10% EtOAc in hexanes). 1H NMR (700 MHz, CDCl3): δ 4.41 (s, 1H), 4.11 (d, J = 9.8 
Hz, 1H), 4.02 (s, 1H), 3.56 (d, J = 9.8 Hz, 1H), 2.69 (dd, J = 16.5, 1.8 Hz, 1H), 2.63 (d, J = 12.7 
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Hz, 1H), 2.44 (td, J = 12.4, 3.1 Hz, 1H), 2.27 (ovrlp, 2H), 2.08 (d, J = 12.8 Hz, 1H), 2.03 (dd, J = 
16.5, 2.5 Hz, 1H), 1.93 (d, J = 13.3 Hz, 1H), 1.86 (m, ovrlp, 2H), 1.74 - 1.68 (m, ovrlp, 2H), 1.65 
(t, J = 13.7 Hz, 1H), 1.51 (m, 1H), 1.36 - 1.22 (m, ovrlp, 3H), 1.11 - 1.02 (m, 24H), 0.92 (s, 9H), 
0.87 (s, 9H), 0.16 (s, 3H), 0.15 (s, 3H), 0.010 (s, 3H), 0.007 (s, 3H). 13C NMR (175 MHz, CDCl3): 
δ 212.0, 156.0, 95.7, 80.2, 68.4, 66.8, 53.6, 49.3, 46.6, 43.7, 41.7, 38.0, 34.9, 30.6, 28.8, 26.8, 25.8, 
25.64, 25.61, 24.8, 20.3, 19.3, 18.1, 18.1, 18.07, 18.05, 12.0, -4.7, -4.8, -4.9, -5.1. HRMS (ESI): 
m/z calcd for C40H77O5Si3





Gaseous ammonia (~1.5 mL) was condensed at -78 C under N2 and a small chip of lithium metal 
(~2 mg) was added and allowed to dissolve. After 30 minutes, (3S,5R,8R,9S,10R,13S,14S)-3,17-
bis((tert-butyldimethylsilyl)oxy)-14-hydroxy-13-methyl-10-(((triisopropylsilyl)oxy)methyl)-
1,2,3,4,5,6,7,8,9,10,12,13,14,15-tetradecahydro-11H-cyclopenta[a]phenanthren-11-one 203 (9.1 
mg, 0.0125 mmol) dissolved in dry THF (0.5 mL) was slowly added to the deep blue reaction 
ammonia solution via syringe and allowed to stir at -78oC for 30 minutes. Then, the reaction was 
quenched dropwise by the addition of a saturated NH4Cl solution until the blue color had 
completely dissipated. The solution was allowed to warm to room temperature as the ammonia 
boiled off. The remaining mixture was extracted 2x with CH2Cl2 (2 mL), dried over Na2SO4, 
filtered, and concentrated. The crude mixture was then solvated in dry THF (1 mL) and cooled to 
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-78oC under N2. 1M Tetrabutylammonium fluoride in THF (15 µL, 0.015 mmol) was added via 
syringe and the reaction was stirred for precisely 5 minutes before being quenched with a saturated 
NH4Cl solution (1 mL) and warmed to room temperature. The crude mixture was then extracted 
3x with CH2Cl2 (2 mL), dried over Na2SO4, filtered, adsorbed onto silica gel, and directly purified 
by flash column chromatography with 10% → 20% → 35% EtOAc in hexanes to afford title 
compound (3S,5R,8R,9S,10R,11R,13S,14S)-3-((tert-butyldimethylsilyl)oxy)-11,14-dihydroxy-13-
methyl-10-(((triisopropylsilyl)oxy)methyl)hexadecahydro-17H-cyclopenta[a]phenanthren-17-
one (204) (5.5 mg, 0.0091 mmol) in 73% yield as a white solid, Rf = 0.7 (50% EtOAc in hexanes). 
1H NMR (500 MHz, CDCl3): δ 4.27 (d, J = 9.8 Hz, 1H), 4.06 (s, 1H), 3.96 (t, J = 10.6 Hz, 1H), 
3.43 (d, J = 9.8 Hz, 1H), 3.15 (d, J = 2.8 Hz, 1H), 2.53 - 2.21 (m, ovrlp, 4H), 1.94 - 1.48 (m, ovrlp, 
11H), 1.47 - 1.35 (m, ovrlp, 2H), 1.31 - 1.05 (m, ovrlp, 26H), 0.88 (s, 9H), 0.03 (s, 3H), 0.02 (s, 
3H). 13C NMR (175 MHz, CDCl3): δ 219.9, 82.3, 70.3, 69.7, 66.5, 53.8, 41.7, 41.5, 40.6, 40.3, 
35.2, 34.4, 33.0, 29.7, 28.8, 27.6, 27.2, 26.7, 25.8, 18.8, 18.1, 18.0, 14.3, 11.9, -4.9. HRMS (ESI): 
m/z calcd for C34H65O5Si2
+ [M+H]+ 609.4371, found 609.4379. IR (film, cm-1): 3483 (br), 2928, 
2865, 1731, 1460, 1252, 1065, 830. [α]D 






(((triisopropylsilyl)oxy)methyl)hexadecahydro-17H-cyclopenta[a]phenanthren-17-one 204 (5.5 
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mg, 0.0091 mmol) was solvated in EtOH (1.0 mL) and triethylamine (25 µL). Hydrazine 
monohydrate (9 mg, 0.18 mmol) was then added and the solution was heated to 50oC and stirred 
for 6 h until all starting material was consumed. The resulting mixture was cooled to room 
temperature and concentrated in vacuo. The crude oil was then dissolved in THF (1.0 mL) and 
triethylamine (25 µL). A solution of I2 (25 mg, 0.0985 mmol) in THF (1 mL) was prepared and 
0.25 mL of this solution was added to the reaction vessel. After 10 minutes, additional I2 solution 
(0.30 mL) was added until a brown color persisted. The mixture was stirred at room temperature 
for 1 hour until it was complete. The solution was then quenched with a saturated Na2S2O3 solution 
(1 mL) and a saturated NaHCO3 solution (1 mL) and stirred vigorously for 20 minutes. The 
resulting mixture was then extracted 3x with EtOAc (2 mL each), dried over Na2SO4, filtered, 
adsorbed onto silica gel, and directly purified by flash column chromatography with 0% → 5% → 
10% → 20% EtOAc in hexanes to afford title compound (3S,5R,8R,9S,10R,11R,13S,14S)-3-((tert-
butyldimethylsilyl)oxy)-17-iodo-13-methyl-10-(((triisopropylsilyl)oxy)methyl)-
1,2,3,4,5,6,7,8,9,10,11,12,13,15-tetradecahydro-14H-cyclopenta[a]phenanthrene-11,14-diol 
(205) (6.0 mg, 0.0084 mmol) in 90% yield, Rf = 0.9 (50% EtOAc in hexanes). 1H NMR (700 MHz, 
CDCl3): δ 6.13 (s, 1H), 4.30 (d, J = 9.8 Hz, 1H), 4.04 (s, 1H), 3.83 (td, J = 12.4, 3.3 Hz, 1H), 3.43 
(d, J = 3.9 Hz, 1H), 3.39 (d, J = 9.8 Hz, 1H), 2.66 (dd, J = 16.5, 1.0 Hz, 1H), 2.31 - 2.24 (m, ovrlp, 
2H), 1.91 (dd, J = 13.2, 2.9 Hz, 1H), 1.88 - 1.75 (m, ovrlp, 3H), 1.75 - 1.67 (m, ovrlp, 2H), 1.68 - 
1.47 (m, ovrlp, 4H), 1.23 - 1.07 (m, ovrlp, 28H), 0.87 (s, 9H), 0.02 (s, 3H), 0.01 (s, 3H). 13C NMR 
(175 MHz, CDCl3): δ 133.7, 110.2, 82.1, 70.5, 69.1, 66.6, 55.3, 46.1, 43.1, 41.8, 41.0, 40.5, 35.2, 
34.5, 28.8, 27.1, 26.7, 25.8, 20.1, 19.6, 18.1, 18.0, 11.9, -4.9. HRMS (ESI): m/z calcd for 
C34H64IO4Si2
+ [M+H]+ 719.3382, found 719.3381. IR (film, cm-1): 3450 (br), 2926, 2856, 1462, 
1380, 1253, 1053, 828. [α]D 









cyclopenta[a]phenanthrene-11,14-diol 205 (15.0 mg, 0.021 mmol) along with Pd(PPh3)4 (5 mg, 
0.0043 mmol), CuCl (31 mg, 0.313 mmol), and LiCl (18 mg, 0.425 mmol) was solvated in dry 
DMSO (1.1 mL) under a N2 atmosphere and stannyl butenolide 73 (30 mg, 0.0804 mmol) was 
added via syringe. The reaction solution was heated to 50oC for 1 hour until the starting material 
was consumed. The solution was then quenched with pH = 7 phosphate buffer (1 mL) and extracted 
4x with EtOAc (1.5 mL each). The organic layers were combined, dried over Na2SO4, filtered, 
adsorbed onto silica gel, and directly purified by flash column chromatography with 0% → 10% 
→ 20% → 30% EtOAc in hexanes to afford title compound 4-((3S,5R,8R,9S,10R,11R,13R,14S)-
3-((tert-butyldimethylsilyl)oxy)-11,14-dihydroxy-13-methyl-10-(((triisopropylsilyl)oxy)methyl)-
2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-
2(5H)-one (206) (13.0 mg, 0.0193 mmol) in 92% yield, Rf = 0.3 (30% EtOAc in hexanes). 1H 
NMR (700 MHz, CDCl3): δ 6.11 (s, 1H), 6.00 (s, 1H), 5.00 (dd, J = 16.2, 1.0 Hz, 1H), 4.92 (dd, J 
= 16.2, 1.0 Hz, 1H), 4.34 (d, J = 9.8 Hz, 1H), 4.05 (s, 1H), 3.93 - 3.85 (m, 1H), 3.52 (d, J = 3.8 Hz, 
1H), 3.40 (d, J = 9.8 Hz, 1H), 2.81 (d, J = 18.2 Hz, 1H), 2.41 (dd, J = 18.5, 3.3 Hz, 1H), 2.30 (d, J 
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= 13.9 Hz, 1H), 2.13 (dd, J = 13.2, 3.0 Hz, 1H), 1.91 -1.66 (m, 6H), 1.66 - 1.48 (m, 3H), 1.36 - 
1.32 (m, ovrlp, 4H), 1.31 - 1.15 (m, ovrlp, 6H), 1.14 - 1.08 (m, 18H), 0.088 (s, 9H), 0.025 (s, 3H), 
0.018 (s, 3H). 13C NMR (175 MHz, CDCl3): δ 174.1, 157.9, 143.4, 131.8, 112.9, 85.3, 71.6, 70.6, 
69.0, 66.5, 52.7, 47.1, 41.8, 40.9, 40.5, 40.5, 35.3, 34.6, 29.7, 28.8, 27.2, 26.7, 25.8, 20.2, 18.1, 
18.0, 18.0, 12.0, -4.9. HRMS (ESI): m/z calcd for C38H67O6Si2
+ [M+H]+ 675.4471, found 
675.4466. IR (film, cm-1): 3473 (br), 2925, 2856, 1747, 1622, 1462, 1255, 1045, 828. [α]D 
25 = 







cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one 206 (13.0 mg, 0.0193 mmol) and 2,6 – lutidine 
(28 µL, 25.9 mg, 0.242 mmol) were solvated in dry CH2Cl2 (4 mL) and cooled to -78
oC under a 
N2 atmosphere. Then, trimethylsilyl trifluoromethanesulfonate (22 µL, 27.0 mg, 0.122 mmol) was 
added via syringe and the reaction was allowed to warm to room temperature. After 2 h, the 
reaction was quenched with a saturated NaHCO3 solution (1.5 mL). The crude mixture was then 
extracted 3x with CH2Cl2 (2 mL each), dried over Na2SO4, filtered, and azeotroped 4x with toluene 
(2 mL each) to remove remaining 2,6-lutidine. The crude material was then solvated in CH2Cl2 (5 
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mL) and adsorbed onto silica gel (5 g). The silica gel was allowed to sit at room temperature 
overnight. Then, the crude material was washed off the silica gel by filtering and eluting with 
100% EtOAc. The filtrate was concentrated and directly purified by flash column chromatography 
with 0% → 5% EtOAc in hexanes to afford title compound 4-((3S,5R,8R,9S,10R,11R,13R,14S)-3-
((tert-butyldimethylsilyl)oxy)-13-methyl-10-(((triisopropylsilyl)oxy)methyl)-11,14-
bis((trimethylsilyl)oxy)-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1H-
cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one (208) (10.0 mg, 0.0122 mmol) in 64% yield, Rf 
= 0.4 (10% EtOAc in hexanes). 1H NMR (500 MHz, CDCl3): δ 6.06 (t, J = 2.5 Hz, 1H), 5.95 (s, 
1H), 5.01 (dd, J = 16.2, 1.5 Hz, 1H), 4.92 (dd, J = 16.2, 1.5 Hz, 1H), 4.02 (s, 1H), 3.82 – 3.93 (m, 
ovrlp, 2H), 3.65 (d, J = 9.5 Hz, 1H), 2.87 (d, J = 17.9 Hz, 1H), 2.44 (dd, J = 18.9, 3.3 Hz, 1H), 
2.25 (d, J = 11.9 Hz, 1H), 1.93 - 1.70 (m, 8H), 1.63 - 1.52 (m, 1H), 1.44 - 1.35 (m, 2H), 1.24 - 1.05 
(m, 27H), 0.88 (s, 9H), 0.023 (s, 9H), 0.014 (s, 6H), 0.007 (s, 9H). 13C NMR (175 MHz, CDCl3): 
δ 174.5, 158.4, 143.3, 133.3, 111.8, 88.7, 71.6, 67.6, 67.4, 67.2, 52.8, 46.1, 42.7, 40.8, 40.3, 39.8, 






tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one 208 (10.0 mg, 0.0122 
mmol) and 10% Palladium on activated carbon (10 mg) were solvated in EtOAc (1.5 mL) and the 
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reaction vessel was purged with N2, and then with H2, and the solution was allowed to stir 
vigorously under an atmosphere of H2. After 30 minutes, all starting material was consumed. The 
reaction solution was then filtered through a pad of celite and silica gel with 100% EtOAc. The 
resulting crude filtrate was a 2.5:1 diastereomeric mixture of C17 epimers. The minor diastereomer 
was then removed by flash column chromatography with 0% → 5% → 10% EtOAc in hexanes. 
The material was then immediately subjected to HF deprotection without further purification. The 
residue was solvated in 450 µL of 1:1 CH2Cl2:MeCN. Then, a stock solution of 18:3:2 
MeCN:H2O:HF was prepared and 700 µL of this solution was added to the reaction vessel. The 
resulting solution was allowed to stir at room temperature for 3 days. Once all the TIPS groups 
had been removed, methoxytrimethylsilane (300 µL) was added and the crude mixture was stirred 
for 3 h. The resulting solution was then concentrated in vacuo, adsorbed onto silica gel, and directly 
purified by flash column chromatography with 0% → 10% MeOH in CH2Cl2 to afford 19-
hydroxysarmentogenin (1) (2.0 mg, 0.0049 mmol) in 42% yield over two steps, Rf = 0.3 (15% 
MeOH in CH2Cl2). 
1H NMR (700 MHz, D3COD): δ 5.91 (s, 1H, H22), 5.02 (dd, J = 18.4, 1.3 Hz, 
1H, H21b), 4.92 (dd, J = 18.4, 0.9 Hz, 1H, H21a), 4.03 (m, 1H, H3), 3.85 (ddd, J = 10.6, 4.2 Hz, 
1H, H11), 3.77 (d, J = 11.1 Hz, 1H, H19b), 3.74 (d, J = 11.1 Hz, 1H, H19a), 2.90 (dd, J = 9.0, 5.7 
Hz, 1H, H17), 2.26 - 2.15 (m, 3H, H1b, 15b, 16b), 2.07 (m, 1H, H5), 1.96 - 1.70 (m, 9H, H1a, 2b, 
4b, 6b, 7b, 8, 9, 15a, 16a), 1.67 (dd, J = 13.2, 4.2 Hz, 1H, H12b), 1.53 (dd, J = 13.2, 10.5 Hz, 1H, 
H12a), 1.57 - 1.50 (m, 1H, H2a), 1.39 - 1.20 (m, 3H, H4a, 6a, 7a), 0.91 (s, 3H, H18). 13C NMR 
(175 MHz, D3COD): δ 177.7 (C23), 177.1 (20), 118.0 (C22), 85.9 (C14), 75.3 (C21), 69.1 (C11), 
67.6 (C3), 66.9 (C19), 51.9 (C17), 51.1 (C13), 50.6 (C12), 42.8, 41.6 (x2) (C10), 35.0, 33.5 (C15), 
32.3 (C5), 29.2, 27.9 (C16), 27.7, 27.1, 22.3, 17.6 (C18). HRMS (ESI): Calculated for C23H35O6
+ 
[M+H]+ 407.2428, found 407.2435. Calculated for C23H34O6Na
+ [M+Na]+ 429.2248, found 
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429.2255. IR (film, cm-1): 3315 (br), 2920, 1735, 1632, 1449, 1022. [α]D 






Table 4.2. Comparison to the reported 19-hydroxysarmentogenin 1H NMR (700 MHz, D3COD)
11: 
Position This work 
δH (Multiplicity, J in Hz, No. of 
H) 
Inoue et al. 
δH (Multiplicity, J in Hz, No. of H) 
22 5.91 (s, 1H) 5.91 (br s, 1H) 
21b 5.02 (dd, J = 18.4, 1.3, 1H) 5.02 (dd, J = 18.3, 1.8, 1H) 
21a 4.92 (dd, J = 18.4, 0.9, 1H) 4.91 (dd, J = 18.3, 1.2, 1H) 
3 4.03 (m, 1H) 4.03 (m, 1H) 
11 3.85 (ddd, J = 10.6, 4.2, 1H) 3.85 (ddd, J = 10.9, 3.5, 1H) 
19b 3.77 (d, J = 11.1, 1H) 3.77 (d, J = 12.0, 1H) 
19a 3.74 (d, J = 11.1, 1H) 3.74 (d, J = 12.0, 1H) 
17 2.90 (dd, J = 9.0, 5.7, 1H) 2.90 (dd, J = 9.2, 5.2, 1H) 
1b, 15b, 16b 2.26 - 2.15 (m, 3H) 2.26-2.15 (m, 3H) 
5 2.07 (m, 1H) 2.07 (m, 1H) 
H1a, 2b, 4b, 6b, 
7b, 8, 9, 15a, 16a 
1.96 - 1.70 (m, 9H) 1.96-1.69 (m, 9H) 
12b 1.67 (dd, J = 13.2, 4.2, 1H) 1.67 (dd, J = 13.2, 4.0, 1H) 
12a 1.53 (dd, J = 13.2, 10.5, 1H) 1.53 (dd, J = 13.2, 10.5, 1H) 
2a 1.57 - 1.50 (m, 1H) 1.58-1.50 (m, 1H) 
4a, 6a, 7a 1.39 - 1.20 (m, 3H) 1.39-1.20 (m, 3H) 














Table 4.3. Comparison to the reported 19-hydroxysarmentogenin 13C NMR (CD3OD)
11: 
Carbon # This work Inoue et al. Δ (δ) 
23 177.7 177.7 0.0 
20 177.1 177.1 0.0 
22 118.0 118.0 0.0 
14 85.9 85.9 0.0 
21 75.3 75.3 0.0 
11 69.1 69.1 0.0 
3 67.6 67.6 0.0 
19 66.9 66.9 0.0 
17 51.9 51.9 0.0 
13 51.1 51.1 0.0 
12 50.6 50.5 0.1 
 42.8 42.8 0.0 
10 41.6 41.6 0.0 
 35.0 35.0 0.0 
15 33.5 33.5 0.0 
5 32.3 32.3 0.0 
 29.2 29.2 0.0 
16 27.9 27.9 0.0 
 27.7 27.7 0.0 
 27.1 27.1 0.0 
 22.3 22.3 0.0 














To a flame dried flask was added (8R,9S,10S,11S,13R,14S,17R)-11,14,17-trihydroxy-10-
(hydroxymethyl)-13-methyl-1,2,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-
cyclopenta[a]phenanthren-3-one 175 (50.0 mg, 0.15 mmol) and S-camphorsulfonic acid (CSA) 
(20.0 mg, 0.086 mmol). The solids were solvated in 4.0 mL of dry dimethylformamide and 2,2-
dimethoxypropane (550 uL) was added via syringe. The solution was allowed to stir at ambient 
temperature for 20 minutes when TLC indicated all starting material was consumed. The crude 
mixture was then diluted with EtOAc (4.0 mL) and quenched with a saturated solution of NaHCO3 
(2.0 mL) and Brine (2.0 mL). The organic layer was washed 3x with a 1:1 mixture of water:brine 
(3.0 mL each). The organic layer was then dried with Na2SO4, filtered, and concentrated. The 
crude residue was then purified by flash column chromatography with 5% → 10% MeOH in 
CH2Cl2 to afford title compound (4aS,4a1S,8aS,9aR,10R,12aS,12bR)-10,12a-dihydroxy-7,7,9a-
trimethyl-3,4,8a,9,9a,10,11,12,12a,12b-decahydro-5H-cyclopenta[1,2]phenanthro[4,4b-
de][1,3]dioxepin-2(4a1H)-one (211) (38.6 mg, 0.10 mmol) in 69% yield as a white solid, Rf = 0.5 
(10% MeOH in CH2Cl2). 
1H NMR (400 MHz, CDCl3): δ 6.51 (dd, J = 9.9, 2.1 Hz, 1H), 6.22 (dd, 
J = 10.0, 2.9 Hz, 1H), 5.78 (s, 1H), 4.27 (s, 1H), 4.16 (t, J = 8.8 Hz, 1H), 3.85 (d, J = 12.7 Hz, 1H), 
3.32 (dd, J = 12.7, 1.6 Hz, 1H), 3.03 (d, J = 11.0 Hz, 1H), 2.71 - 2.58 (m, ovrlp, 2H), 2.52 - 2.43 
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(m, 1H), 2.23 - 2.10 (m, 1H), 1.95 - 1.83 (m, 1H), 1.68 (dd, J = 14.6, 3.4 Hz, 1H), 1.59 - 1.41 (m, 
ovrlp, 4H), 1.36 (s, ovrlp, 4H), 1.33 (s, 3H), 1.31 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 199.7, 
157.0, 137.9, 128.8, 126.0, 100.8, 83.1, 82.1, 65.4, 61.8, 48.1, 40.7, 38.8, 35.0, 34.0, 30.8, 29.6, 
29.0, 25.4, 24.4, 21.2. IR (film, cm-1): 3346 (br), 2920, 1644, 1613, 1363, 1281, 1220, 1066, 1022, 
730. HRMS (ESI): Calculated for C22H31O5
+ [M+H]+ 375.2166, found 375.2164. [α]D 
25 = +60.2 






2(4a1H)-one 211 (28.0 mg, 0.075 mmol) and Dess-Martin periodinane (140.0 mg, 0.330 mmol) 
were added successively to a dry flask and solvated in 3.0 mL of CH2Cl2 and 30.0 uL of pyridine. 
The solution was allowed to stir at room temperature for 1.5 hours until all SM was consumed. If 
the reaction seems to stall by TLC, 1 drop of H2O can be added to promote further conversion to 
product. The solution was then quenched with saturated solutions of Na2S2O3 (2.0 mL) and 
NaHCO3 (1.5 mL) and stirred at room temperature for 45 minutes. The organic layer was then 
extracted, dried with Na2SO4, filtered, and concentrated. The crude residue was then purified by 




decahydro-5H-cyclopenta[1,2]phenanthro[4,4b-de][1,3]dioxepine-2,10-dione (218) (25.0 mg, 
0.067 mmol) in 90% yield as a white solid, Rf = 0.7 (10% MeOH in CH2Cl2). 
1H NMR (700 MHz, 
CDCl3): δ 6.59 (dd, J = 9.9, 2.1 Hz, 1H), 6.28 (dd, J = 10.0, 3.0 Hz, 1H), 5.80 (s, 1H), 4.22 (s, 1H), 
3.85 (d, J = 12.8 Hz, 1H), 3.32 (dd, J = 12.8, 1.4 Hz, 1H), 3.17 (d, J = 11.2 Hz, 1H), 2.67 - 2.59 
(m, ovrlp, 2H), 2.54 (m, ovrlp, 3H), 2.03 - 1.96 (m, 1H), 1.90 - 1.79 (m, ovrlp, 2H), 1.69 (dd, J = 
14.5, 3.3 Hz, 1H), 1.54 - 1.44 (m, ovrlp, 2H), 1.37 (dd, J = 14.5, 2.7 Hz, 1H), 1.35 (s, 3H), 1.33 (s, 
3H), 1.29 (s, 3H). 13C NMR (176 MHz, CDCl3): δ 220.4, 199.5, 156.5, 136.8, 129.1, 126.3, 101.0, 
81.6, 65.1, 61.6, 53.1, 47.7, 40.7, 38.1, 37.5, 33.9, 33.9, 30.7, 26.8, 25.3, 24.4, 16.9. IR (film, cm-
1): S17 3448 (br), 2935, 1729, 1650, 1615, 1376, 1220, 1072, 881. HRMS(ESI): m/z calcd for 
C22H29O5
+ [M+H]+ 373.2010, found 373.2006. [α]D






decahydro-5H-cyclopenta[1,2]phenanthro[4,4b-de][1,3]dioxepine-2,10-dione 212 (14.0 mg, 
0.0376 mmol) and 10% Palladium on activated carbon (5.0 mg) were added to a vial and solvated 
in 1.0 mL of a 3:1:1 mixture of EtOAc:MeOH:CH2Cl2. The vial was purged with N2 and then with 
H2 and allowed to stir vigorously at room temperature under an atmosphere of H2. After 20 
minutes, TLC showed complete conversion of starting material. The crude mixture was filtered 
150 
 
through a plug of celite and the filtrate was concentrated. By NMR, the crude mixture was a 2.3:1 
diastereomeric mixture of trans:cis A/B ring junctions. Without further purification, the residue 
was solvated in dry THF (1.0 mL) and cooled to -78oC under a N2 atmosphere. Then, a solution of 
LiAl(OtBu)3H (22.0 mg, 0.087 mmol) in THF (0.50 mL) was added slowly to the reaction vessel 
via syringe. The solution was then allowed to warm to -40oC and was stirred at that temperature 
for 2.5 hours. Then, the reaction was quenched with a saturated solution of NH4Cl (0.50 mL) and 
brine (1.50 mL), and diluted with CH2Cl2 (2.0 mL) as it was brought to room temperature. The 
aqueous layer was extracted 2x with CH2Cl2 (2.0 mL each) and the combined organic layers were 
dried with Na2SO4, filtered, and concentrated. Crude NMR indicated a retention of 2.3:1 d.r., 
indicating completely stereoselective reduction of the C3 ketone. The crude residue was then 
purified by flash column chromatography with 66% EtOAc in hexanes to afford title compound 
(2S,4aR,4a1S,8aS,9aS,12aS,12bR,14aS)-2,12a-dihydroxy-7,7,9a-trimethyltetradecahydro-5H-
cyclopenta[1,2]phenanthro[4,4b-de][1,3]dioxepin-10(2H)-one (214) (8.4 mg, 0.022 mmol) in 59% 
yield over 2 steps as a white solid, Rf = 0.2 (66% EtOAc in hexanes). 1H NMR (500 MHz, CDCl3): 
δ 4.11 (s, 1H), 3.77 (d, J = 12.5 Hz, 1H), 3.72 - 3.64 (m, 1H), 3.61 (d, J = 12.5 Hz, 1H), 2.46 - 2.35 
(m, ovrlp, 3H), 2.30 - 2.19 (m, 1H), 2.17 - 2.10 (m, 1H), 2.10 - 1.99 (m, 1H), 1.92 - 1.82 (m, 2H), 
1.74 - 1.67 (m, 1H), 1.61 - 1.48 (m, 2H), 1.44 - 1.35 (m, 2H), 1.34 - 1.27 (m, ovrlp, 8H), 1.24 (s, 
3H), 1.22 - 1.16 (m, ovrlp, 2H), 0.91 (d, J = 11.7 Hz, 1H), 0.70 (td, J = 13.3, 3.4 Hz, 1H). 13C NMR 
(176 MHz, CDCl3): δ 221.5, 100.5, 82.9, 71.1, 65.1, 57.8, 53.1, 51.1, 43.0, 39.1, 37.8, 37.5, 36.9, 
33.6, 33.0, 31.0, 27.6, 26.8, 25.5, 25.2, 24.2, 16.6. IR (film, cm-1): 3461 (br), 2928, 1730, 1457, 
1379, 1278, 1218, 1134, 1080. HRMS(ESI): m/z calcd for C22H35O5
+ [M+H]+ 379.2485, found 
379.2487. [α]D 









cyclopenta[1,2]phenanthro[4,4b-de][1,3]dioxepin-10(2H)-one 214 (20 mg, 0.0528mmol) was 
solvated in EtOH (4 mL) and triethylamine (150 μL). Hydrazine monohydrate (53 mg, 1.058 
mmol) was then added and the solution was heated to 50oC and stirred for 6 h until all starting 
material was consumed. The resulting mixture was cooled to room temperature and concentrated 
in vacuo. The crude oil was then re-dissolved in THF (4 mL) and triethylamine (150 μL). A 
solution of I2 (25 mg) in THF (1 mL) was prepared and 0.8 mL of this solution was added to the 
reaction vessel. After 10 minutes, additional I2 solution (0.30 mL) was added until a brown color 
persisted. The mixture was stirred at room temperature for 1 hour until it was complete. The 
solution was then quenched with a saturated Na2S2O3 solution (2 mL) and a saturated NaHCO3 
solution (2 mL) and stirred vigorously for 20 minutes. The resulting mixture was then extracted 
3x with EtOAc (5 mL each), dried over Na2SO4, filtered, adsorbed onto silica gel, and directly 
purified by flash column chromatography with 0% → 5% → 10% → 20% EtOAc in hexanes to 
afford title compound (2S,4aR,4a1S,8aS,9aS,12aS,12bR,14aS)-10-iodo-7,7,9a-trimethyl-
1,3,4,4a1,8a,9,9a,12,12b,13,14,14a-dodecahydro-5H-cyclopenta[1,2]phenanthro[4,4b-
de][1,3]dioxepine-2,12a(2H)-diol (215) (19 mg, 0.0389 mmol) in 74% yield as a white solid. 1H 
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NMR (700 MHz, CDCl3) δ 6.07 (dd, J = 3.1, 2.0 Hz, 1H), 4.08 (s, 1H), 3.78 (d, J = 12.5 Hz, 1H), 
3.67 (tt, J = 10.6, 4.9 Hz, 1H), 3.60 (dd, J = 12.8, 1.4 Hz, 1H), 2.51 (dd, J = 16.6, 2.0 Hz, 1H), 
2.40 (dt, J = 13.0, 3.6 Hz, 1H), 2.33 (td, J = 12.2, 4.3 Hz, 1H), 2.26 (dd, J = 16.6, 3.1 Hz, 1H), 
2.21 (dq, J = 12.9, 3.5 Hz, 1H), 1.92 (dd, J = 14.1, 3.7 Hz, 1H), 1.88 – 1.82 (m, 1H), 1.69 (ddt, J 
= 12.6, 5.1, 2.6 Hz, 1H), 1.57 – 1.49 (m, 1H), 1.38 (td, J = 12.7, 10.8 Hz, 1H), 1.33 (m, 1H), 1.31 
(s, 3H), 1.30 (s, 3H), 1.27 (dt, J = 13.5, 3.2 Hz, 1H), 1.23 (s, 3H), 1.22 – 1.15 (m, 1H), 1.07 – 1.04 
(m, 2H), 0.78 (d, J = 11.8 Hz, 1H), 0.70 (td, J = 13.4, 3.6 Hz, 1H). 13C NMR (176 MHz, CDCl3) 
δ 133.3, 111.7, 100.6, 82.4, 71.2, 64.2, 57.8, 54.4, 51.0, 43.6, 43.0, 42.5, 38.9, 37.9, 36.4, 32.9, 
31.0, 27.7, 26.7, 25.5, 24.3, 22.0. IR (film, cm-1): 3389 (br), 2926, 1456, 1374, 1154, 1065, 1036, 
734.  [α]D








de][1,3]dioxepine-2,12a(2H)-diol 215 (15.0 mg, 0.031 mmol) along with Pd(PPh3)4 (8.5 mg, 0.007 
mmol), CuCl (55 mg, 0.555 mmol), and LiCl (33 mg, 0.7783 mmol) was solvated in dry DMSO 
(2.0 mL) under a N2 atmosphere and stannyl butenolide 73 (55 mg, 0.147 mmol) was added via 
syringe. The reaction solution was heated to 50oC for 1 hour until the starting material was 
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consumed. The solution was then quenched with pH = 7 phosphate buffer (1 mL) and extracted 4x 
with EtOAc (1.5 mL each). The organic layers were combined, dried over Na2SO4, filtered, 
adsorbed onto silica gel, and directly purified by flash column chromatography with 0% → 10% 
→ 20% → 30% EtOAc in hexanes to afford 4-((2S,4aR,4a1S,8aS,9aR,12aS,12bR,14aS)-2,12a-
dihydroxy-7,7,9a-trimethyl-1,2,3,4,4a1,8a,9,9a,12,12a,12b,13,14,14a-tetradecahydro-5H-
cyclopenta[1,2]phenanthro[4,4b-de][1,3]dioxepin-10-yl)furan-2(5H)-one 216 (10.0 mg, 0.0225 
mmol) in 66% yield. 1H NMR (500 MHz, CDCl3) δ 6.07 (t, J = 2.8 Hz, 1H), 5.99 (s, 1H), 5.01 – 
4.88 (m, 2H), 4.08 (s, 1H), 3.78 (d, J = 12.5 Hz, 1H), 3.68 (dq, J = 11.0, 5.3 Hz, 1H), 3.62 (dd, J 
= 12.5, 1.5 Hz, 1H), 2.66 (dt, J = 18.5, 1.8 Hz, 1H), 2.44 – 2.37 (m, 2H), 2.33 (td, J = 12.1, 4.1 
Hz, 1H), 2.22 (dd, J = 12.8, 3.7 Hz, 1H), 2.13 (dd, J = 14.1, 3.7 Hz, 1H), 1.86 (ddd, J = 13.3, 5.3, 
2.4 Hz, 1H), 1.70 (ddt, J = 12.5, 4.9, 2.4 Hz, 1H), 1.60 – 1.48 (m, 1H), 1.43 (s, 3H), 1.41 – 1.34 
(m, 2H), 1.32 (s, 6H), 1.30 – 1.16 (m, 3H), 1.10 (qd, J = 12.5, 3.7 Hz, 1H), 0.82 (d, J = 11.7 Hz, 
1H), 0.70 (td, J = 13.4, 3.6 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 174.3, 158.3, 144.2, 131.9, 
112.7, 100.7, 85.6, 71.7, 71.1, 64.4, 57.8, 52.1, 51.1, 44.3, 43.0, 40.2, 39.0, 37.9, 36.2, 32.9, 31.0, 
27.7, 26.8, 25.4, 24.5, 20.7. HRMS (ESI): m/z calcd for C26H37O6
+ [M+H]+ = 445.2585, found 
445.2587. IR (film, cm-1): 3413 (br), 2933, 2863, 17386, 1621, 1376, 1218, 1038, 731. [α]D
27 = 













de][1,3]dioxepin-10-yl)furan-2(5H)-one 216 (13.0 mg, 0.0293 mmol) and 2,6 – lutidine (68 μL, 
0.587 mmol) were solvated in dry CH2Cl2 (1.5mL) and cooled to -78
oC under a N2 atmosphere. 
Then, trimethylsilyl trifluoromethanesulfonate (53 μL, 65.2 mg, 0.294 mmol) was added via 
syringe and the reaction was allowed to warm to room temperature. After 2 h, the reaction was 
quenched with a saturated NaHCO3 solution (1.5 mL). The crude mixture was then extracted 3x 
with EtOAc (2.5 mL each), dried over Na2SO4, filtered, and azeotroped 4x with toluene (5 mL 
each) to remove remaining 2,6-lutidine. The crude material was then adsorbed onto silica gel and 
directly purified by flash column chromatography with 0% → 5% EtOAc in hexanes to afford title 
compound 4-((2S,4aR,4a1S,8aS,9aR,12aS,12bR,14aS)-7,7,9a-trimethyl-2,12a-
bis((trimethylsilyl)oxy)-1,2,3,4,4a1,8a,9,9a,12,12a,12b,13,14,14a-tetradecahydro-5H-
cyclopenta[1,2]phenanthro[4,4b-de][1,3]dioxepin-10-yl)furan-2(5H)-one (217) (8.5 mg, 0.0143 
mmol) in 49% yield. 1H NMR (700 MHz, CDCl3) δ 6.00 (s, 1H), 5.99 (s, 1H), 4.98 (dt, J = 16.2, 
1.1 Hz, 1H), 4.88 (dt, J = 16.2, 1.2 Hz, 1H), 4.02 (s, 1H), 3.76 (d, J = 12.4 Hz, 1H), 3.62 (m, 2H, 
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overlap), 2.60 – 2.54 (m, 1H), 2.44 (dd, J = 18.7, 3.4 Hz, 1H), 2.36 (dt, J = 12.9, 3.6 Hz, 1H), 2.30 
(td, J = 12.3, 4.1 Hz, 1H), 2.08 (m, 2H, overlap), 1.71 (dd, J = 13.7, 4.1 Hz, 1H), 1.62 – 1.53 (m, 
2H), 1.44 (td, J = 12.7, 10.6 Hz, 1H), 1.37 – 1.31 (m, 1H), 1.32 – 1.31 (s, 6H), 1.30 (s, 3H), 1.27 
– 1.11 (m, 3H), 1.00 (qd, J = 12.6, 3.9 Hz, 1H), 0.73 (d, J = 12.0 Hz, 1H), 0.64 (td, J = 13.4, 3.6 
Hz, 1H), 0.10 (s, 9H), 0.02 (s, 9H). 13C NMR (176 MHz, CDCl3) δ 174.4, 158.4, 145.3, 131.7, 
112.6, 100.5, 89.9, 71.8, 71.5, 64.3, 57.9, 53.0, 51.1, 44.6, 43.2, 39.3, 39.0, 38.4, 36.7, 33.2, 31.3, 
27.9, 27.2, 25.5, 24.4, 21.4, 2.7, 0.4. HRMS (ESI): Calculated for C32H32O6Si2 [M+H]
+ = 
589.3375, found 589.3369. IR (film, cm-1): 2938 (br), 1782, 1749, 1621, 1248, 1217, 1089, 836. 
[α]D






de][1,3]dioxepin-10-yl)furan-2(5H)-one 217 (3.0 mg, 0.0051 mmol) was solvated in EtOAc (1 
mL) and 10% Pd/C (1 mg) was added. The vessel was purged with N2, and then with H2. The 
solution was stirred vigorously under 1 atm of H2 until all starting material was consumed. The 
reaction was then filtered through a pad of celite with EtOAc and concentrated in vacuo. The crude 
oil was then dissolved in 0.3 M HCl in MeOH (1 mL) and stirred at ambient temperature. After 1 
hour, all starting material was consumed and the reaction was quenched with saturated NaHCO3 
until pH = 7. The solution was extracted 5x with a 2:1 mixture of CHCl3:EtOH (2 mL each). The 
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organic layers were combined and dried over Na2SO4, filtered, and concentrated. The crude 
material was then purified by flash column chromatography with 0% → 5% → 10% MeOH in 
DCM to afford panogenin (173) (1.14 mg, 0.0028 mmol) in 55% yield. 1H NMR (500 MHz, 
D3COD) δ 5.90 (s, 1H, H22), 5.02 (dd, J = 18.4, 1.8 Hz, 1H, H21a), 4.90 (dd, J = 18.3, 1.7 Hz, 
1H, H21b), 4.12 (d, J = 2.9 Hz, 1H, H11), 3.84 (d, J = 11.7 Hz, 1H, H19a), 3.64 (d, J = 11.8 Hz, 
1H, H19b), 3.61 – 3.54 (m, 1H, H3), 2.85 – 2.78 (m, 1H, H17), 2.30 (dt, J = 13.2, 3.6 Hz, 1H, 
H1a), 2.24 – 2.05 (m, 4H, H8, H16a, H14a, H7a), 1.92 – 1.83 (m, 1H, H16b), 1.83 – 1.73 (m, 3H, 
H12a, H2a, H14b), 1.69 – 1.62 (m, 1H, H4a), 1.58 (dd, J = 14.8, 3.0 Hz, 1H, H12b), 1.47 – 1.35 
(m, 2H, H2b, H4b), 1.35 – 1.19 (m, 4H, H5, H6a, H6b, H7b) ), 1.19 – 1.15 (m, 1H, H9), 1.14 (s, 
3H, H18), 0.86 (td, J = 13.6, 3.7 Hz, 1H, H1b). 13C NMR (126 MHz, CD3OD) δ 176.3 (C23), 
175.2 (C20) , 116.0 (C22), 85.3 (C14), 73.4 (C21), 69.4 (C3), 64.8 (C11), 56.6 (C19), 52.8 (C9), 
50.7 (C17), 48.7 (C13), 45.0 (C12), 44.6 (C5), 38.5 (C10), 37.0 (C4), 35.1 (C8), 31.4 (C15), 29.9 
(C2), 29.7 (C1), 26.6 (C7), 26.4 (C6), 25.9 (C16), 17.7 (C18). HRMS (ESI): m/z calcd for 
C23H35O6 [M+H]
+ = 407.2428, found 407.2429. IR (film, cm-1):  3379 (br), 2923, 2491, 1733, 
1652, 1448, 1185, 1028. [α]D






(((triisopropylsilyl)oxy)methyl)hexadecahydro-17H-cyclopenta[a]phenanthren-17-one 220 (50 
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mg, 0.101 mmol) was solvated in EtOH (8 mL) and triethylamine (286 μL). Hydrazine 
monohydrate (101.4 mg, 2.024 mmol) was then added and the solution was heated to 50oC and 
stirred for 6 h until all starting material was consumed. The resulting mixture was cooled to room 
temperature and concentrated in vacuo. The crude oil was then re-dissolved in THF (8 mL) and 
triethylamine (286 μL). A solution of I2 (84 mg) in THF (1 mL) was prepared and 0.25 mL of this 
solution was added to the reaction vessel. After 10 minutes, additional I2 solution (0.30 mL) was 
added until a brown color persisted. The mixture was stirred at room temperature for 1 hour until 
it was complete. The solution was then quenched with a saturated Na2S2O3 solution (3 mL) and a 
saturated NaHCO3 solution (3 mL) and stirred vigorously for 20 minutes. The resulting mixture 
was then extracted 3x with EtOAc (5 mL each), dried over Na2SO4, filtered, adsorbed onto silica 
gel, and directly purified by flash column chromatography with 0% → 5% → 10% → 20% EtOAc 
in hexanes to afford title compound (3S,5R,8R,9S,10R,11S,13S,14S)-17-iodo-13-methyl-10-
(((triisopropylsilyl)oxy)methyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,15-tetradecahydro-14H-
cyclopenta[a]phenanthrene-3,11,14-triol (221) (56 mg, 0.0926) in 92% yield. 1H NMR (700 MHz, 
CDCl3) δ 6.07 (s, 1H), 4.98 (s, 1H), 4.46 (d, J = 10.3 Hz, 1H), 4.13 (s, 1H), 4.05 (s, 1H), 3.34 (d, 
J = 10.3 Hz, 1H), 2.55 (dd, J = 16.4, 1.9 Hz, 1H), 2.34 – 2.25 (m, 2H), 2.14 (dd, J = 14.4, 3.5 Hz, 
1H), 2.00 – 1.83 (m, 3H), 1.70 (d, J = 12.4 Hz, 1H), 1.65 – 1.57 (m, 2H), 1.57 – 1.45 (m, 2H), 1.37 
– 1.31 (m, 1H), 1.31 (s, 3H), 1.27 – 1.21 (m, 2H), 1.18 (dt, J = 15.2, 7.5 Hz, 3H), 1.10 (t, J = 6.9 
Hz, 21H), 1.07 – 1.02 (m, 1H). 13C NMR (176 MHz, CDCl3) δ 132.9, 112.5, 83.1, 70.2, 66.0, 63.2, 
54.0, 43.2, 42.9, 39.7, 39.3, 35.6, 34.9, 33.2, 27.5, 25.4, 23.6, 21.3, 20.6, 18.0, 18.0, 11.9. HRMS 
(ESI): m/z calcd for C28H50IO4Si
+ [M+H]+ = 605.2523, found 605.2512. [α]D










221 (50 mg, 0.083 mmol) along with Pd(PPh3)4 (20 mg, 0.0165 mmol), CuCl (123 mg, 01.24 
mmol), and LiCl (70.3 mg, 1.655 mmol) were solvated in dry DMSO (7.0 mL) under a N2 
atmosphere and stannyl butenolide 73 (105 mg, 0.280 mmol) was added via syringe. The reaction 
solution was heated to 50oC for 1 hour until the starting material was consumed. The solution was 
then quenched with pH = 7 phosphate buffer (4 mL) and extracted 4x with EtOAc (7 mL each). 
The organic layers were combined, dried over Na2SO4, filtered, adsorbed onto silica gel, and 
directly purified by flash column chromatography with 0% → 10% → 20% → 30% EtOAc in 
hexanes to afford 4-((3S,5R,8R,9S,10R,11S,13R,14S)-3,11,14-trihydroxy-13-methyl-10 
(((triisopropylsilyl)oxy) methyl)-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1H-
cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one (222) (39 mg, 0.069 mmol) in 84% yield. 1H 
NMR (500 MHz, CDCl3) δ 6.07 (d, J = 2.8 Hz, 1H), 6.04 (s, 1H), 5.03 – 4.86 (m, 2H), 4.46 (d, J 
= 10.3 Hz, 1H), 4.14 (s, 1H), 4.05 (s, 1H), 3.35 (d, J = 10.4 Hz, 1H), 2.70 (dd, J = 18.4, 2.3 Hz, 
1H), 2.45 (dd, J = 18.3, 3.5 Hz, 1H), 2.38 – 2.22 (m, 2H), 2.02 – 1.83 (m, 4H), 1.76 – 1.71 (m, 
1H), 1.66 – 1.57 (m, 2H), 1.56 – 1.46 (m, 2H), 1.51 (s, 3H), 1.40 – 1.32 (m, 2H), 1.26 (t, J = 7.1 
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Hz, 1H), 1.24 – 1.13 (m, 2H), 1.14 – 1.04 (m, 21H). 13C NMR (126 MHz, CDCl3) δ 174.3, 158.2, 
144.8, 131.4, 112.8, 86.3, 71.6, 70.2, 65.9, 63.3, 51.6, 43.9, 40.6, 39.6, 39.3, 35.5, 34.7, 33.2, 27.5, 
25.4, 23.6, 20.7, 19.9, 18.1, 18.0, 11.9. HRMS (ESI): m/z calcd for C32H52O6SiNa
+ [M+Na]+ = 
583.3431, found 583.3424. [α]D








yl)furan-2(5H)-one 222 (33 mg, 0.0589 mmol) and 2,6 – lutidine (137 μL, 1.18 mmol) were 
solvated in dry CH2Cl2 (5 mL) and cooled to -78
oC under a N2 atmosphere. Then, trimethylsilyl 
trifluoromethanesulfonate (107 μL, 0.59 mmol) was added via syringe and the reaction was 
allowed to warm to room temperature. After 2 h, the reaction was quenched with a saturated 
NaHCO3 solution (3 mL). The crude mixture was then extracted 3x with EtOAc (2.5 mL each), 
dried over Na2SO4, filtered, and azeotroped 4x with toluene (5 mL each) to remove remaining 2,6-
lutidine. The crude material was then adsorbed onto silica gel and directly purified by flash column 
chromatography with 0% → 5% EtOAc in hexanes. The resulting polysilylated product was 
immediately redissolved in EtOA (4 ml) and 10% Pd/C (6 mg) was added. The vessel was flushed 
with N2, and then with H2. The reaction was stirred at ambient temperature under 1 atm of H2 for 
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15 minutes. The crude mixture was filtered through celite with EtOAc and concentrated in vacuo. 
The resulting residue was directly purified by flash column chromatography with 0% → 5% 
EtOAc in hexanes to afford 4-((3S,5R,8R,9S,10R,11S,13R,14S,17R)-13-methyl-10-
(((triisopropylsilyl)oxy)methyl)-3,11,14-tris((trimethylsilyl)oxy)hexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one (7 mg, 0.009 mmol) (224) in 15% yield. 1H 
NMR (700 MHz, CDCl3) δ 5.83 (s, 1H), 4.74 (dd, J = 3.5, 1.8 Hz, 2H), 4.09 – 3.95 (m, 3H), 3.67 
(d, J = 10.4 Hz, 1H), 2.70 (d, J = 13.3 Hz, 1H), 2.48 (t, J = 7.7 Hz, 1H), 2.21 (td, J = 14.2, 3.8 Hz, 
1H), 2.14 (td, J = 12.4, 3.5 Hz, 1H), 2.06 – 1.97 (m, 1H), 1.96 – 1.84 (m, 2H), 1.85 – 1.71 (m, 4H), 
1.72 – 1.66 (m, 1H), 1.48 (d, J = 13.8 Hz, 1H), 1.40 – 1.33 (m, 3H), 1.32 – 1.24 (m, 2H), 1.20 (d, 
J = 13.9 Hz, 1H), 1.14 (d, J = 14.5 Hz, 1H), 1.08 (d, J = 3.7 Hz, 21H), 1.04 (s, 3H), 0.13 (s, 9H), 
0.13 (s, 9H), 0.07 (s, 9H). 13C NMR (176 MHz, CDCl3) δ 174.3, 173.8, 117.3, 91.9, 73.9, 67.2, 
66.9, 65.7, 51.6, 50.4, 47.6, 41.6, 40.0, 35.3, 34.3, 34.1, 28.8, 27.2, 27.0, 25.5, 24.0, 23.1, 21.2, 
18.2, 12.2, 2.9, 1.0, 0.2. HRMS (ESI): m/z calcd for C41H82NO6Si4
+ [M+NH4]
+ = 796.5219, found 
796.5212. [α]D





(7 mg, 0.009 mmol) was solvated in 0.3 M HCl in MeOH (2 mL). The solution was allowed to stir 
at ambient temperature for 1 hour. The reaction was then quenched with sat. NaHCO3 until pH = 
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7. The solution was extracted 5x with a 2:1 mixture of CHCl3:EtOH. The combined organic layers 
were dried with Na2SO4, filtered, and concentrated. The resulting crude material was adsorbed 
onto silica gel and purified directly by flash column chromatography with 0% → 5% → 10% 
MeOH in DCM to afford 4-((3S,5R,8R,9S,10R,11S,13R,14S,17R)-3,11,14-trihydroxy-10-
(hydroxymethyl)-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one 
(174) (2.1 mg, 0.0052 mmol) in 57% yield. 1H NMR (700 MHz, CD3OD) δ 5.90 (s, 1H), 5.03 (d, 
J = 18.7 Hz, 1H), 4.91 (d, J = 18.4 Hz, 1H), 4.25 (d, J = 11.4 Hz, 1H), 4.05 (s, 2H), 3.16 (d, J = 
11.4 Hz, 1H), 2.83 (dd, J = 9.2, 5.6 Hz, 1H), 2.22 – 2.13 (m, 3H), 1.99 – 1.92 (m, 2H), 1.93 – 1.85 
(m, 3H), 1.84 – 1.78 (m, 3H), 1.72 (tt, J = 14.0, 4.6 Hz, 1H), 1.65 – 1.57 (m, 3H), 1.56 – 1.50 (m, 
1H), 1.38 (qd, J = 13.5, 4.6 Hz, 1H), 1.32 (dd, J = 13.8, 2.9 Hz, 1H), 1.24 – 1.19 (m, 1H), 1.14 (s, 
3H). 13C NMR (176 MHz, CD3OD) δ 176.3, 175.2, 116.0, 85.5, 73.4, 67.6, 65.0, 64.9, 50.8, 48.8, 
45.2, 38.7, 37.8, 34.8, 34.4, 32.0, 31.5, 26.1, 26.0, 24.7, 22.6, 20.4, 17.8. HRMS (ESI): m/z calcd 
for C23H34O6Na
+ [M+Na]+ = 429.2253, found 429.2271. [α]D






cyclopenta[1,2]phenanthro[4,4b-de][1,3]dioxepin-10(2H)-one (9 mg, 0.0238 mmol) was solvated 
in 0.3 M HCl in MeOH (2 mL). The solution was allowed to stir at ambient temperature for 1 hour. 
The reaction was then quenched with sat. NaHCO3 until pH = 7. The solution was extracted 5x 
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with a 2:1 mixture of CHCl3:EtOH. The combined organic layers were dried with Na2SO4, filtered, 
and concentrated. The resulting crude material was adsorbed onto silica gel and purified directly 
by flash column chromatography with 0% → 5% → 10% MeOH in DCM to afford 
(3S,5R,8R,9S,10R,11S,13S,14S)-3,11,14-trihydroxy-10-(hydroxymethyl)-13-
methylhexadecahydro-17H-cyclopenta[a]phenanthren-17-one (WK-5-199) (4.5 mg, 0.0133 
mmol) in 56% yield. 1H NMR (700 MHz, CD3OD) δ 4.24 (d, J = 11.5 Hz, 1H), 4.10 (d, J = 2.7 
Hz, 1H), 3.58 (ddt, J = 14.0, 7.9, 4.6 Hz, 1H), 3.16 (d, J = 11.5 Hz, 1H), 2.47 – 2.40 (m, 1H), 2.36 
– 2.22 (m, 3H), 2.10 (dt, J = 14.7, 3.5 Hz, 1H), 2.01 – 1.97 (m, 1H), 1.97 – 1.86 (m, 2H), 1.80 – 
1.71 (m, 3H), 1.57 (dd, J = 14.5, 3.1 Hz, 2H), 1.50 (dd, J = 14.8, 3.2 Hz, 3H), 1.37 – 1.25 (m, 3H), 
1.23 (s, 3H), 1.18 (td, J = 14.5, 3.7 Hz, 1H). 13C NMR (176 MHz, CD3OD) δ 222.9, 82.2, 69.9, 
67.3, 63.3, 52.5, 39.6, 38.7, 38.3, 37.2, 34.8, 33.9, 32.0, 28.8, 28.2, 25.8, 24.8, 18.5, 14.9. HRMS 
(ESI): m/z calcd for C19H30NaO5
+ [M+Na]+ = 361.1991, found 362.1988. [α]D







cyclopenta[1,2]phenanthro[4,4b-de][1,3]dioxepin-10(2H)-one (20 mg, 0.053 mmol) was solvated 
in 0.3 M HCl in MeOH (4 mL). The solution was allowed to stir at ambient temperature for 1 hour. 
The reaction was then quenched with sat. NaHCO3 until pH = 7. The solution was extracted 5x 
with a 2:1 mixture of CHCl3:EtOH. The combined organic layers were dried with Na2SO4, filtered, 
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and concentrated. The resulting crude material was adsorbed onto silica gel and purified directly 
by flash column chromatography with 0% → 5% → 10% MeOH in DCM to afford 
(3S,5S,8R,9S,10R,11S,13S,14S)-3,11,14-trihydroxy-10-(hydroxymethyl)-13-
methylhexadecahydro-17H-cyclopenta[a]phenanthren-17-one (WK-5-197) (8 mg, 0.0237 mmol) 
in 45% yield. 1H NMR (700 MHz, CD3OD) δ 4.16 (d, J = 2.8 Hz, 1H), 3.87 (d, J = 11.8 Hz, 1H), 
3.67 (d, J = 11.8 Hz, 1H), 3.58 (tt, J = 10.5, 4.8 Hz, 1H), 2.42 – 2.35 (m, 1H), 2.34 – 2.26 (m, 3H), 
2.20 – 2.10 (m, 2H), 1.91 – 1.84 (m, 1H), 1.80 – 1.76 (m, 1H), 1.67 (dt, J = 12.4, 2.6 Hz, 1H), 1.56 
(dd, J = 14.7, 3.2 Hz, 1H), 1.47 – 1.37 (m, 3H), 1.38 – 1.28 (m, 4H), 1.28 – 1.20 (m, 1H), 1.23 (s, 
3H), 1.17 (dd, J = 12.4, 2.4 Hz, 1H), 0.86 (td, J = 13.5, 3.6 Hz, 1H). 13C NMR (176 MHz, CD3OD) 
δ 222.9, 82.1, 69.3, 63.5, 56.5, 52.8, 52.5, 44.5, 38.5, 37.0, 36.8, 34.1, 32.0, 29.8, 29.7, 26.2, 25.8, 
24.7, 14.9. HRMS (ESI): m/z calcd for C19H30NaO5
+ [M+Na]+ = 361.1991, found 362.1987. 
[α]D








cyclopenta[1,2]phenanthro[4,4b-de][1,3]dioxepin-10-yl)furan-2(5H)-one (4 mg, 0.0077 mmol) 
was solvated in 0.3 M HCl in MeOH (4 mL). The solution was allowed to stir at ambient 
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temperature for 1 hour. The reaction was then quenched with sat. NaHCO3 until pH = 7. The 
solution was extracted 5x with a 2:1 mixture of CHCl3:EtOH. The combined organic layers were 
dried with Na2SO4, filtered, and concentrated. The resulting crude material was adsorbed onto 
silica gel and purified directly by flash column chromatography with 0% → 5% → 10% MeOH in 
DCM to afford 4-((3S,5S,8R,9S,10R,11S,13R,14S)-3,11,14-trihydroxy-10-(hydroxymethyl)-13-
methyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1H-cyclopenta[a]phenanthren-17-
yl)furan-2(5H)-one (WK-5-198) (2 mg, 0.0049 mmol) in 64% yield. 1H NMR (700 MHz, CD3OD) 
δ 6.23 (s, 1H), 6.00 (s, 1H), 5.13 (d, J = 16.7 Hz, 1H), 5.00 (d, J = 16.8 Hz, 1H), 4.15 (d, J = 3.0 
Hz, 1H), 3.89 (d, J = 11.8 Hz, 1H), 3.68 (d, J = 11.8 Hz, 1H), 3.58 (tt, J = 10.7, 4.8 Hz, 1H), 2.77 
– 2.69 (m, 1H), 2.41 – 2.33 (m, 3H), 2.28 (dd, J = 14.7, 3.6 Hz, 1H), 2.21 (d, J = 10.6 Hz, 1H), 
1.78 (d, J = 12.9 Hz, 1H), 1.66 (d, J = 13.0 Hz, 1H), 1.46 (s, 3H), 1.41 (dt, J = 23.6, 12.6 Hz, 2H), 
1.37 – 1.20 (m, 5H), 1.08 (d, J = 12.4 Hz, 1H), 0.84 (td, J = 13.5, 3.5 Hz, 1H). 13C NMR (176 
MHz, CD3OD) δ 175.2, 159.9, 143.4, 132.6, 110.1, 85.3, 71.6, 69.4, 63.2, 56.5, 52.8, 50.6, 44.2, 
43.1, 39.4, 38.4, 37.0, 33.8, 29.8, 26.4, 26.3, 18.9. HRMS (ESI): m/z calcd for C23H32NaO6
+ 
[M+Na]+ = 427.2097, found 427.2092. [α]D












cis-α-C/D junction of 196 
 
 




C18 Carbon shift 
In addition to the more concrete structural proof, our research into the topic of steroidal 
C/D ring junctions revealed an interesting and strong correlation between the C18 carbon NMR 
shift and the ring junction stereochemistry. It became apparent that steroids of similar structure 
having a cis-C/D junction with β-oriented –Me and β-oriented –OH (natural junction) often 
produce a characteristic C18 shift of 15 – 17 ppm. In contrast, a cis-C/D junction with α-oriented 
–Me and α-oriented –OH produce a C18 shift in the range of 20-21 ppm.31 This is a theme we have 
noticed in the literature and throughout our own work on the synthesis of cardenolides. 
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NOE of panogenin (173) 
 










C5 stereochemical evidence derived from 13C NMR shift correlations: 
A thorough collection and review of cardiac glycoside 13C NMR shifts has been 
published.31 Several strong correlations and patterns relating to specific 13C shifts and 
stereochemical/structural features were noted. In particular, certain isomers often show 
characteristic carbon shifts which deviate significantly enough from its other isomers to constitute 
evidence of a steroids configuration. The authors note the following tell-tale shifts (Table 4.4.): 
Table 4.4. 13C NMR Evidence for Configuration at C5. 
Carbon No. 5α – derivatives 5β – derivatives 
C5 44.7 ± 0.4 36.0 ± 0.6 
C9 50.0 ± 0.3 35.5 ± 0.4 
 
Accordingly, our synthetic sample of cis-panogenin (174) shows carbon shifts of: 
C5: 34.84  C9: 37.79 
These shifts are in accord with those noted for 5β-derivatives.  
 
And our sample of panogenin (173) shows carbon shifts of: 
 C5: 44.99  C9: 52.78 
Again, in agreement with known shifts for 5α-derivatives. 
 
For 19-hydroxysarmentogenin (1), the shifts are: 
C5: 32.28 C9: 41.61 








Na+/K+ATPase Inhibition Assay 
 Serial dilutions (double digit nanomolar to millimolar range) of the test compounds were 
prepared in 2:1 DMSO:S3 buffer. The S3 buffer contains 0.01 M NaCl, 0.01 M MgCl2, 0.1 M Tris 
+ HCl to pH 7.2. The Na+/K+ATPase purchased from Sigma-Aldrich was isolated from porcine 
cerebral cortex and contained 0.4 units/mg protein, 14.4% protein content, and 0.0576 units/mg 
solid. A solution of the enzyme preparation dissolved in the S3 buffer was made at a concentration 
of 1.7 mg crude enzyme solid per 1.0 mL S3 buffer. 93 µL of the enzyme/S3 solution was pipetted 
into each well designated to receive the enzyme. Then, 7 µL of test compound solution (or vehicle) 
was pipetted into the designated wells. Test compounds were allowed to incubate with the enzyme 
for 10 minutes at 37oC. At the same time, a solution of ATP disodium salt in the S2 buffer was 
prepared. The S2 buffer contains 0.10 M NaCl, 0.005 M KCl, 0.003 M MgCl2, 0.001 M EGTA, 
and 0.08 M Tris + HCl to pH 7.4. The ATP solution was prepared at a concentration of 0.01088 
M ATP. After the 10 minute preincubation time of the enzyme/inhibitor mixture, 50.0 µL of the 
ATP solution is added to the designated wells to begin the enzymatic reaction. The reaction is 
allowed to proceed for 10 minutes at 37oC. It was determined that the enzymatic reaction and 
phosphate production is linear over this timeframe by testing the phosphate production at various 
concentrations of the enzyme. After the allotted time, 100 µL of Biomolgreen (a commercial 
phosphate detection reagent sold by Enzo Life Sciences) is pipetted into each well to stop the 
reaction. After 30 minutes, optical density at 620 nm is measured. The measured OD620 values are 
blanked to the control wells (background signal is subtracted), and then divided by the maximum 
control signal (signal of the uninhibited control) to generate a percent activity value, which is 
plotted and used to determine IC50 (using the log(inhibitor) vs response profile on PRISM). Values 
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Conclusions and Future Directions 
5.1. Introduction 
 The development of new synthetic approaches to complicated chemical scaffolds can allow 
medicinal chemists to access new structures for biological evaluation. The ability to test novel 
architectures and analogues is crucial for the discovery and development of new or improved 
therapeutics. Natural products architectures of high chemical complexity are often economically 
unjustifiable to pursue in an industrial setting. Synthetic routes can be too long and arduous to 
justify the work required to produce a single target analog. Often, these complicated analogues are 
instead targeted via a semi-synthetic approach. However, semi-synthetic approaches can 
dramatically hinder the region of chemical space which is easily accessible because the starting 
material has such predefined chemical moieties and configurations which are often challenging to 
overcome. For example, expanding or contracting ring sizes, accessing and controlling internal 
stereocenters, functionalizing inert positions, and producing enantiomers are some tasks which can 
be difficult to achieve via semi-synthesis. 
 Cardenolides are a class of cardiotonic steroids which have been used clinically for over 
200 years to treat congestive heart failure, and recent discoveries have demonstrated highly 
promising anticancer activity as well (see discussion in Chapter 1, section 1.7.). These complex 
steroids are unoptimized for the human body and are well known for their poor therapeutic 
windows. As a result. there has been much interest in developing new synthetic access to this class 
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of steroids and many groups have successfully reported landmark efforts at synthetically accessing 
cardenolides (see discussion in Chapter 2). However, total syntheses are often too long (30+ steps) 
or semi-synthetic approaches are insufficiently modular for a practical drug-oriented approach to 
these steroids.  
5.2. Conclusions 
 In Chapter 3, we set out to design a drug-oriented approach to the cardenolide class of 
steroids. This meant we ingrained the aspects of diversification and modularity from the outset of 
the synthetic design. We devised a disconnection approach illustrated in Scheme 5.1.1 
Scheme 5.1. Synthetic Methodology Design for Accessing Steroidal Cores. 
 
 This approach was attractive because we imagined it would allow for the pre-installation 
of functional handles and diversity elements on the starting substrates 94 and 94. These handles 
could be carried through the sequence to provide steroidal cores of unique structure. The described 
method could also allow for great stereocontrol. The ability to control internal ring junction 
stereocenters and peripheral configurations was paramount to our approach. In these rigid ring 
systems, stereochemical manipulation can have a profound impact on the overall shape of the 
molecule and modulate binding contacts in ways which may lead to unique and improved 
bioactivity. Finally, this approach is highly concise; allowing the steroidal cores (6 stereocenters 




 Our first goal was to describe an asymmetric variant of the initial Michael addition. This 
reaction is highly hindered and already worth noting since only a handful of examples exist in the 
literature describing such conjugate additions forming vicinal quaternary and tertiary 
stereocenters. A catalyst screen revealed the optimal chiral controller as being 139; a cyclopropyl 
biphenyl BOX ligand in conjunction with Cu(II) hexafluorantimonate. A variety of uniquely 
structured β-ketoesters and 2-substituted enones could be successfully coupled under these 
conditions. This allowed the synthesis of a library of Michael adducts in excellent selectivity. This 
ability to introduce asymmetry and control these hindered stereocenters is imperative in a drug-
development approach. We could achieve 82–95% yield, 90–96% ee, and 4:1 to >20:1 dr across 
the board for Michael adducts (Scheme 5.2.). Some important features to note include uniquely 
sized ring systems, such as 5-membered A rings and 6-membered D rings, as well variable alkyl 
substitution at the C13 position – a modification which would be highly difficult to produce semi-
synthetically. 
Scheme 5.2. Summary of Asymmetric Michael Addition Results. 
 
 At this stage cyclization studies were undertaken to affect a double aldol reaction and 
complete the steroidal nucleus. We discovered stereodivergent conditions for producing the 
steroidal cores. Depending on the conditions used, we could produce cis-α-C/D or cis-β-C/D ring 
junctions (Scheme 5.3.) in high selectivities and yield. Again, this stereocontrol is a primary goal 
of our overall approach. To this effect, our library of Michael adducts could be converted to a 
178 
 
library of steroidal cores containing the same unique structural features such as unnatural ring 
sizes, sites of substitution, and stereochemical patterns. In Chapter 3 section 3.9., there is a detailed 
discussion of the factors which control this diastereoselective C ring closure reaction. 
Scheme 5.3. Summary of Stereodivergent Cyclization Results. 
 
 In Chapter 4, we describe our efforts to expand and elaborate upon the developed 
methodology for the total synthesis of several natural and unnatural cardenolides. We chose four 
targets: 19-hydroxysarmentogenin, trewianin aglycone, panogenin, and cis-panogenin. These 
targets represent all four isomers of the C5/C11 position of the general 19-hydroxysarmentogenin 
architecture. To access these targets, several modifications, illustrated in Figure 5.1. had to be 
addressed.  
We envisioned making these adjustments in key phases. In line with our primary tenant, 
we planned to pre-install the oxygenation at C3 and C11 before the key Michael 
addition/cyclization sequence. This would allow the production of a highly functionalized key 
intermediate amenable to divergence. This would conclude phase 1. Phase 2 would be the 
stereodivergent control of the C5 and C11 positions – completing the core structure of each target. 
While phase three is installation of the butenolide ring. Importantly, we hoped to minimize the 
steps required to complete phase 1. At this stage, all the important oxygenation is set in the 
molecule and only stereodivergent elaboration of the cores remains. By constructing a complex 
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and functionalized intermediate in a concise fashion, we can gain access to a variety of potential 
derivatives and analogues resulting from subsequent transformations.  
Figure 5.1. Targets and Required Modifications. 
 
We discovered that oxygenation at the eventual C11 position could be achieved via an 
organocatalytic α-oxidation of an intermediate aldehyde, allowing the synthesis of fragment 182 
in 3 steps, 15 g scale, and up to 95% ee. The oxygenation at C3 proved to be more difficult. After 
much trial and error of unique fragments, we found vinyl chloride 192 to be the most effective 
fragment for the ensuing sequence. After the Michael addition/cyclization sequence, a cis-α-C/D 
steroidal core is produced. Following epimerization of the cis-α-C/D ring junction into a cis-β 
orientation, a global reduction/transposition sequence effectively removes oxygenation at C7 and 
transfers it to the key C3 position and completes the phase 1 synthesis of key intermediate 175 
(Scheme 5.4.).2 At this stage, comparison to the route described by Inoue et al. reveals significant 
progress. Our key intermediate 175 is produced in 10 total steps, nearly the same steps required to 
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make only the A/B ring fragment in the previous approach. In addition, one of the key 
intermediates in the previous approach requires 23 total steps to access, which is more steps than 
will be required for the completion of the entire target via our method (21 total steps). 
Scheme 5.4. Summary of Route to 175 and Stereodivergent Elaboration to Targets. 
 
 At this point, key intermediate 175 is elaborated in a stereodivergent fashion to the cores 
of all four targets (Scheme 5.4.). Targets with an α-oriented hydroxy at C11 require 6 steps to 
produce the core, while targets with a β-oriented hydroxy group require 4 steps. Planning of the 
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synthetic routes and using the inherent structural features of the intermediates allowed strategic 
stereocontrol at the key positions C5 and C11. With the cores in hand, we completed the synthesis 
by installing the C17 β-oriented butenolide ring on all four targets via a known 5 step sequence. 
Overall, we synthesized all four C5/C11 isomers in 19-21 total steps. This represents a significant 
improvement over previous approaches as well as the capacity to access multiple cardenolide 
structures from a single, drug-oriented approach.  
 With the desired compounds in hand, I spent time developing a biochemical inhibition 
assay to test the ability of our steroids to inhibit the Na+/K+ATPase pump. The assay I developed 
is based on the colorimetric detection of phosphate production, which is directly correlated to the 
activity of the Na+/K+ATPase pump. We discovered a few structure-activity relationships which 
corroborate both the mode of binding and previously suggested results (see discussion in Chapter 
1, section 1.5.) (Figure 5.2.). First, the orientation at C5 seems to be of little or no importance for 
our aglycones. It is surmised that the C5 configuration will have a more dramatic effect on IC50 
with glycosylate congeners. This is because the difference between a cis- and trans-A/B ring 
junction has a significant impact on the 3-dimensional orientation of the key C3 hydroxy group 
which could affect the position of the sugar moiety within the binding pocket. Additionally, the 
orientation of the C11 alcohol appears to be significant. Our results suggest that a β-oriented 
alcohol improves the inhibitory capacity. Examination of the binding mode described by co-
crystallographic analysis with cardenolides indicates the importance of polar binding contacts on 
the β-face of these steroids while the primary interactive force on the α-face is nonpolar in nature, 
corroborating these results. Finally, the removal of the butenolide ring at C17 completely destroyed 
inhibitory activity up to the millimolar range and when the butenolide ring is present, changing its 
orientation from β-oriented to planar (by introducing C16-C17 unsaturation) dramatically reduces 
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its inhibitory capacity. It appears that the raw presence of the butenolide ring is insufficient for 
inhibiting the pump in this assay, and the β-orientation at C17 is crucial. This supports previous 
reports that the specific orientation at C17 is paramount to the activity of cardenolides. 
Figure 5.2. Summary of Observed Structure-activity Relationships. 
 
 Overall, a new synthetic approach was designed from a drug-oriented perspective to allow 
for the concise, two step synthesis of uniquely functionalized steroidal cores with excellent 
stereocontrol. This methodology was expanded upon to allow for the expedient synthesis of a 
heavily functionalized key intermediate with preinstalled functional handles. Here, remarkable 
chemical complexity is constructed in just 10 total steps from simple substrates. This intermediate 
is then elaborated in a stereodivergent fashion into four cardenolides epimeric at the C5/C11 
positions in just 19-21 total steps. These steroids were then evaluated in a biochemical inhibition 
assay to derive some interesting structure-activity relationships. 
5.3. Future Directions 
 Currently, our lab continues to explore the capacity of our described approach to access 
more heavily functionalized cardenolides. We are interested in producing additional structural 
analogues of these cardenolides including C3 glycosylated derivatives, appending unique 
heterocycles at C17, exploring steroids of unnatural isomeric configurations at positions other than 
C5 and C11, and building up additional sites of oxygenation including C1 and C5.  We hope to 
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acquire purified α-isoforms of the Na+/K+ATPase pump to allow for isoform selectivity studies to 
be performed via biochemical assay. It will be interesting to determine if some unique relationships 
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